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Abstract 
Endothelial-to-mesenchymal transition (EndMT) is a biological process that 
allows the transdifferentiation of endothelial cells into mesenchymal cells, thus 
originating cells capable of novel functions necessary for the surrounding 
environment. EndMT regulates endocardial cushion formation during embryo 
development, and it is stimulated by the TGFβ/BMP family of ligands. In adults, 
EndMT is activated upon an injury event or during pathological conditions like organ 
fibrosis, cerebral cavernous malformation, cancer-associated fibroblast generation, 
and others. Hence, it is necessary to better characterize the molecular regulators 
cooperating with TGFβ signaling in driving EndMT, to possibly provide novel 
therapeutic targets to treat these pathological conditions. Here we studied YAP, a 
co-transcriptional regulator involved in several cell biology processes, among which 
epithelial-to-mesenchymal transition (EMT). Since EndMT is considered a 
“specialized” form of EMT, and since YAP and TGFβ signaling were shown to cross-
talk in other contexts, we hypothesized that YAP contributes to EndMT by 
modulating TGFβ signaling, and characterized the underlying molecular 
mechanism.  
Results here presented demonstrate that YAP is required for a complete TGFβ-
mediated EndMT response in vitro, and that YAP contributes specifically to SMAD3-, 
but not SMAD1-, driven EndMT gene transcription.  
We provide novel evidence that YAP positively regulates EndMT playing the 
twofold role of acting as SMAD3 co-transcriptional factor on the promoter of EndMT 
target genes and, in parallel, preventing GSK3β-mediated SMAD3 linker 
phosphorylation, thus protecting SMAD3 from degradation. YAP is therefore 
emerging as a possible candidate target to inhibit pathological TGFβ-driven EndMT. 
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Chapter 1 - Introduction 
1.1 Vascular Endothelium 
The innermost layer of blood vessels is composed by an organized, continuous 
stratum of endothelial cells (ECs), and it is referred as vascular endothelium 
(Potente and Makinen, 2017). Initially, vascular ECs were considered a simple 
physical barrier that separate blood from the surrounding tissues, but, over the time, 
it became more and more clear that ECs are true determinants of vascular 
architecture and functions (Sena et al., 2013). Through well-defined steps, indeed, 
the vascular endothelium gives rise to an extremely organized vascular network – 
the blood vasculature – consisting of hierarchically-structured blood vessels, that 
nourish body tissues by transporting nutrients, gases and metabolites along with 
blood cells (Potente and Makinen, 2017). To regulate vascular function, ECs 
respond to biomolecular and mechanical stimuli by finely tuning molecular 
responses, and they engage with other cell types, such as perivascular cells 
(vascular smooth muscle cells (vSMCs), pericytes and mural cells), circulating cells 
and organ-specific constituents (Potente and Makinen, 2017). The vascular 
endothelium is therefore responsible for multiple vascular functions, such as 
vascular growth and remodeling, lumen formation, vessel homeostasis, 
permeability, vasoconstriction and vasodilation and control of immune responses 
(Sena et al., 2013). Hence, maintaining proper EC integrity is crucial to avoid 
vascular dysfunction. 
1.1.1 Vascular development and remodeling 
The vascular endothelium originates early during the embryo development 
through a process known as vasculogenesis, that is the formation of de novo blood 
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vessels (Figure 1, upper part) (Goldie et al., 2008; Potente and Makinen, 2017). 
This process initially occurs in the yolk-sac, when, at embryonic day 7.5 (E7.5), 
endothelial precursors confine hematopoietic cells in primitive structures known as 
blood islands (Choi, 2002). Afterwards, blood islands fuse together and give rise to 
a primitive vascular network, which undergoes extensive vascular remodeling to 
ultimately form the yolk sac vasculature. 
Meanwhile, in the embryo proper, angioblasts differentiate from the mesoderm 
to become EC precursors (Potente and Makinen, 2017). Generation and 
differentiation of angioblasts is driven by signaling from multiple growth factors, like 
the bone morphogenic protein 4 (BMP4) and the fibroblast growth factor 2 (FGF2) 
(Marcelo et al., 2013; Winnier et al., 1995). While BMP4 and FGF2 signaling are 
fundamental for mesodermal development, vascular endothelial growth factor 
(VEGF) signaling is employed for subsequent EC proliferation and migration and it 
is also crucial for vasculature development (Carmeliet et al., 1996; Ferrara et al., 
1996). VEGFR1 (Flt-1) and VEGFR2 (Flk-1) receptors are activated in response to 
VEGF-A stimulation, while VEGFR3 is bound by VEGF-C. The differential activation 
of these receptors not only guide EC proliferation but also determine EC 
specification in either tip or stalk cells. Tip cells function as leader cells that sprout 
from pre-existing blood vessels to pave the way for the formation of new ones, in a 
process termed angiogenesis (Potente and Makinen, 2017). Following tip cells there 
are proliferating stalk cells, which contribute to the actual vessel formation and 
lumenization. Interestingly, tip cells present potently activated VEGFR2 and 
VEGFR3-mediated signaling, together with high secretion of Delta-like protein 4 
(Dll4). Dll4, then, binds to Notch receptors on neighboring ECs, leading to VEGFR2 
and VEGFR3 reduced expression along with VEGFR1 up-regulation and 
consequent VEGF-A sequestration (Hellstrom et al., 2007; Jakobsson et al., 2010). 
In this way, tip ECs tightly control the fate of adjacent cells and determine their stalk 
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identity. Accordingly, endothelial-specific deletion of Notch-1 sustains tip cell 
formation (Hellstrom et al., 2007). Moreover, other reports have demonstrated that 
the VEGF co-receptor neuropilin 1 (Nrp-1) blocks transforming-growth factor b 
(TGFβ)-BMP signaling driving Notch down-stream target genes expression and, 
thus, promote a tip cell-fate determination (Aspalter et al., 2015; Larrivee et al., 
2012; Moya et al., 2012). 
Vascular network maturation not only requires adequate proliferation and 
migration of ECs to form tube vessels (angiogenesis), but also employs tightly 
coordinated vascular remodeling and mechanosensing. The proliferating activity of 
ECs is kept under control by retinoic acid (RA) and TGFβ -initiated signaling, which 
up-regulate the expression and the activity of cell-cycle progression inhibitors (like 
p21, p15 and p27) (Hannon and Beach, 1994; Lai et al., 2003; Reynisdottir et al., 
1995). Additionally, TGFβ promotes fibronectin (Fn1) production and deposition in 
the extracellular matrix (ECM), which engages with either aVb3 to promote ECs 
proliferation or a5b1 integrin to inhibit it (Bohnsack et al., 2004; Marcelo et al., 2013). 
Branching vessels can also originate through the remodeling of existing vasculature, 
in a process whereby interstitial tissue is formed within a vessel lumen and give rise 
to splitting vessels (intussusception). Vascular remodeling, moreover, can occur 
though removal of unnecessary sprouts, known as vascular regression. Finally, 
activation of transcriptional regulators in response to biochemical and mechanical 
stimuli determines the endothelial specification into arteries, venules, capillaries to 
form a structured and circular closed vascular network system (Potente and 
Makinen, 2017). 
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Figure 1. Vascular system development. The development of a vascular network begins with 
the differentiation of angioblasts (considered EC progenitors) from the mesoderm to form blood 
islands and acquire an arterial or venous identity, under the influence of different growth factors. 
Blood islands and primitive form of vessels eventually coalesce, originating a primitive vascular 
network. This then undergoes sprouting angiogenesis and vascular remodeling to form a 
hierarchical network consisting of arteries, veins and capillaries. Furthermore, myeloid and 
lymphoid cell lineages develop from hematopoietic stem cells originating from arterial hemogenic 
endothelium, and the lymphatic network system arise from the venuous endothelium. Finally, ECs 
attain organ-specific features thank to the recruitment of perivascular cells and to the contribution 
of tissue-specific biomolecular and mechanical factors. Taken from: Herbert, SP “Molecular 
control of endothelial cell behaviour during blood vessel morphogenesis” 2011, Nat Rev Mol Cell 
Bio 12, 551-564 
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1.1.2 Vascular differentiation  
During vasculature development in the embryo, the primitive vessels not only 
undergo extensive remodeling but also acquire distinctive molecular tracts that allow 
them to differentiate first into arteries or veins, and later into lymphatic vessels 
(Figure 1, central part). Arteries and veins form a closed circular network, where 
blood is pumped by the heart into arteries, flows through arterioles, reaches the 
tissues through capillaries along with nutrients and gases, and finally returns to the 
heart by first passing through venules and then through veins. Initially, it was thought 
that the hemodynamic forces originated by the flowing blood were those responsible 
for the endothelium differentiation in either arteries or veins (le Noble et al., 2004). 
Indeed, arteries are continuously exposed to high-pressure blood flow, which they 
sustain in concert with layers of smooth muscle cells and connective tissue. Veins, 
instead, collect low-pressure blood flowing back to the heart. However, later studies 
have also pointed several molecular determinants that contribute to arterial-venous 
specification. Particularly, this specification seems to be genetically determined 
even before blood begins to flow in response to cardiac contraction (E 8.5).  
Among the first arterial-venous determinants are the EphB receptors and their 
ligands; in particular, preceding the onset of circulation, EphB2 expressing ECs 
acquire arterial specifications, while vein ECs express EphB4 (Wang et al., 1998). 
The currently established model suggests that VEGF-A binds to VEGFR2 and Nrp-
1 co-receptor to activate and then cooperate with Notch-mediated signaling, leading 
ultimately to EphB2 expression and EphB4 suppression (Gu et al., 2003; Lawson et 
al., 2002). Studies in zebrafish reported that vegf knockdown (KD) suppressed the 
expression of EphB2 and sustained that one of EphB4, causing defective arterial 
identification. Interestingly, this phenotype was rescued upon Notch signaling 
activation, strongly suggesting a marked inter-pathway cooperation to drive arterial 
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specification (Lawson et al., 2002). In the venous endothelium, instead, expression 
of chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) 
prevents Nrp-1 and Notch signaling activation, and thus promotes a venous identity 
(You et al., 2005).  
The Wingless-Int1 (Wnt)/b-catenin signaling pathway is also a crucial 
determinant for arterial-venous differentiation. Corada and colleagues have indeed 
shown that b-catenin promotes the expression of the Notch-ligand Dll4 in the 
developing embryo vasculature, which then activates Notch1 and Notch4 receptors 
(Corada et al., 2010). By overexpressing b-catenin, the authors observed a 
prominent arterial specification of the endothelium in conjunction with a strongly 
reduced venous differentiation, resembling what described in a Dll4 gain-of-function 
situation (Trindade et al., 2008). Subsequently, Corada showed that the expression 
of the transcriptional factor Sox17 is crucial for arterial differentiation and, 
remarkably, it is triggered by b-catenin (Corada et al., 2013). Sox17, in turns, 
triggers the expression of Notch-related signaling molecules that promote Notch 
signaling activation. Hence, Wnt and Notch signaling are markedly inter-regulated 
and together they drive the endothelium towards an arterial specification. 
Development of the lymphatic vasculature starts around E9, when the 
transcriptional factor Sox18 starts to be expressed by venous ECs and 
progressively induces prospero homeobox protein 1 (PROX1) expression and 
venous EC transdifferentiation into lymphatic ECs (LECs) (Francois et al., 2008). 
PROX1 is considered the key regulator of lymphatic EC specification, that together 
with COUP-TFII, drive the expression of VEGFR3, whose activation stimulates LEC 
angiogenesis from the cardinal vein. Additional sprouting from other veins concurs 
to establish a primitive lymphatic structural plexus.   
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1.1.3 Endothelial heterogeneity  
The vascular tree can further specialize by adapting the EC features to meet 
the needs of different tissues and organs (Figure 1, bottom part) (Potente and 
Makinen, 2017). Such level of specialization confers a high degree of heterogeneity 
among different endothelia, in terms of both morphology and function. Structurally, 
the endothelium can be classified in continuous, fenestrated and 
discontinuous/sinusoidal (Figure 2) (Atkins et al., 2011). 
A continuous non-fenestrated endothelium is primarily observed in brain, heart, 
lung and skin vessels, where the need of controlled solute and cell passage is of 
primary importance (Figure 2B). ECs lining these vascular beds achieve such strict 
control by forming inter-endothelial junctions between adjacent cells. Their function 
is to impede diffusion of solutes larger than 3 nm in radius, preventing what is known 
as paracellular or diffusive pathway, and thus making the endothelium a physical 
“barrier” that separate circulating blood from the nearby tissues (Bazzoni and 
Dejana, 2001; Komarova and Malik, 2010). In this way, big solutes need to be 
actively transported through trans-cellular pathway to cross the endothelium, that is 
through caveolae or vesciculovacuolar organelles. Alternatively, solutes can be 
Figure 2. Heterogeneity among different endothelia lining organ-specific vascular beds. 
Endothelium can be: A) Continuous fenestrated, B) Continuous non-fenestrated, or C) 
Discontinuous/sinusoidal. For detailed description, please refer to the main text. Taken from: 
Velazquez, O “Cells of the Vascular System” https://clinicalgate.com/cells-of-the-vascular-
system/ 
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uptaken thanks to specific transporters. In the brain, for example, a form of highly 
specialized endothelium, called “blood brain barrier” (BBB), expresses high levels 
of the glucose transporter GLUT1 to satisfy the high demand of glucose in the brain 
(Potente and Makinen, 2017). Inter-endothelial junctions are classified into two main 
groups, named tight and adherens junctions (from now on respectively abbreviated 
as TJs and AJs). Both TJs and AJs consist of transmembrane proteins that build 
homophilic interactions between contiguous cells and convey intracellular signaling 
by engaging with cytosolic partners (Dejana, 2004). Thus, junctions are not only a 
simple site of attachment between neighboring cells, but are true signaling modules 
that sense the extracellular environment and respond by modulating molecular 
pathways monitoring cell proliferation and apoptotic rate, EC polarity, lumen 
formation and, more generally, vascular homeostasis. Transmembrane components 
of the TJs include prevalently Claudins, Junctional adhesion molecules (JAMs), and 
Endothelial cell-selective adhesion molecule (ESAM), while their cytosolic 
counterparts are represented by Occludins, Zonula Occludens (ZO) 1 and 2, 
Cingulin, Zonula Occludens associated nucleic-acid-binding protein (ZONAB), and 
Partitioning defective protein (Par) 3 and 6 (for a more comprehensive explanation, 
see Figure 3) (Dejana et al., 2009). Endothelial AJs are formed by interacting 
Vascular Endothelial-cadherin (VE-cadherin or Cdh5) proteins, whose expression 
is specific for the endothelium and begins early during development (Breier et al., 
1996; Lampugnani et al., 1992). In the cytosol, VE-cadherin binds to the catenins b-
catenin, plakoglobing (or g-catenin) and p120 and, indirectly, to a-catenin. Catenins, 
in turn, contribute to junctional stability, support AJs-actin cytoskeleton interaction, 
and form complexes with other signaling partners to convey a variety of intracellular 
messages (Figure 3) (Dejana et al., 2009). VE-cadherin clustering and junctional 
stabilization goes in parallel with increasing EC density, so that, when cells reach 
confluency, VE-cadherin limits cellular overgrowth, modulates the activity of 
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membrane receptors (like TGFβRII and VEGFR2), and induces TJs formation 
(Lampugnani et al., 2006; Rudini et al., 2008; Taddei et al., 2008). The expression 
of the endothelial-specific Claudin-5, indeed, is increased as a result of VE-cadherin 
expression and clustering (Taddei et al., 2008). By controlling various properties 
and aspects of ECs, thus, VE-cadherin functions as a master regulator of vascular 
homeostasis, whose genetic ablation results in collapse and regression of the 
vascular system (Carmeliet et al., 1999). Moreover, ECs express another member 
of the cadherin family, the neuronal cadherin (N-cadherin or Cdh2), which is not 
involved in endothelial cell-cell interaction, rather it seems to mediate connections 
between ECs and perivascular cells, like pericytes and vSMCs (Dejana et al., 2009). 
Intriguingly, Giampietro et al. reported that VE-cadherin limits N-cadherin 
expression by sequestering b-catenin at the cytoplasmic membrane and impeding 
its transcriptional activity, thus attenuating N-cadherin transcription (Giampietro et 
al., 2012). Accordingly, constitutively active b-catenin promotes N-cadherin 
expression while diminishing the one of VE-cadherin. Nowadays, this cadherin 
switch is considered a hallmark of endothelial-to-mesenchymal transition (EndMT), 
a biological process that will be further discussed in section 1.2. 
Notably, in fenestrated and discontinuous vessels, the adhesive and 
permeability properties of the inter-endothelial junctions are more loose compared 
to the continuous endothelium. A fenestrated endothelium is characteristic of organs 
involved in either filtration or secretion, like kidney glomeruli, glands and intestinal 
mucosa (Figure 2A) (Atkins et al., 2011). In these organs, the presence of big 
transcellular pores (around 70 nm in diameter) allows a quick exchange of 
molecules between the circulating blood and the nearby tissues. Finally, a 
discontinuous endothelium is observed in liver and bone marrow vessels, where the 
presence of large fenestrae (around 100-200 nm in diameter) permits cellular 
trafficking (Figure 2C). 
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Considering what described so far, vessel can differentiate in organ-specific 
vasculature and contribute to fulfill the needs of surrounding tissues by acquiring 
different phenotypic characteristics. This differentiation is elicited by external and 
tissue-specific stimuli, such as through the interaction with locally-resident cell 
types, through the exposure to different growth factors, in response to variable ECM 
composition and stiffness, in response to different mechanical forces (Potente and 
Makinen, 2017). Moreover, once the vasculature reaches a mature and definitive 
state, ECs do not sprout or undergo angiogenesis any longer, unless challenged by 
injuries or pathological conditions like tumors. Thus, a mature endothelium enters 
in a reversible quiescence status, in which ECs stop migrating and proliferating and 
form a monolayer of fully functional cells (Potente and Makinen, 2017).  
 
Figure 3. Endothelial tight and adherens junctions and their cytoplasmic partners. 
Junctions between ECs can be mainly grouped in two: Tight junctions (TJs), or Adherens 
junctions (AJs). 1) TJs comprise different families of proteins, like claudins, occludins, JAMs or 
ESAM. ECs express several claudins, like Claudin-1, -3, -5 and -12 but only Claudin-5 is specific 
for the endothelium. Claudin-5 is highly expressed in brain endothelium and, together with 
Claudin-3, contribute to control brain permeability. (continues on the next page) 
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(continues from the previous page) TJs are connected to the actin cytoskeleton through 
cingulin and ZO proteins 1, 2 and 3, while ZONAB is a transcriptional factor. Moreover, TJs 
can recruite polarity complex proteins Par3/Par6/aPKC and contribute to cell polarization. JAM 
are also involved in permeability control, but the exact mechanism is still not fully elucidated. 
2) AJs are formed by homophilic interacting cadherins. In the endothelium, the prominent form 
of cadherin is VE-cadherin, whose cytoplasmic tail is bound to catenins and contributes to 
modulate intracellular signaling important for ECs homeostasis. Catenins include p120, 
involved in VE-cadherin stabilization and signaling, plakoglobin, contributing to junctional 
stability, and b-catenin, the Wnt canonical transcriptional factor. b-catenin can function both 
as cell junction scaffolding protein, interacting with multiple partners and promoting junctional 
stability, as well as a transcriptional regulator. For example, junctional b-catenin can associate 
to monomeric a-catenin and may negatively impact on actin polymerization (yet the exact 
molecular mechanism is still under investigation). Conversely, junctional destabilization 
induces b-catenin nuclear translocation and activation of its transcriptional program. In 
addition to catenins, VE-cadherin can associate to growth factor receptors, like VEGFR2 and 
TGFβR, and modulate their signaling activity. Taken from: Dejana, E. “The control of vascular 
integrity by endothelial cell junctions: molecular basis and pathological implications.” Dev Cell. 
2009;16(2):209-21. 
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1.2 Endothelial-to-mesenchymal transition (EndMT) 
1.2.1 General characteristics of endothelial-to-mesenchymal transition 
Endothelial-to-mesenchymal transition (EndMT) is a biological process that 
occurs when ECs differentiate to become mesenchymal-like cells, detach from an 
organized endothelium, migrate, and invade surrounding tissues (van Meeteren and 
ten Dijke, 2012). During mesenchymal differentiation, ECs lose some endothelial-
specific characteristics, like quiescence, junctional stability, and the expression of 
the endothelial markers VE-cadherin, Claudin-5 and CD31 (or PECAM1, platelet 
endothelial cell adhesion molecule 1). In parallel, ECs acquire mesenchymal-like 
tracts, that is they become more invasive and migratory and they express 
transcription factors responsible for the EndMT switch like Snai1 (also known as 
Snail), Snai2 (or Slug) and Twist1 along with mesenchymal markers such as a-
Smooth Muscle Actin (aSMA, encoded by Acta2), transgelin (SM22a), Fibronectin-
1 (Fn1), Fibroblast Specific Protein-1 (FSP1, also known as S100a4), N-Cadherin, 
and Serpine1 (or PAI-1). The EndMT process confers high plasticity to ECs and 
physiologically occurs during embryo development (Markwald et al., 1975). In 
adults, instead, EndMT is generally switched off, although it can be re-activated 
upon an injury event or during pathological conditions, such as kidney and 
pulmonary fibrosis (van Meeteren and ten Dijke, 2012), cerebral cavernous 
malformation (CCM) (Maddaluno et al., 2013), and cancer-associated fibroblasts 
(CAFs) generation (Zeisberg et al., 2007a), as later discussed in section 1.2.6. 
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EndMT resembles and shares common characteristics with the more-widely 
known epithelial-to-mesenchymal transition (EMT), which is a key epithelial cell 
mechanism involved in several embryogenesis steps (Type I EMT) (Kalluri and 
Weinberg, 2009). Similar to ECs undergoing EndMT, epithelial cells differentiating 
into mesenchymal cells during EMT progressively lose their epithelial molecular 
markers, like the expression of epithelial cadherin (E-cadherin, or Cdh1), ZO-1, 
Cytokeratin and Desmoplakin, while acquiring mesenchymal ones. Of note, during 
either EMT or EndMT, there is a progressive degradation of the basal lamina caused 
by increased MMP-2 and MMP-9 matrix metalloproteinase activity, paralleled with 
an increased deposition of Fn1 and type I and III collagen, that can in turn activate 
different integrin-mediated signaling and lead to cytoskeletal reorganization of 
neighboring cells. EMT does not occur only during embryonic development, but also 
Figure 4. Schematic overview of endothelial-to-mesenchymal transition. ECs undergoing 
EndMT due to sustained TGFβ exposure progressively lose their specific characteristics and, 
instead, acquire more mesenchymal-like features. TGFβ-mediated EndMT occurs during 
development, in response to either temporary or chronic inflammation resulting in organ fibrosis, 
or during cancer progression. Taken from: van Meeteren LA, ten Dijke P. Regulation of 
endothelial cell plasticity by TGF-beta. Cell Tissue Res. 2012;347(1):177-86 
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during wound healing, tissue regeneration and organ fibrosis (Type II EMT). 
According to Kalluri and Weinberg, this second type of EMT is triggered by an 
inflammatory response, and terminates once the source of inflammation is removed 
(Kalluri and Weinberg, 2009). Since in fibrotic conditions the inflammatory status is 
continuous, EMT can ultimately lead to severe organ alterations. Finally, a third type 
of EMT is observed during tumorigenesis and tumor progression, when cancer cells 
become highly invasive and migratory and contribute to tumor metastatization 
(Kalluri and Weinberg, 2009).  
Both EMT and EndMT are triggered by similar signaling pathways, among which 
TGFβ and Wnt signaling are the predominant molecular inducers.  
1.2.2 Canonical TGFβ signaling pathway 
The canonical TGFβ signaling cascade is a central molecular pathway, known 
to regulate tumor-suppressive functions, like cell proliferation, apoptosis, and cell 
differentiation, but also tumor-promoting processes, like cell migration, ECM 
production, EMT and EndMT (Massague, 2012; van Meeteren and ten Dijke, 2012). 
These apparently opposite functions can be explained through the existence of 
numerous ligands, types of receptors, co-receptors, and intracellular modulators 
that are differently activated depending both on the type and on the amount of the 
stimulating ligand (Massague, 2012; Weiss and Attisano, 2013). The TGFβ 
superfamily of ligands, indeed, comprises three isoforms of TGFβ (TGFβ1, TGFβ2, 
TGFβ3), more than twenty BMPs, Activins, Inhibins, Growth Differentiation Factors 
(GDFs), and Mullerian Inhibitory Factors (MIFs), all having a dimeric structure with 
a cysteine structural motif. The signaling is propagated by ligand-activated receptors 
presenting serine/threonine kinase activity, which are broadly divided in type I (TbRI) 
and type II (TbRII) receptors. The human genome encodes seven different type I 
receptors, named activin receptor-like kinase (ALK1-7), and five type II receptors, 
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which are TGFβ type II receptor (TGFβR2), BMP type II receptor (BMPRII), activin 
receptor 2A and 2B (ACVR2A, ACVR2B) and anti-Muellerian hormone type II 
receptor (AMHRII). Receptors belonging to TbRI or TbRII family have a similar 
structure, composed of a cysteine-rich extracellular domain, a single 
transmembrane spanning region and a cytoplasmic tail bearing a kinase domain 
(Weiss and Attisano, 2013).  
In a canonical context, a TGFβ or BMP ligand binds to a multimeric receptor 
complex formed by two TbRII and two TbRI, and cause TbRI phosphorylation and 
activation by TbRII (Figure 5) (Massague, 2012). Once phosphorylated, TbRI 
undergoes a conformational change, and releases FK506 binding-protein (FKBP12) 
masking its kinase domain. As a result, the affinity of the receptor complex towards 
the intracellular signaling modulators “small mothers against decapentaplegic” 
(SMADs) is increased and leads to SMAD phosphorylation in a conserved SSXS 
motif at their C-term. Once the receptor-activated SMADs (R-SMADs) have been 
phosphorylated, they bind to SMAD4, and together shuttle to the nucleus, where 
they regulate the expression of different genes depending on the co-transcriptional 
partner engaged.  
Mammals express 8 different SMAD isoforms, classified in R-SMADs, common 
mediator SMAD (co-SMAD), and inhibitory SMADs (I-SMADs) (Massague et al., 
2005). R-SMADs comprise SMAD1, SMAD2, SMAD3, SMAD5 and SMAD8, and 
are activated by the TGFβ receptor complex to modulate gene expression. In ECs, 
TGFβ preferentially activates SMAD2 and SMAD3 by binding to ALK5-TGFβR2 
complex, while BMP triggers SMAD1, -5 and -8 phosphorylation and activation 
through ALK1- TGFβR2 (van Meeteren and ten Dijke, 2012). Thus, SMAD2 and 
SMAD3 are known as the canonical TGFβ-induced R-SMADs, while SMAD1, -5 and 
-8 are usually referred as BMP-induced R-SMADs. Interestingly, in ECs TGFβ can 
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also bind to ALK1 and promote SMAD1 phosphorylation (Goumans et al., 2003a; 
Goumans et al., 2002). The activation of either one or the other response can be 
modulated by the amount of TGFβ and by presence of the co-receptor endoglin, 
which has stimulatory activity on the TGFβ/ALK1 signaling axis while blocking the 
TGFβ/ALK5 one (Lebrin et al., 2004; Velasco et al., 2008). Thus, TGFβ co-receptors 
provide another level of signaling differentiation. Once phosphorylated at their C-
term, all R-SMADs interact with the co-SMAD SMAD4 and form an heteromeric 
complex that helps R-SMAD nuclear translocation and gene transcription 
(Massague, 2012). Finally, the activated mechanism is counteracted by the 
inhibitory activity of the I-SMAD, SMAD6 and SMAD7, whose mode of action differs 
between them. Indeed, SMAD7 blocks the TbRI activation, while SMAD6 prevents 
SMAD1 binding to SMAD4. Interestingly, TGFβ drives the expression of the I-
Figure 5. Canonical TGFβ/BMP signaling overview in ECs. Upon TGFβ or BMP ligand binding, 
TbRII phosphorylates and activates TbRI. TbRI, then, phosphorylates and activates down-stream 
target molecules, that are canonically represented by R-SMADs. ALK5 drives SMAD2 and 
SMAD3 C-term phosphorylation, while ALK1 phosphorylates SMAD1, -5 and -8. Subsequently, 
R-SMADs form a complex with SMAD4, translocate to the nucleus and, there, drive transcription 
of different sets of genes, like Serpine1 by SMAD2/3 and Id1 by SMAD1. Adapted from: Goumans 
MJ, Ten Dijke P. TGF-beta Signaling in Control of Cardiovascular Function. Cold Spring Harb 
Perspect Biol. 2017. 
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SMADs, providing a negative forward mechanism that helps terminating the elicited 
signaling (Goumans and Ten Dijke, 2017).  
In basal conditions, R-SMADs continuously shuttle in and out of the nucleus, 
until a TGFβ stimulus induces their C-term phosphorylation and nuclear 
accumulation (Hill, 2009). From the structural point of view, R-SMAD are formed by 
two globular domains named Mad-homology 1 and 2 (MH1 and MH2). The MH1 
domain lies at the N-term of all R-SMADs and of SMAD4 and mediates binding to 
DNA (Massague et al., 2005). Notably, SMAD2 does not have DNA binding 
capabilities, due to an additional short insert found in the binding region of its MH1 
domain. MH2, instead, is found at the C-term and serves as a docking site for 
different R-SMAD binding partners, such as cytoplasmic interactors, TGFβ-
activated receptor complex, and different co-transcriptional factors. Connecting 
MH1 with MH2, there is a linker region, which differs greatly among the different R-
SMADs and contains phosphorylation sites for different classes of protein kinases, 
like mitogen-activated protein kinases (MAPKs), cyclin-dependent kinases (CDKs), 
and glycogen synthase kinase (GSK), to cite few (Massague, 2012). Indeed, the 
linker region provides important regulatory sites that, once phosphorylated, promote 
SMAD binding to co-transcriptional partners and/or SMADs turnover. Accordingly, 
recent studies have proposed that Erk2 MAPK phosphorylates SMAD1 at S186, 
S195, S206, S214 and SMAD3 at S204, priming these proteins for subsequent E3-
ubiquitin ligases recruitment and proteosomal degradation (Figure 6) (Alarcon et 
al., 2009). The ubiquitin ligases responsible for terminating SMAD signaling are 
Smurf1 in case of SMAD1, and Nedd4L for SMAD3 (Gao et al., 2009; Zhu et al., 
1999). Hence, MAPKs-induced linker phosphorylation prevents SMADs activation 
by targeting them to destruction and occur without ligand stimulation. Interestingly, 
SMAD3 linker region is of primary importance for its transcriptional activity, since 
mutants lacking this region are not capable of driving gene expression even after 
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TGFβ stimulation and C-term phosphorylation (Velden et al., 2011). Indeed, it has 
been shown that, in the nucleus, CDK8/9 phosphorylate SMAD1 at S206 and S214 
in response to BMP, thus stimulating the recruitment of the co-transcriptional factor 
yes-associated protein (YAP) and target gene expression (Figure 6) (Alarcon et al., 
2009). Similarly, upon TGFβ, CDK8/9 phosphorylate SMAD3 at T179 and S208 and 
favor the binding to Pin1 co-transcription factor (Alarcon et al., 2009). Recruitment 
of transcriptional partners, then, prevents the subsequent GSK3β-mediated 
phosphorylation of SMAD1 (at T202 and S210) (Alarcon et al., 2009) and of SMAD3 
(at S204) (Wang et al., 2009a), thus impeding their subsequent interaction with E3 
ubiquitin ligases and proteosomal degradation (Aragon et al., 2011). In conclusion, 
by phosphorylating different residues in the linker region of SMAD1 and SMAD3 
upon BMP/TGFβ stimulation, CDK8/9 promote SMAD1 and -3 transcriptional 
activity and, at the same time, prevent their subsequent degradation by recruiting 
co-transcription factors that mask the sites targeted by GSK3β.  
Once in the nucleus, R-SMADs bind to the consensus sequence 5’-CAGAC-3’ 
on the DNA, known as “Smad binding element” (SBE) (Hill, 2016). SMAD1, instead, 
preferentially binds to CG-rich sequences that were found in the promoter regions 
of BMP-regulated genes, like Smad6, Id1 (Inhibitor of differentiation 1) and others. 
R-SMADs have low DNA-binding affinity and, thus, they need to synergize with co-
transcriptional modulators in order to control gene transcription, for example with 
members of the FoxO family, run-related transcription factor 2 (Runx2), ATF3 and 
several others (for a more detailed list, please refer to (Hill, 2016)). The final 
biological outcome of the signaling cascade can be therefore modulated not only by 
the amount and type of ligand, or by the receptors and the co-receptor activated, 
but also by the co-transcriptional regulator bound by the SMADs. 
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1.2.3 TGFβ signaling in ECs 
Genetic studies on TGFβ signaling members in mice and humans have shown 
the central importance of this molecular pathway in driving vascular development 
and vascular dysfunctions (Jakobsson and van Meeteren, 2013). Indeed, mouse 
models bearing genetic inactivation in one of the TGFβ/BMP signaling members 
(either ligands, or receptors, or SMADs) often die early during embryo development 
Figure 6. R-SMAD activation and turnover. 1) TGFβ or BMP stimulation results in SMAD3 and 
SMAD1 C-term phosphorylation, respectively. 2) Once in the nucleus SMAD1 is further 
phosphorylated in its linker region by CDK8/9 at S206 and S214. Similarly, SMAD3 is 
phosphorylated by CDK8/9 in T179 and S208. The phosphorylation at these residues co-
adiuvates SMAD binding to transcriptional co-activators, like YAP for SMAD1 and Pin1 for 
SMAD3. 3) At the same time, phosphorylation at these residues primes R-SMADs for an 
additional linker phosphorylation mediated by GSK3β (S204 in SMAD3, and T202 and S210 in 
SMAD1), which are then recognized by ubiquitin ligases and target R-SMAD for degradation. 
However, R-SMAD can also undergo linker phosphorylation without ligand stimulation. In this 
case, MAPK-mediated phosphorylation contributes to maintain R-SMAD expression levels low, 
as it targets them to degradation. Taken from: Macias MJ, Martin-Malpartida P, Massague J. 
Structural determinants of Smad function in TGF-beta signaling. Trends Biochem Sci. 
2015;40(6):296-308 
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and show cardiovascular alterations and impaired pericyte and vSMC recruitment 
(reviewed in (Goumans and Ten Dijke, 2017)). 
 TGFβ can exert multiple and divergent functions on ECs. For example, TGFβ 
was shown to promote but also to inhibit angiogenesis, and this apparently opposite 
role can be due to different causes, like the concentration of the ligand, the duration 
of the treatment, cellular density and the types of receptors expressed on the cellular 
membrane (Goumans and Ten Dijke, 2017). TGFβ can indeed bind to two different 
TbRI in ECs: ALK5 (known also as TGFβRI) or, with lower affinity, ALK1 (or Acvrl1), 
the last one being expressed strictly in ECs (Figure 5).  
TGFβ signaling through ALK5-TGFβR2 complex stimulates the phosphorylation 
of SMAD2 and SMAD3 and, in turn, induces the expression of PAI-1, which 
negatively regulates EC migration (Dennler et al., 1998; Goumans et al., 2002). 
Moreover, TGFβ-ALK5 signaling axis arrests cell proliferation and cell migration by 
upregulating the expression of cell-cycle regulating genes, such as p21 and p15 
(Zhang et al., 2016). On the reverse side, inhibiting ALK5 activity with the specific 
inhibitor SB-431542 stimulates EC proliferation and sheet formation of mouse 
embryonic cultured ECs (Watabe et al., 2003). SB-431542 treatment of ECs, 
moreover, up-regulates Claudin-5 expression, thus conferring a role for ALK5 in 
controlling vascular permeability. Interestingly, clustering of VE-cadherin is essential 
for proper TGFβ signaling in ECs, as cells lacking VE-cadherin expression display 
reduced R-SMADs phosphorylation and signaling (Rudini et al., 2008). Moreover, 
TGFβ signaling activation is impaired in VE-cadherin positive ECs upon junctional 
dismantling, thus suggesting that the clustering of VE-cadherin occurring in 
confluent EC monolayer is essential to trigger a proper TGFβ signaling activation. It 
has to be noted that VE-cadherin interacts with all the TGFβ-receptor complex 
components, that are ALK5, ALK1, TGFβR2 and endoglin. Thus, TGFβ signaling 
through ALK5 contributes to maintain ECs in quiescent state by inhibiting cell 
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proliferation, migration and angiogenesis, and plays a role in controlling ECs 
permeability. 
Nevertheless, studies have shown that TGFβ can also activate ALK1-mediated 
signaling cascade and induce SMAD1/5 phosphorylation, leading to EC 
proliferation, migration and tube formation (Goumans et al., 2003b). Hence, TGFβ 
can also promote angiogenesis, and it does it by inducing ALK1 signaling cascade. 
Accordingly, EC migration and tube formation are partly driven by Id1 expression, 
which is stimulated by TGFβ-ALK1 signaling axis (Goumans et al., 2002). These 
indications support a pro-angiogenic role of TGFβ signaling through ALK1, and set 
the TGFβ-ALK1 signaling axis as a positive regulator of EC proliferation and 
migration. 
Although TGFβ-ALK5 and TGFβ-ALK1 signaling cascade result in opposite 
biological outputs, they have been shown to interact and regulate each other. 
Accordingly, ECs lacking ALK5 expression display not only an impaired TGFβ-ALK5 
signaling, but also an impaired TGFβ-ALK1 activity, as ALK5 is required for ALK1 
recruitment into the TGFβ receptor complex (Goumans et al., 2003b). Nevertheless, 
ALK1 can negatively regulate ALK5-induced R-SMAD signaling. Thus, balancing of 
ALK1 and ALK5 signaling in ECs is required for finely modulating EC functions and 
homeostasis. Controlling this tight balance intervene the amount and duration of the 
signaling, but also the expression of the co-receptor endoglin. Endoglin is 
abundantly expressed in ECs, especially in highly proliferating ones (van Meeteren 
and ten Dijke, 2012). Studies have shown that endoglin can potentiate the TGFβ-
ALK1 axis and also inhibit the TGFβ-ALK5 signaling cascade (Lebrin et al., 2004; 
Velasco et al., 2008). Accordingly, pancreatic tumor mouse models heterozygous 
for endoglin showed an increased expression of the ALK5-induced target genes Fn1 
and Serpine1 (Anderberg et al., 2013). 
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Of note, members of the BMP family of ligands are also required for proper 
vascular development, as their genetic inactivation can result in defective 
cardiovascular development and impaired angiogenesis. Among the ligands, BMP2 
and BMP4 were shown to positively regulate EC proliferation and migration, and 
induce angiogenesis (Medici et al., 2011). BMP9, instead, inhibits VEGF-stimulated 
angiogenesis and FGF2-induced EC proliferation and migration (Scharpfenecker et 
al., 2007).  
In conclusion, both TGFβ and BMP signaling are crucial regulator of vascular 
development and homeostasis and, deregulation in their signaling activity might 
result in vascular pathologies, like arteriovenous malformation (AVMs), remodeling 
of retinal vasculature, cardiac fibrosis, improper heart valve formation, CCM and 
endothelial tumors (hemangiomas) (Goumans and Ten Dijke, 2017). Importantly, 
TGFβ and BMP signaling have been proposed as master drivers of EndMT, and 
further explanation will be provided in the following sections.  
1.2.4 TGFβ-driven EndMT 
EndMT is a biological process through which ECs, under the continuous 
exposure to TGFβ or BMP ligands (but also Wnt and Notch), transdifferentiate into 
mesenchymal-like cells (Gong et al., 2017). All the three TGFβ isoforms (TGFβ1, -
2 and -3), indeed, have been reported to stimulate EndMT in vitro and in vivo, 
although TGFβ2 has been shown to be the prominent inducer of embryonic EndMT 
that occurs during heart-valve formation (Azhar et al., 2009; Medici et al., 2010). 
TGFβ1 or TGFβ3 null mice, instead, developed normal heart cushions, and similar 
results have been recapitulated in chick embryos (Azhar et al., 2009; Boyer et al., 
1999; Camenisch et al., 2002). It seems then that TGFβ1 and TGFβ3 do not to play 
a role during the EndMT observed in the developing heart of mice and chicks. Yet, 
TGFβ3 has been reported to promote post-EndMT invasion and migration of cells 
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in the chick embryo (Boyer et al., 1999), while TGFβ1 is involved in the EndMT-
driven cardiac fibrosis (Zeisberg et al., 2007b).  
In vitro studies have shown that EC progenitors can undergo phenotypic 
transformation into smooth-muscle-like cells once stimulated with TGFβ1, and the 
resulting EndMT process is driven by ALK5-mediated signaling (Moonen et al., 
2010). Moreover, TGFβ1 can promote EndMT of adult coronary ECs and of a mouse 
microvascular endothelial cell line (MMEC) (Li et al., 2009; Zeisberg et al., 2007b). 
Interestingly, EC-specific ALK5 null mice fail to undergo EndMT during cardiac 
development, and specific inhibition of ALK through SB-431542 resulted in defective 
EndMT response of cultured ECs (Sridurongrit et al., 2008; Watabe et al., 2003). 
Later evidence suggested that TGFβ2 promotes EndMT by activating both ALK2 
and ALK5, which co-immunoprecipitate and activate both R-SMAD signaling 
pathways (Medici et al., 2010). One year later, by attempting to unravel the 
molecular mechanism through which TGFβ2 induces EndMT, the same group 
showed that ECs undergoing transdifferentiation displayed Snai1 enhanced 
expression. This, in turn, resulted in decreased VE-cadherin and CD31 expression, 
while FSP-1 and aSMA were found to be up-regulated (Medici et al., 2011). 
However, Snai1 alone overexpression was not capable of inducing an EndMT 
phenotype, and, other studies have indeed reported that many transcription factors 
are involved in the activation of an effective EndMT response, like Snai2, zinc finger 
E-box-binding homeobox-1 (ZEB-1), Smad-interacting protein-1 (SIP-1), lymphoid 
enhancer-binding factor-1 (LEF-1), and Twist1 (Medici et al., 2010). 
Interestingly, several ligands belonging to the BMP family have also been shown 
to positively regulate the EndMT differentiation. For example, BMP2 and BMP4 
signaling through ALK2 could induce an EndMT response during heart valve 
formation, while specific inhibition of ALK2 impaired the activation of this response 
(Medici et al., 2010). Moreover, genetic deletion of either BMP2, BMP4 or ALK2 
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prevented embryonic EndMT due to a failure in the heart valve formation (Liu et al., 
2004; Ma et al., 2005). Conversely, BMP7 was shown to inhibit EndMT through the 
SMAD1/5/8 signaling pathway activated by ALK2 (Zeisberg et al., 2007b). Although 
these seem to be contradictory results, they strongly suggest that the EndMT 
response can be differentially modulated in response to distinctive TGFβ/BMP 
ligands, probably thanks to the enrolment of different SMAD co-transcriptional 
factors. Thus, further studies are required to better define the molecular 
mechanisms driven by different TGFβ/BMP ligands under context-specific 
conditions. 
1.2.5 Physiological EndMT  
The first reported case of EndMT was described in 1975, when Markwald and 
colleagues identified it as a crucial differentiation process necessary for the cardiac 
valve formation occurring in embryo development (Markwald et al., 1975). During 
heart development, two distinct types of cardiac cells are originated from 
cardiogenic mesodermal cells, named myocardial cells and endocardial cells 
(Yamagishi et al., 2009). Endocardial cells are actual ECs expressing EC-specific 
markers, like VE-cadherin, CD31, Tie1 and Tie2. They take part in the generation 
of cardiac valves in the atrioventricular (AV) canal, which divides the atria from the 
ventricles, and in the outflow tract (OFT), whose function is to connect the ventricles 
to the aortic sac and guarantee a correct blood flow (Figure 7). 
At initial stages, cushions found in the AV and OFT are formed by an inner layer 
of myocardial cells and an outer layer of endocardial cells, separated by a stratum 
of ECM known as cardiac jelly (Figure 7). Myocardial cells release BMP2 as a 
triggering signal that elicits an autocrine endocardial TGFβ production (Ma et al., 
2005; Rivera-Feliciano and Tabin, 2006; Sugi et al., 2004). TGFβ, in turns, 
stimulates endocardial/ECs to undergo EndMT, acquire mesenchymal phenotype, 
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delaminate from the endocardium, migrate toward the cardiac jelly and contribute to 
form cushions in the AV region and in the OFT, finally originating cardiac valves 
(Yamagishi et al., 2009). 
As previously discussed, all the three TGFβ isoforms have been implicated in 
the endocardial cushion formation at different levels. Indeed, as nicely reviewed by 
Yamagishi and colleagues, TGFβ1 expression is initially found in the endocardium 
at E8, and when the EndMT process begins, it is mainly retrieved in the ECs forming 
the cardiac cushion tissue (Yamagishi et al., 2009). TGFβ2, instead, is expressed 
both in the OFT and AV during cushion formation. Its importance in driving heart-
valve EndMT has been repeatedly shown, both in vitro and in vivo experiments, and 
mice lacking TGFβ2 expression fail to form the AV cushion (Millan et al., 1991). After 
the EndMT takes place, TGFβ3 is expressed in the endocardium and in 
mesenchymal cells (Millan et al., 1991). In vitro studies have shown that TGFβ3 
stimulates an EndMT phenotype only in “pre-activated AV ECs”. Thus, TGFβ3 
Figure 7. Endocardial cushion formation is driven by EndMT. During embryo development, 
the heart valves originate from endocardial cushions in the atrioventricular (AV) zone and in the 
outflow tract (OTF). These cushions are formed by a layer of myocardial cells and one of 
endocardial cells, divided by a cardiac jelly composed of ECM. Endocardial cells undergo EndMT 
to form the cushions under TGFβ-driven stimulation. Taken from: Goumans MJ, Ten Dijke P. 
TGF-beta Signaling in Control of Cardiovascular Function. Cold Spring Harb Perspect Biol. 2017 
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seems to be required only after the onset of EndMT (Boyer et al., 1999; Camenisch 
et al., 2002). In vivo studies have revealed that both TGFβ1- and TGFβ3-null mice 
do not develop cardiac cushion formation defects (Azhar et al., 2009), although 
TGFβ1 knock-out (KO) embryos born from TGFβ1-/- mothers display disorganized 
AV valves along with other cardiac defects (Letterio et al., 1994). Instead, cardiac 
valve development strictly requires TGFβ2 expression, as shown by KO mice 
experiments (Azhar et al., 2009). Taken together, these results demonstrate that 
the three mammalian isoforms of TGFβ are involved in the heart-cushion EndMT, 
but probably are expressed by myocardial and/or endocardial cells during different 
developmental steps and their spatiotemporal expression needs to be better 
clarified. 
Moreover, BMP ligands have also been described as regulators of heart-
cushion EndMT. For example, heart-specific BMP2 KO mice are characterized by 
impaired AV cushion formation, but normal OFT (Ma et al., 2005). Also, specific 
BMP4 deletion in the heart resulted in defective OFT valve formation, while BMP5, 
-6, or -7 null mice display fairly normal heart development (Liu et al., 2004; 
Yamagishi et al., 2009). 
1.2.6 Pathological EndMT 
1.2.6.1 EndMT during fibrosis in the heart, kidneys and lungs 
Fibrosis is a condition wherein continuous exposure to inflammatory cytokines 
stimulates fibroblasts differentiation into myofibroblasts, which, in turn, promote 
ECM production, tissue hardening, and ultimately lead to organ structural and 
functional changes and failure. (Myo)fibroblasts can originate from a pool of locally 
resident interstitial fibroblasts, but can also derive from epithelial cells undergoing 
transdifferentation. Interestingly, in the past years ECs have also been pointed as a 
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source of fibroblasts during tissue fibrosis in the heart, kidneys, liver and lungs (van 
Meeteren and ten Dijke, 2012). 
A pioneer study in 2007 has demonstrated that EndMT contributes to cardiac 
fibrosis. By using lineage-tracing cell systems under the endothelial specific Tie1 
promoter, Zeisberg and colleagues have shown that around 30% of cardiac 
fibroblasts have EC origin and they arise from an EndMT process driven by 
TGFβ1/SMAD3 signaling axis (Zeisberg et al., 2007b). In the same study, the 
authors have also proposed that BMP7 expression can revert the TGFβ1-induced 
EndMT both in vitro and in vivo. More recently, administration of an orally active 
ALK5 inhibitor, that prevent the receptor kinase activity, resulted in reduced cardiac 
fibrosis and ameliorated cardiac output, although cardiac dilation was also observed 
(Engebretsen et al., 2014). Moreover, the TGFβ co-receptor endoglin has been 
linked to cardiac fibrosis promotion, since endoglin-deficient mice showed a reduced 
cardiac fibrosis in a mouse model where heart failure is induced by pressure-
overload (Kapur et al., 2012).  
EndMT has been proven to drive kidney fibrosis too. By using three different 
animal mouse models of chronic kidney disease, Zeisberg and colleagues have 
indeed reported that around 30 to 50% of activated fibroblasts express the 
endothelial marker CD31 along with fibroblast-specific markers (Zeisberg et al., 
2008). As EndMT is often triggered by TGFβ/BMP signaling pathways, researchers 
have then focused on their possible involvement in kidney fibrosis development. 
Interestingly, studies have documented that SMAD3 conditional KO (cKO) mice do 
not develop kidney fibrosis, and SMAD3 inhibitors are be able to delay the 
development of diabetic nephropathy by blocking EndMT (Sato et al., 2003; van 
Meeteren and ten Dijke, 2012). Moreover, Li and colleagues have reported that 
exposure of primary renal cultured ECs to TGFβ1 reduced VE-cadherin and CD31 
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expression while promoting aSMA increase, thus suggesting that TGFβ can 
promote EndMT in the kidney (Li et al., 2009).  
Moreover, EndMT has been associated with lung fibrosis development. By 
inducing lung fibrosis in a lineage-tracing animal model system, Hashimoto and 
colleagues have indeed demonstrated that activated fibroblasts derive from ECs 
during a lung fibrotic response (Hashimoto et al., 2010). Interestingly, TGFβ and 
Ras signaling were reported as mediator of this EndMT. 
All these indications, along with others, support the idea that TGFβ signaling is 
deeply involved in cardiac, renal and lung fibrosis, and understanding how it 
mechanistically regulates EndMT could be of primary importance for improving 
currently available treatments. 
1.2.6.2 EndMT in cancer, FOP and CCM diseases 
A tumor mass consists of cells having a malignant behavior, embedded in a 
stroma of ECM and cells of various origins (Wang et al., 2017). In order to grow and 
expand, tumor cells require a favorable environment that fosters their proliferation 
and help them invading nearby tissues. 
Within the tumor stroma, contributing to generate an advantageous 
environment, there are fibroblasts, and, in particular, a sub-population of them 
named cancer-associated fibroblasts (CAFs). CAFs are considered key promoters 
of tumor growth and progression, and consist of activated fibroblasts, whose newly 
acquired phenotype contributes to the oncogenic transformation of epithelial cells 
within the tumor. The population of CAFs derives from cells of different origins, 
mainly from locally resident fibroblasts, but also cells composing the basal 
membrane or periadventitial cells. Interestingly, a 2008 work by Zeisberg and 
colleagues has revealed for the first time that CAFs can also have an endothelial 
origin (Zeisberg et al., 2007a). Indeed, by performing immunostaining of tumor 
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tissues coming from a melanoma mouse model, the authors found that tumor stroma 
fibroblasts were positive both for mesenchymal markers (FSP1 and aSMA) and for 
the endothelial marker CD31. In particular, around 40% of FSP1 and 10% aSMA 
positive fibroblasts were also co-expressing CD31, thus suggesting an endothelial 
origin. To prove this hypothesis, the authors employed a lineage-tracing cell system, 
where the expression of Cre recombinase enzyme is under the control of the 
endothelial specific promoter Tie2 (Figure 8). Tie2Cre mice were then crossed with 
Rosa26LacZ mice, so that, once the Cre recombinase expression was induced, ECs 
were permanently “labeled” and could be traced even after a presumed 
transdifferentiation. Thanks to this system, Zeisberg and colleagues observed that 
many CAFs were indeed of endothelial origin, and strongly suggested that ECs 
generated CAFs through an EndMT switch. The authors have also shown that 
sustained exposure to TGFβ1 of cultured ECs generated cells positive for FSP1, 
Figure 8. Lineage-tracing system strategy to label ECs undergoing EndMT. In order to 
specifically express Cre recombinase only in the endothelium, Cre gene is placed under the 
control of the endothelial-specific promoter Tie2. Thus, the Rosa26 reporter vector mediates lacZ 
expression once the loxP sites flanking a stop codon are genetically excised by Cre recombinase 
expressed in ECs. As a result, the irreversible expression of lacZ marker occurs only in ECs, and 
this allows to trace back activated fibroblasts to ECs that underwent EndMT. Taken from: Potenta 
S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. 
Br J Cancer. 2008;99(9):1375-9 
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again suggesting that endothelial-derived CAFs could originate from ECs 
undergoing EndMT. Further evidence of ongoing EndMT in tumor context comes 
from a 2013 work from Pietras’ group (Anderberg et al., 2013). In this very 
interesting paper, the authors generated pancreatic tumor mouse models 
heterozygous for the TGFβ co-receptor endoglin (RIP1-Tag2;Eng+/-) and observed 
an increased tumor dissemination in mutant mice compared to control ones. The 
augmented metastatic spread was not due to an increased tumor vessel 
permeability or density, rather it could be accounted for an ongoing EndMT. Indeed, 
the authors found a markedly reduced expression of the endothelial specific marker 
CD31 paralleled by an increased number of aSMA positive ECs in RIP1-Tag2;Eng+/- 
mice. Moreover, they observed a significantly increased expression of Twist1 and 
of the ALK5-induced EndMT genes Fn1 and Serpine1 specifically in ECs isolated 
from RIP1-Tag2;Eng+/- mice. Very interestingly, the increased tumor cell 
transmigration observed upon endoglin KO in ECs was strongly reduced by using 
TGFβRI specific inhibitors. In conclusion, these data suggested that ALK5-mediated 
EndMT in RIP1-Tag2;Eng+/- contributes to metastatic spread and, thus, EndMT is 
emerging as a driving process that favors tumor progression. 
Fibrodysplasia ossificans progressive (FOP) is a sever genetic disorder in which 
muscle and ligaments are progressively replaced by bone tissue, in a process 
known as heterotypic ossification (HO). One of the leading causes of FOP disease 
is represented by an autosomal dominant activating mutation of the BMP TbRI ALK2 
(Shore et al., 2006). Therefore, ALK2 and downstream SMAD signaling are 
continuously activated. Interestingly, a transgenic mouse model for HO, wherein 
ALK2 is constitutively activated, showed that ectopic bone cells expressed also 
endothelial-specific markers, like VE-cadherin, Tie1, Tie2 and von Willebrand Factor 
(vWF) (Medici et al., 2010). Subsequent in vivo analyses, using lineage-tracing 
systems, have clearly demonstrated that mesenchymal cells responsible for HO at 
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early stage disease were of endothelial origin, thus proving that EndMT is a key 
molecular mechanism that drive ossification in FOP (Medici et al., 2010). 
Moreover, in the past years, our group has discovered that EndMT is the driving 
mechanism that contributes to vascular lesion development in CCM pathology 
(Maddaluno et al., 2013). This devastating disease mainly affects the brain 
microcirculation, as it induces the formation of enlarged, irregular, leaky and multi-
lumen blood vessels that are prone to rupture and can lead to brain hemorrhages. 
CCM can occur both in a sporadic or familial form, and etiological causes for familial 
CCM are loss-of-function mutations in any of the three CCM genes (CCM1, CCM2 
or CCM3). We reported for the first time that brain lesions in CCM are formed by 
ECs undergoing EndMT, as shown by the acquisition of mesenchymal (FSP1, 
aSMA, N-cadherin, Snai2 and Krüppel-like factor 4 (KLF4)) and stem cell markers 
(CD44 and Id1), paralleled by a loss of Claudin-5 expression (Maddaluno et al., 
2013). We further found that deletion of CCM1 led to the activation of the MEKK3-
MEK5-ERK5-MEF2 signaling cascade, resulting in a strong upregulation of KLF4 in 
ECs in vivo (Cuttano et al., 2016). KLF4, in turn, causes BMP6 production and 
BMP/SMAD1 signaling activation. Interestingly, the EndMT switch observed in 
CCM1 deficient mice is promoted by both KLF4 transcriptional activity and KLF4-
dependent BMP signaling activation, because their inhibition through genetic or 
pharmacological approaches markedly reduced CCM lesion development and 
progression. Remarkably, genetic ablation of KLF4 in CCM1 KO mice prevented 
their death, indicating that KLF4 could be a crucial therapeutic target for the 
treatment of CCM (Cuttano et al., 2016). 
Taken together, these reports have shown a clear correlation between the 
EndMT switch occurring in numerous pathologies and the TGFβ/BMP signaling. 
Future studies will then investigate how to prevent pathological EndMT by 
modulating TGFβ/BMP signaling and, thus, provide novel therapeutic strategies. 
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1.3 Yes-Associated Protein (YAP) 
1.3.1 The discovery of YAP as a target of the Hippo signaling pathway 
The Hippo signaling pathway is a serine-kinase cascade and the first YAP 
regulatory pathway described. The different proteins composing the pathway core 
were discovered individually in Drosophila melanogaster, through genetic screening 
aiming at identifying novel tumor suppressors and genes regulating organ growth 
(Figure 9). The first one to be identified was the kinase Warts (Wts) in 1995, 
encoded by lats gene (Xu et al., 1995), and, few years later, a similar screening 
approach allowed the identification of Salvador (Sav) as a Wts adaptor protein 
(Tapon et al., 2002). Subsequently, in 2003, four different groups found Hippo as 
the kinase responsible for Wts phosphorylation and activation and described that 
Hippo loss-of-function approaches led to increased proliferation and apoptosis 
overcome (Harvey et al., 2003; Jia et al., 2003; Pantalacci et al., 2003; Wu et al., 
2003). The last component discovered was the Wts cofactor Mob as tumor 
suppressor (Mats) (Lai et al., 2005). Notably, loss of any of the Hippo core 
components resulted in uncontrolled cell proliferation, reduced apoptosis and tissue 
overgrowth. In addition to this, the discovery of their physical and functional 
interaction led to the establishment of a novel pathway named after the commonly 
shared phenotype of overgrowth resembling a hippopotamus (Hippo), where the 
kinase Hippo phosphorylates and activates the downstream Wts kinase in concern 
with Sav and Mob co-adiuvators. By that time, however, the downstream target was 
not yet identified. 
It was not until 2005 that the Hippo core components Wts, Sav and Hippo were 
linked to the downstream effector Yorkie (Yki) (Huang et al., 2005). In this milestone 
paper, Huang and colleagues showed that Wts kinase binds to and phosphorylates 
Yki, thereby inhibiting the transcription of down-stream target genes. Interestingly, 
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Yki overexpression resulted in increased cell proliferation and tissue overgrowth, 
phenocopying what previously observed in loss-of-function analysis of Wts, Sav and 
Hippo. In light of these results, the authors concluded that the Hippo signaling 
pathway is a negative regulator of Yki transcriptional activity and proposed Yki as a 
novel potential oncogene.  
Intriguingly, the core components of the Hippo signaling cascade are conserved 
throughout metazoan, and this includes mammals as well. Parallel studies 
performed in human and mouse cell lines allowed the identification of the Hippo 
mammal orthologues, illustrated in Figure 9. Hippo orthologue are represented by 
Mammalian STE-20 kinase 1 and 2 (Mst1/2); Sav1, also known as hWW45, is the 
orthologue of Sav; Msp-one-binder 1/2 (Mob1/2) are the orthologue of Mats; Large 
tumor suppressor 1 and 2 (LATS 1/2) are the orthologue of Wts; and Yes-associated 
protein (YAP) together with transcriptional activator with a PDZ-binding domain 
(TAZ) are Yki mammal orthologues. Very interestingly, these proteins share a high 
degree of homology with their correspondent protein and, functionally, human 
LATS1, MATS1, MST2 and YAP can rescue loss-of-function mutations of their 
respective orthologues in D. melanogaster (Edgar, 2006). Moreover, subsequent 
studies showed that the Hippo signaling pathway functions in a similar way in 
mammals as in Drosophila (Camargo et al., 2007; Dong et al., 2007; Hao et al., 
2008; Zhao et al., 2007), corroborating the importance of this pathway in controlling 
tissue growth and preventing cancer development. 
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1.3.2 YAP protein structure and main functions 
YAP is a 65 kDa protein, initially identified by Marius Sudol in 1994 as an 
interactor of the tyrosine-kinase c-Yes (Sudol, 1994; Sudol et al., 1995a). YAP SH3-
binding motif was shown to mediate YAP-c-Yes interaction, but little is known about 
the biological function of this interaction. Functionally, YAP is the orthologue of the 
Drosophila protein Yki together with TAZ and, like Yki, it is a downstream effector of 
the well-conserved signaling cascade Hippo pathway (Huang et al., 2005; Zhao et 
al., 2007).  
Humans possess 8 different isoforms of YAP, broadly divided in two main 
classes containing either one (YAP1) or two WW domains (YAP2) (Gaffney et al., 
2012; Komuro et al., 2003) (Figure 10). These domains are composed of around 
D. melanogaster Mammals 
Figure 9. The core components of the Hippo signaling pathway in D. melanogaster and 
mammals. Once triggered, the Hippo kinase (MST1/2 in mammals) phosphorylates and activates 
the downstream effector kinase Wts (LATS 1/2) through the aid of the co-activators Sav (SAV1) 
and Mob (MOB1/2). Activated Wts, in turns, phosphorylates Yorkie (YAP or TAZ in mammals) in 
several serine residues, promotes its cytoplasmic retention and negatively regulates Yorkie co-
transcriptional activity. To simplify the parallelism between D. melanogaster and mammal Hippo 
pathway, orthologs are illustrated with the same color. Adapted from: Varelas, X. Development 
2014;141:1614-1626 
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30 to 35 amino acids comprising two conserved tryptophan (W) residues and 
mediate binding to partner proteins bearing a proline-rich motif PPxY (where P 
stands for proline, x for any amino acid and Y for tyrosine) (Sudol et al., 1995a; 
Sudol et al., 1995b). PPxY motif is found in many different proteins, like 
transcriptional factors and proteins mediating YAP localization and activity. 
Interestingly, many components of the Hippo signaling pathway (including YAP 
itself) bear this motif, and they employ it to interact with YAP and regulate its 
localization and activity. Furthermore, this motif is found in SMADs, like SMAD1 and 
-3, and studies have documented their importance in mediating the binding between 
YAP and SMADs (Aragon et al., 2011). 
At YAP C-term lies a PDZ-binding motif, through which proteins carrying a PDZ 
domain interact with YAP. These proteins can be transmembrane or cytoskeleton 
proteins (Ye and Zhang, 2013).  
Figure 10. Regulatory domains of YAP1, YAP2, Yki and TAZ. Comparison between YAP1 and 
YAP2 isoforms with Yki and TAZ show that all of them contain WW domains and a TEAD binding 
domain. Other important domains are the transactivation at the C-term found on YAP1/2 and on 
TAZ, together with a PDZ-binding motif. YAP1 and YAP2 possess also a prolin-rich motif at their 
N-term. The residues important for YAP cytoplasmic retention are also illustrated. Details about 
the function of each domain are explained in the main text. Taken from: Robert Neil Judson “The 
Role of Yes-Associated Protein (YAP) in Skeletal Muscle Satellite Cells and Myofibres” 
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Activated LATS1/2 phosphorylates YAP in five different serine (S) residues: 
S61, S109, S127, S164, and S381 (Basu et al., 2003; Zhao et al., 2007). Among 
these residues, S127 is probably the most important to regulate YAP localization, 
since phosphorylated S127 increases YAP binding affinity to 14-3-3 protein and 
causes its cytoplasmic retention (Basu et al., 2003). Additionally, S127 can be 
phosphorylated by Akt kinase, resulting in cytoplasmic sequestration by 14-3-3 too 
(Basu et al., 2003). Phosphorylation at S381 by LATS1/2, instead, is involved in 
YAP turnover as it promotes further phosphorylation at S384 and S387 by CK1d/e 
kinase and ubiquitination by SCFbeta-TRCP E3 ligase, leading ultimately to YAP 
proteosomal degradation. These residues lye within the transactivation domain 
(TAD) located at the C-term of both YAP and TAZ, but missing in Yki. Thus, 
YAP/TAZ and Yki share evolutionarily conserved domains, functions and regulatory 
pathway, although some differences have evolved to finely tune YAP/TAZ 
localization and turnover in mammals. By substituting the five serine residues S61, 
S109, S127, S164, and S381 with alanine (YAP 5SA), Zhao and colleagues 
demonstrated that YAP 5SA localizes predominantly in the cell nucleus, where it 
strongly promotes cell proliferation and loss of contact-inhibition growth. These 
indications support the idea that YAP is an oncogene and the Hippo pathway work 
to prevent oncogenic transformation by negatively regulating YAP (Zhao et al., 
2009; Zhao et al., 2007).  
One of the key molecular functions of YAP is to promote gene transcription by 
serving as a transcriptional co-activator (Yagi et al., 1999). Since YAP lacks a DNA 
binding-motif and cannot bind DNA on its own, joined effort from several groups has 
been made to identify transcriptional factors interacting with YAP. These factors 
include, among others, b-catenin, MYC, p53, p73, SMAD1/2/3/4 and RUNX 1/2/3 
(reviewed in (Varelas, 2014)). Consequently, YAP can regulate an array of diverse 
biological functions depending on the transcriptional partner engaged, as further 
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discussed in section 1.3.5. The most characterized class of YAP transcriptional 
partners is however represented by TEAD protein family (Scalloped in Drosophila), 
which includes TEAD1-4. This protein family bind to YAP through the TEAD-binding 
domain lying at YAP N-term to promote the transcription of proliferation genes and 
restrain apoptosis and differentiation (Vassilev et al., 2001; Wu et al., 2008; Zhang 
et al., 2008; Zhao et al., 2008). Indeed, YAP-TEAD binding inhibition results in 
reduced proliferation of the epidermis and of cardiomyocytes in mice (Schlegelmilch 
et al., 2011; von Gise et al., 2012). This supports the idea that YAP-TEAD interaction 
is crucial for YAP tissue growth promoting activity and genome-wide studies 
corroborated the importance of this interaction, since most of YAP and TEAD 
genomic loci are in common (Stein et al., 2015; Zanconato et al., 2015). 
As mentioned at the beginning of this section, Yki has two mammal orthologs, 
YAP and TAZ. Both proteins are regulated by the Hippo signaling and function as 
downstream co-transcriptional factors. TAZ structure is quite similar to the one of 
YAP, reaching a 46% identity in their aminoacidic sequence (Zhao et al., 2008). 
Nevertheless, differences exist (Figure 10), which can partially explain the different 
phenotypes displayed by total YAP KO mice versus total TAZ KO mice (discussed 
in the following section), suggesting that YAP and TAZ do not compensate for each 
other’s functions. 
1.3.3 YAP and the Hippo pathway in mammals: regulators of development, 
tissue homeostasis, tissue regeneration, and cancer 
Given the importance of Yki and Hippo signaling pathway in regulating cell 
proliferation, apoptosis and organ growth in D. melanogaster (Huang et al., 2005), 
it is not surprising that researchers began to extensively characterize the role of 
YAP and of the Hippo core components in mammals. Studies on total YAP KO mice 
revealed that mutated embryos die around E8.5, due to defects in chorioallantoic 
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fusion, yolk sac vasculogenesis and body axis elongation (Morin-Kensicki et al., 
2006), reinforcing the idea that YAP is required for proper control of tissue growth 
at early stage development. Conversely, total TAZ KO mice were only partially 
embryonic lethal, with survivors showing polycystic kidneys and lung emphysema 
(Tian et al., 2007). Thus, YAP and TAZ functions are required for proper embryo 
development and they cannot fully compensate for each other’s biological activities.  
In order to avoid embryonic lethality and to better characterize how YAP controls 
organ size, two independent groups analyzed YAP biological functions in mammals 
by utilizing inducible liver-specific YAP overexpression approaches (Camargo et al., 
2007; Dong et al., 2007). Both studies showed that overexpression of YAP caused 
liver overgrowth due to a boost in cell proliferation rather than an increase in cell 
size. The observed phenotype was due to YAP aberrant activity that promoted 
resistance to apoptosis, and could be rescued after hampering YAP overexpression, 
thus indicating that YAP contributes to regulate liver size. Notably, following reports 
on loss-of-function mutations in the Hippo core components resulted in a similar 
phenotype (Lu et al., 2010; Nishio et al., 2016; Zhou et al., 2009). These seminal 
works showed that YAP is a key regulator of liver growth. Shortly after, other studies 
showed that a correct YAP activity is required for proper tissue growth in skin 
(Schlegelmilch et al., 2011), pancreas (Zhang et al., 2013) and neural tube (Cao et 
al., 2008).  
Conversely, depletion of YAP expression specifically in the gut did not alter 
normal intestinal development or homeostasis (Cai et al., 2010). This study, instead, 
pointed YAP as an important regulator of intestinal tissue regeneration following 
injury. Moreover, in the heart, where cardiomyocytes stop proliferating a week right 
after birth and cardiac injuries are healed through the formation of fibrotic scars 
rather than through cardiomyocyte proliferation, YAP has been found to promote 
cardiomyocyte proliferation following heart injury (von Gise et al., 2012; Xin et al., 
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2013). This finding not only define a prominent role for Hippo and YAP in cardiac 
tissue regeneration, but also opened up novel possible ways to improve heart 
regeneration after injury. The biological functions of YAP in mammals, thus, seem 
to be tissue and context-specific and further studies are required to better define its 
role in different mechanisms. Yet YAP is emerging as an important regulator of 
many biological processes required for proper tissue development and 
homeostasis, making it a very interesting clinical target in a variety of disorders. 
Consistently with its pro-proliferative and anti-apoptotic effects, the activity of 
YAP has also been linked to cancer development and tumor progression. Indeed, 
overexpressing YAP in liver results in hepatocellular carcinoma development 
already after 3-10 weeks (Camargo et al., 2007; Dong et al., 2007). It should be 
noted that hepatocellular carcinoma can also arise upon loss-of-function mutation 
in the Hippo core components, even if this takes much longer to develop. Hence, 
other pathways along with the Hippo pathway seem to be required to finely control 
YAP localization and transcriptional activity, as it will be better explained in the 
section 1.3.4. Further studies have shown that overexpression of YAP in MCF10A 
cells caused hyperproliferation and loss of contact-inhibition growth (Overholtzer et 
al., 2006). Moreover, these mutated cells became more invasive and migratory and 
showed altered expression of epithelial markers, letting the authors conclude that 
YAP actively promotes EMT and cellular transformation. As discussed in section 
1.2.1, EMT is emerging as a key regulatory mechanism that drives tumor 
development and metastatic dissemination. Thus, one way through which YAP can 
contribute to tumor progression is being a positive EMT regulator. Subsequent 
similar findings supported this hypothesis (Pei et al., 2015; Yuan et al., 2016; Zhao 
et al., 2009) and, more importantly, it was demonstrated that silencing of YAP can 
rescue the EMT phenotype of certain cell systems (Wang et al., 2016b). From the 
molecular point of view, YAP stimulates an EMT response by inducing the 
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expression of EMT markers and driving factors, like Snai1 and Snai2, and ZEB1 
(Shao et al., 2014; Wang et al., 2016b; Xiao et al., 2015). Although these indications 
support the idea that YAP works as an oncogene, the underlying mechanisms are 
not yet fully elucidated and seem to be tissue- and context-specific. Indeed, in breast 
cancer, YAP was found to play a tumor-suppressive rather than a tumor-promoting 
role (Yuan et al., 2008). Hence, more detailed and tumor-specific studies are 
required. 
Moreover, Yap gene is often found amplified in a variety of human cancers, such 
as medulloblastomas, esophageal squamous carcinomas and hepatocellular 
carcinomas (Fernandez et al., 2009; Overholtzer et al., 2006; Snijders et al., 2005; 
Zender et al., 2006). Interestingly, YAP expression is found upregulated in cancers 
prone to metastasize to lymph-nodes (Liang et al., 2014; Wang et al., 2010; Zhou 
et al., 2013). While in the primary sites of these tumors YAP expression is 
upregulated, the sub-cellular localization and activity of YAP in metastasis are even 
more altered. However, an exhaustive analysis of YAP sub-cellular localization and 
expression in different malignancies is missing and should distinguish between 
primary and secondary sites in order to better identify in which biological processes 
YAP is involved.  
While YAP is considered an oncogene and is often found amplified in cancer, 
the expression and activity of Hippo pathway components are not dysregulated as 
often as YAP in human cancer. This suggests that other pathways along with the 
Hippo signaling likely contributes to regulate YAP activity and will be discussed in 
the following section. 
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1.3.4 Upstream regulators of Hippo pathway and other YAP regulatory 
pathways 
The spatial regulation of YAP within a cell is mainly determined by its 
phosphorylation status at Ser127 (Basu et al., 2003). Indeed, once YAP is 
phosphorylated at Ser127 (pYAP S127), is recognized and bound by 14-3-3 protein, 
ultimately resulting in cytoplasmic retention and nuclear exclusion. pYAP S127 is 
primarily mediated by LATS 1/2 kinases, belonging to the canonical Hippo signaling 
module (Hao et al., 2008). As a result, when the Hippo signaling cascade is turned 
ON, YAP is phosphorylated and segregated in the cytoplasm. On the contrary, when 
the Hippo pathway is shut OFF, YAP phosphorylation is terminated and so YAP is 
free to shuttle to the nucleus (Figure 11).  
Figure 11. Canonical Hippo pathway overview. When the Hippo signaling is activated (Hippo 
ON), LATS1/2 are phosphorylated and activated by MST1/2. Subsequently, phosphorylated 
LATS1/2 trigger YAP or TAZ phosphorylation at Ser 127 or Ser 89, respectively, and cause their 
binding to 14-3-3 protein and cytoplasmic retention. Further post-translational modifications lead 
to YAP or TAZ proteosomal degradation. When the Hippo signaling cascade is prevented (Hippo 
OFF), YAP and TAZ are no longer phosphorylated and thus they can shuttle to the nucleus where 
they drive the expression of target genes, such as connective tissue growth factor (CTGF), 
Cysteine-rich angiogenic inducer 61 (CYR61), Inhibin beta A (INHBA) and others. Taken from: 
Moroishi T. “The emerging roles of YAP and TAZ in cancer”, Nat Rev Cancer. 2015;15(2):73-9. 
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Although nowadays the Hippo core components along with their functions have 
been extensively characterized, much effort is still needed to properly define their 
upstream regulators. That said, researcher have already found a plethora of Hippo 
regulatory mechanisms, whose common characteristics are that they sense the 
extracellular environment and that their final output is to determine YAP localization 
and activity. 
1.3.4.1 Cell density and cell polarity 
In several studies, one recurrent observation is that YAP S127 phosphorylation 
and sub-cellular localization reflect cellular density (Giampietro et al., 2015; Varelas 
et al., 2010; Zhao et al., 2007). Indeed, while in sparse cultured cells YAP is mostly 
confined to the nucleus, with increasing cells density YAP gets phosphorylated at 
S127 and sequestered in the cytoplasm by interacting with 14-3-3 protein (Zhao et 
al., 2007). Thus, YAP sub-cellular localization depends on cell density. Moreover, 
while the cellular density increases, cells begin to interact with each other by forming 
AJs, and originate a polarized stratum of cells.  
It is not surprising, then, that both junctional and polarity complexes are involved 
in regulating YAP sub-cellular localization. In confluent epithelial cells, indeed, 
clustering of E-cadherin activates the Hippo signaling pathway to phosphorylate 
YAP and sequesters it in the cytoplasm (Kim et al., 2011). In this way, formation of 
epithelial AJs prevents YAP pro-proliferative activity and controls contact-inhibition 
growth (Figure 12, panel A). Moreover, two independent studies demonstrated that 
the E-cadherin binding partner a-catenin binds to pYAP S127 and prevents its 
nuclear accumulation in confluent epithelial cells (Schlegelmilch et al., 2011; Silvis 
et al., 2011). Although these studies reported that YAP is phosphorylated at S127 
by either LATS1/2 or by an unknown kinase upon clustering of epithelial AJs, both 
reports agreed on the importance of AJs in preventing YAP nuclear accumulation 
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and YAP-mediated cell proliferation. Thus, when cells are in a confluent state, they 
adhere with each other by forming homophilic E-cadherin-E-cadherin interactions 
that, in turn, trigger Hippo pathway activation and YAP nuclear exclusion and 
prevent uncontrolled cell-proliferation. 
Additionally, Merlin/NF2, a membrane-associated protein that connects to the 
cytoskeleton (McClatchey and Giovannini, 2005), was shown to potently induce the 
canonical Hippo signaling cascade and thus repress YAP activity (Figure 12, panel 
A) (Striedinger et al., 2008; Zhang et al., 2010). Accordingly, Merlin is a tumor 
suppressor, whose inactivation results in the development of the benign tumor 
Neurofibromatosis Type II (Rouleau et al., 1993). Merlin was also found to interact 
and be activated by Angiomotin (AMOT) protein family at TJs (Li et al., 2015; Yi et 
al., 2011). AMOT are important regulators of cell polarity and cytoskeleton stability, 
that were found to regulate YAP activity at different levels and both in a positive and 
negative manner (Figure 12, panel B). Indeed, AMOT can function as YAP co-
factor (Yi et al., 2013), but can also trigger LATS activation to restrict YAP 
transcriptional activity (Adler et al., 2013; Paramasivam et al., 2011). Interestingly, 
AMOT can retain YAP in the cytoplasm by directly interacting with it (Chan et al., 
2011; Mana-Capelli et al., 2014; Zhao et al., 2011). This association is mediated by 
AMOT PPxY motif and YAP WW domains and thus it is independent of YAP 
phosphorylation at S127 (Chan et al., 2011; Zhao et al., 2011). Consequently, 
AMOT can control YAP sub-cellular localization and activity independently from 
LATS-induced phosphorylation at S127, opening up a novel additional mechanism 
that coordinates YAP nuclear translocation. In addition, YAP and F-actin compete 
for binding to AMOT (Chan et al., 2011; Zhao et al., 2011). Upon LATS1/2 
phosphorylation of AMOT, F-actin dissociates from AMOT, favoring the interaction 
between YAP and AMOT and YAP cytoplasmic sequestration. Hence, AMOT 
inhibits YAP nuclear activity through several mechanisms, which can be either 
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dependent or not by LATS and further studies will better explain its mode of action 
under specific cellular contexts. Along with AMOT, other cell polarity proteins, such 
as Crumbs, Pals and Patj can inhibit YAP nuclear localization and activity (Figure 
12, panel A) (Varelas et al., 2010). Thus, cell polarization is emerging as an 
important process that restricts YAP transcriptional activity.  
Collectively these studies showed that both cell density and cell polarity 
contribute to tissue homeostasis by properly balancing YAP localization and nuclear 
activity. Conversely, their alteration results in an increased YAP nuclear localization, 
and this can likely contribute to EMT and cancer development. 
1.3.4.2 GPCR receptors 
Another recently discovered YAP regulatory mechanism takes place through 
the G-protein coupled receptors (GPCR) (Figure 12, panel A). This large family of 
receptors senses the extracellular signals and, upon ligand binding, triggers a 
signaling cascade through their cognate G-proteins. Depending on the G-protein 
coupled to the receptor, the Hippo signaling pathways is either inhibited or triggered. 
For example, lysophosphatidic acid, thrombin and sphingosine-1-phosphate (S1P) 
ligands signal through GPCRs coupled to Gα12/13 or Gαq/11 and function as potent 
activators of YAP by inducing assembly of the actin cytoskeleton (Miller et al., 2012; 
Mo et al., 2012; Yu et al., 2012). Conversely, epinephrine and glucagone ligands, 
which signal through Gαs-coupled receptors, promote pYAP S127 and thus repress 
its target gene activation (Yu et al., 2012).   
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Figure 12. Upstream regulators of YAP. YAP upstream regulators can be divided in those that 
activate the canonical Hippo pathway to restrict YAP nuclear localization and activity (upper panel, 
A) from those that directly control YAP (lower panel, B).  
A) Hippo can be activated by clustering of AJs, by cell polarization and by GPCRs acting through 
Gαs, whereas it is turned off in response to GPCRs coupled to Gα12/13 or Gαq/11. 
B) YAP nuclear/cytoplasmic shuttling and activity is also under the control of mechanisms 
independent from the Hippo signaling pathway. Rho GTPases activity in response to mechanical 
stress signaling induces actin stress fiber formation, that, in turn, promote YAP nuclear 
localization and activity by deactivating unknown kinases responsible for YAP phosphorylate. F-
actin competes with YAP for AMOT binding and thus favors its nuclear translocation. AMOT can 
directly bind to YAP PPxY motif through its WW domains and retain in the cytoplasm. However, 
the p130 isoform of AMOT can engage with YAP in the nucleus and act as a transcriptional co-
activator of YAP-TEAD. (continues on the next page) 
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1.3.4.3 Mechanotransduction 
Along with soluble factors, cells can covert mechanical signals into intracellular 
biochemical inputs - a process referred as mechanotransduction (Wang et al., 
2009b) - by sensing changes in the extracellular environment that affect cell shape, 
cell size and the rigidity of the ECM (Dupont et al., 2011). All these mechanical 
inputs translate in a dynamic regulation of the actin cytoskeleton, that, in turn, control 
YAP nuclear localization (Figure 12, panel B). The activity of Rho GTPase and the 
formation of actin stress fibers, indeed, were shown to sustain YAP nuclear 
accumulation and target gene regulation. Conversely, YAP nuclear activity was 
prevented in response to inhibitors of tension-related proteins. Thus, cells grown in 
soft extracellular matrix or in a confined area display a high level of YAP in the 
cytoplasm, while cells grown in stiff ECM or allowed to spread show a predominant 
YAP nuclear localization (Dupont et al., 2011; Halder et al., 2012). Controversies 
about the kinase responsible for pYAP S127 have been reported. Piccolo’s group 
excluded LATS1/2, since they observed that YAP activity could not be restored after 
LATS1/2 silencing when actin fibers formation is inhibited (Aragona et al., 2013). On 
the contrary, Guan and Sasaki’s groups reported that LATS activity is shut off by 
the formation of stress fibers, leading ultimately to YAP target gene expression 
(Wada et al., 2011; Zhao et al., 2012). Mechanical signals, therefore, have emerged 
as novel regulator of YAP localization and activity, but clearly more studies are 
required to better elucidate how the actin cytoskeleton modulates YAP. 
 
(continues from the previous page) Additionally, AMOT phosphorylation by LATS kinase 
promote YAP protesomal degradation. For detailed explanations, please refer to the main text.  
Taken from: Low BC “YAP/TAZ as mechanosensors and mechanotransducers in regulating 
organ size and tumor growth.” FEBS Lett. 2014;588(16):2663-70 
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1.3.5 Crosstalk with other signaling pathways 
1.3.5.1 YAP and canonical Wnt signaling 
The Wnt pathway is a fundamental signaling cascade required for the polarity 
of the primary body axis and for proper embryo development, as well as for tissue 
homeostasis in adults (reviewed in (Nusse and Clevers, 2017)). Upon Wnt 
stimulation, the downstream effector b-catenin is activated, translocates from the 
cytoplasm to the nucleus, and drives the transcription of target genes.  In a “Wnt 
OFF” situation, instead, b-catenin protein levels are kept under tight control by the 
combined effort of several proteins clustered together in a multimeric complex 
known as b-catenin destruction complex (DC) (Figure 13, left panel). DC is 
composed of the scaffolding proteins Disheveled (Dvl) and Axin, of APC, of two 
constitutively active kinases, GSK3 and CK1, and of the E3 ubiquitin ligase bTrCP. 
In the DC, Axin binds to b-catenin, while GSK3 and CK1 phosphorylate it in a 
sequential manner in Ser45, Thr41, Ser37 and Ser33. This phospho degron-motif 
is then recognized by bTrCP, targeting b-catenin for proteosomal degradation. In 
this way, the DC complex finely controls b-catenin protein levels and prevents its 
nuclear translocation. In a “Wnt ON” scenario, a seven-transmembrane receptor 
called Frizzled (Fz) recognizes and binds to Wnt ligands to initiate the signaling 
cascade (Figure 13, right panel). In particular, Fz forms a heterodimer with Lrp5/6 
co-receptors, engages to the DC and interrupts its activity, ultimately restricting b-
catenin degradation and promoting its nuclear translocation (Figure 13, right 
panel). Once in the nucleus, b-catenin interacts with T-cell factor/lymphoid 
enhancer-binding-factor-1 (TCF) or LEF to drive the expression of target genes, 
such as Axin1, Cyclin D1 and c-Myc. 
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In the past years, Wnt/b-catenin and Hippo signaling pathways have been 
shown to modulate each other at different levels. Initially, heart-specific Sav1 KO 
mice showed an increased cardiomyocyte proliferation due to high nuclear YAP 
and, concomitantly, an up-regulation of the Wnt target genes Sox2, Snai2 and 
Survivin (Heallen et al., 2011). More in-depth analysis revealed that these mice had 
an enhanced b-catenin nuclear-staining and their crossing with heterozygous b-
catenin mice (Salv/b-catf/+ cKO) rescued target gene expression levels as well as 
cell proliferation rate. Moreover, immunoprecipitation analysis showed that b-
catenin binds to total YAP but not to pYAP, suggesting that their interaction occurs 
in the nucleus. Indeed, b-catenin and YAP were able to drive Sox2 and Snai2 gene 
expression together, as shown by sequential chromatin immunoprecipitation (ChIP) 
Figure 13. Canonical Wnt signaling overview. When a Wnt ligand is not present (Wnt OFF), a 
destruction (DC) complex formed by Dvl, Axin, APC, two constitutively active kinases, GSK3 and 
CK1, and the E3 ubiquitin ligase bTrCP bind to β-Catenin and target it to proteosomal 
degradation. Upon ligand binding (Wnt ON), Frizzled receptor complex with Lrp co-receptor and 
together recruit the DC to the cytosolic membrane. This causes conformational changes in the 
DC, which ultimately lead to β-Catenin release and nuclear accumulation, where it drives gene 
transcription. Taken from: Nusse R “Wnt/beta-Catenin Signaling, Disease, and Emerging 
Therapeutic Modalities.” Cell. 2017;169(6):985-99. 
 61 
analyses. Intriguingly, a 2014 study by Piccolo’s group has demonstrated that, in a 
“WNT OFF” situation, YAP is incorporated in the DC, where it sustains b-catenin 
degradation by serving as bTrCP docking site (Figure 14D-E) (Azzolin et al., 2014). 
Moreover, the authors showed that Axin directly binds to YAP and proposed that 
the DC functions as a cytoplasmic “trap” for YAP, restraining its nuclear activity. 
Conversely, DC disassembly upon WNT stimulation or by APC silencing led to b-
catenin stabilization and YAP nuclear accumulation. However, the study did not 
investigate whether pYAP S127 is dispensable for YAP recruitment to the DC and 
whether nuclear YAP functions either as b-catenin co-transcriptional factor upon 
Wnt stimulation or drives the expression of a parallel set of genes. Collectively, 
these results set YAP as an important modulator of the Wnt/b-catenin signaling and 
reveal a dual-mode of action that depends both on the cellular compartment and on 
the presence/absence of the Wnt signal. In the cytoplasm of unstimulated cells, YAP 
contributes to b-catenin degradation and limits its transcriptional program; nuclear 
YAP, instead, works as b-catenin co-transcriptional factor. Although further studies 
are required to better elucidate how Wnt/b-catenin and Hippo signaling pathways 
cross-talks, it is becoming more and more clear that YAP and b-catenin signaling 
are intertwined, and clarifying their role will help unravelling molecular mechanisms 
often altered in pathological disorders. 
1.3.5.2 YAP and canonical TGFβ and BMP signaling 
Interplays between Hippo and Wnt signaling are not elusive, since YAP and the 
TGFβ-effectors SMADs have repeatedly shown to interact with each other. The first 
described evidence of a possible pathway crosstalk reported that YAP interacted 
with the inhibitory SMAD7, but not SMAD6 (Figure 14B) (Ferrigno et al., 2002). This 
interaction was partly mediated by the PY motif found on SMAD7, since mutation in 
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this site did not fully abolished YAP-SMAD7 complex formation, and thus suggesting 
that other domains are required for their binding. Moreover, the authors reported 
that YAP and SMAD7 act synergistically to repress TGFβ signaling, likely because 
the presence of full-lenght YAP reinforced SMAD7- TGFβRI complex formation. 
Thus, the author concluded that YAP is a negative regulator of the TGFβ signaling. 
Later on, YAP and SMAD7 structural interactions were unraveled, showing that YAP 
binds to SMAD7 PY motif through its WW1 domain (Aragon et al., 2011).  
Furthermore, Alarcón and colleagues showed that YAP binds to SMAD1 in 
response to BMP2, and it functions as SMAD1 transcriptional co-activator to drive 
the expression of Id1 and Id2 (Alarcon et al., 2009). Interestingly, phosphorylation 
in the SMAD1 linker region was required for YAP and SMAD1 association, and it 
was observed around 20 minutes after BMP2 stimulation, preceded by SMAD1 C-
terminal phosphorylation. Hence, the authors concluded that YAP promotes BMP-
regulated target genes expression by acting as SMAD1 co-transcriptional factor. Of 
note, they also observed a weak YAP-SMAD3 interaction, which did not however 
require TGFβ-mediated SMAD3 linker phosphorylation. A subsequent study from 
the same group showed that S206 phosphorylation in SMAD1 linker site, mediated 
by CDK8/9, served as a docking site for YAP WW1 domain, while SMAD1 PY motif 
was recognized and bound by YAP WW2 domain (Aragon et al., 2011). By binding 
to pS206 SMAD1, YAP hindered the subsequent GSK3-mediated phosphorylations 
at T202 and S210, therefore impeding SMURF1 binding to SMAD1 and SMAD1 
degradation. In conclusion, the authors proposed a model where YAP binds to 
pS206 SMAD1 in the nucleus and sustains SMAD1-driven target gene expression 
by working as a transcriptional co-factor. At the same time, binding of YAP to 
SMAD1 prevented additional SMAD1 phosphorylations and proteosomal 
degradation.  
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By attempting to clarify how cell density and cell polarity complexes impact on 
Hippo and TGFβ signaling, Varelas and colleagues have demonstrated that 
YAP/TAZ are required for SMAD2/3 nuclear accumulation and gene expression in 
response to TGFβ, in a cell-density dependent manner (Figure 14I) (Varelas et al., 
2010). Confluent Eph4 cells, indeed, not only displayed high levels of YAP/TAZ but 
also of SMAD2/3 in the cytoplasm, even after TGFβ stimulation. The high density of 
the cells negatively affected SMAD2/3-driven target gene expression too. 
Conversely, stimulating sparse cells with TGFβ caused SMAD2/3 nuclear 
accumulation and target gene expression. Of note, YAP/TAZ were mainly localized 
in the nucleus of sparse cells, likely because of low Hippo pathway activation. 
Indeed, depletion of LATS1/2 (the kinase responsible for YAP and TAZ cytoplasmic 
sequestration) coupled with TGFβ treatment in confluent cells resulted in SMAD2/3 
and YAP/TAZ re-localization to the nucleus and increased Ctgf and PAI-1 
expression. Interestingly, Varelas showed that formation of cell-cell AJs and polarity 
complexes prevented YAP/TAZ and SMAD2/3 nuclear accumulation, as well as 
down-stream target genes expression. Taken together, these results showed for the 
first time that cytoplasmic YAP/TAZ prevent SMAD2/3 nuclear accumulation, while 
sustaining SMAD2/3-driven target gene expression. Somehow, cytoplasmic 
YAP/TAZ impacted on SMAD2/3 nuclear accumulation, probably by retaining 
SMAD2/3 in the cytoplasm, but the mechanism was not fully clarified by the authors. 
Moreover, pYAP S127 (cytoplasmic YAP) interacted with SMAD2 only in response 
to TGFβ, leaving unsolved how cytoplasmic YAP could retain SMAD2 in basal 
conditions of high dense cultured cells. Whether YAP/TAZ are required for 
SMAD2/3 nuclear import or nuclear retention or whether YAP/TAZ play different 
roles in different cell-compartments was not investigated. In support to this work, 
another group observed a very weak SMAD2 and SMAD3 nuclear translocation in 
response to TGFβ in confluent HT29 and HaCaT cells (Grannas et al., 2015). 
 64 
Proximity ligation assays showed also that YAP and SMAD2/3 form few complexes 
in the cytoplasm of both sparse and dense cultured cells; however, after treatment, 
an increased association at the level of the nucleus was observed only in sparse 
cells, supporting the idea that cell density play a role both in TGFβ and in YAP/TAZ 
signaling. Yet, conflicting data were subsequently reported (Nallet-Staub et al., 
2015), raising the need to better clarify how TGFβ, YAP/TAZ and cell density 
modulate each other as well as better elucidating whether cytoplasmic YAP/TAZ 
versus nuclear YAP/TAZ can have different functions. 
YAP and SMAD3 were also shown to form a transcriptionally active complex 
together with TEAD4 and p300, driving CTGF expression and thus fostering 
mesothelioma progression (Fujii et al., 2012). Not only, YAP/TAZ and TEAD, 
together with SMAD2/3 and OCT4 were also found to balance the expression of 
pluripotency genes and inhibit the differentiating program of human embryonic stem 
cells (hESC) (Beyer et al., 2013). Notably, this study proposed for the first time that 
YAP/TAZ can also repress target genes expression. YAP/TAZ-TEAD and SMAD2/3 
complex formation was also observed in a metastatic breast cancer cell line, where 
it promoted cell migration and cell transformation in response to TGFβ (Hiemer et 
al., 2014). While both nuclear and cytoplasmic interactions occurred in untreated 
conditions, an increased nuclear localization and complex formation was observed 
in stimulated cells. Of note, YAP/TAZ-TEAD and SMAD2/3 were shown to drive 
gene expression both together and in separate complexes as well as in both positive 
and negative manner, adding further complexity to the already multifaceted 
molecular situation.  
Following studies have added further complexity on how YAP and SMAD 
signaling are inter-regulated. A study performed in hESC reported that YAP 
competes with SMAD to prevent activation of the differentiation program sustained 
by b-catenin/LEF-1 (Estaras et al., 2015). Moreover, in breast tumor initiating cells, 
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the expression of YAP negatively correlated with that of SMAD3 (Sun et al., 2016). 
Conversely, liver-specific deletion of MOB1a/1b (LATS1/2 co-activators), resulted in 
liver hyperplasia and early lethality due to enhanced YAP and SMAD2/3 nuclear 
translocation and TGFβ2/3 growth factor release (Nishio et al., 2016). The authors 
could greatly rescue the phenotype by crossing liver-specific MOB1a/1b mice with 
YAP floxed/floxed (YAPf/f) or TAZf/f or Tgfbr2f/f mice, thus further showing an inter-
pathways regulation.   
A recent report showed that, similarly to YAP/TAZ, SMAD2/3 localization and 
signaling in response to TGFβ is also regulated by matrix stiffness (Szeto et al., 
2016). By treating cultured fibroblasts with verteporfin, an inhibitor of YAP 
transcriptional activity, there was a significant reduction of YAP and TAZ protein 
levels, concomitant with SMAD2 and 3 down-regulation, resulting in a diminished 
SMAD2/3 transcriptional activity in response to TGFβ. Thus, the authors concluded 
that the reduced expression of YAP and TAZ observed upon verteporfin treatment 
contributed to lower SMAD2/3 nuclear accumulation and signaling, and proposed 
verteporfin as a novel inhibitor of renal fibrogenesis. 
In conclusion, YAP and SMADs signaling have repeatedly reported to modulate 
each other, both in a positive and negative manner. This probably depends on the 
cellular context as well as on the sub-cellular localization of YAP and SMADs. 
Therefore, future studies will help clarifying this intricate, but certainly very 
important, pathway cross-talk. 
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Figure 14. YAP regulates both Wnt and TGFβ signaling at different levels. YAP is involved 
in both TGFβ and Wnt signaling at different levels, which are schematically and synthetically 
presented here. Due to continuous expanding studies in the field, not all the molecular interactions 
so far described are depicted in this 2015 illustration. Thus, for more details, please refer to the 
main text. A) Upon TGFβ stimulation, SMAD3 is phosphorylated at the C-term, aided also by Axin 
B) YAP binds to SMAD7 and promote TGFβ-signaling inactivation. Instead, Axin can promote 
SMAD7 degradation, and thus TGFβ stimulated signaling C) Cytoplasmic TAZ was reported to 
inhibit Dvl phosphorylation and modulate Wnt signaling both in a positive and negative manner, 
depending on the ligand bound to the receptor D) YAP and TAZ are phosphorylated by the Hippo 
pathway kinases LATS1/2 and retained in the cytoplasm where E) YAP can take part to the b-
catenin DC and contribute to b-catenin proteosomal degradation F) When Wnt binds to its 
receptor, the DC is inhibited and thus YAP and b-catenin are free to shuttle to the nucleus G) F-
actin polymerization blocks the Hippo pathway kinase activity and, thus, favors YAP 
dephosphorylation and nuclear accumulation (continues on the next page) 
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1.3.6 YAP in the vascular endothelium 
1.3.6.1 Total-YAP and EC-specific YAP KO mice display vascular defects 
The first hint that YAP is a key determinant for the vasculature development 
emerged from the generation of total-YAP KO mice (YAP-/-), where genetic ablation 
of YAP caused embryonic lethality at E8.5 due to a lack of yolk-sac vascular 
organization, concurrent with defects in chorioallantoic fusion and embryo body axis 
development (Morin-Kensicki et al., 2006). Of note, yolk-sacs from YAP-/- mice were 
positive for the endothelial-marker CD31, but failed to form an organized 
vasculature, indicating that YAP is required for yolk-sac vasculogenesis but not for 
endothelial precursors formation. Conversely, vasculogenesis occurred both in the 
allantois and in the proper embryo of mutant mice, although vessels in the embryo 
were abnormally positioned. Taken together, these results suggested that YAP is a 
key regulator of early stage embryo development and of yolk-sac vasculogenesis. 
8 years later, Zhang and colleagues generated a Tie2-Cre YAPf/f mouse 
reporter, which specifically ablates YAP both in endocardial and in vascular-
endothelial cells in a constitutive manner (Zhang et al., 2014). Interestingly, these 
mice were embryonic lethal and only one homozygous mutant was retrieved out of 
197 weaned mice. Clear morphological defects were already evident at E10.5. 
Indeed, while at E9.5 both the embryonic and the yolk-sac vascular plexuses did 
not show obvious differences between mutant and control mice, at E10.5 there was 
a striking growth delay of mutant mice, accompanied with defects in yolk-sac 
(continues from the previous page) H) YAP, TAZ, SMAD2/3 and b-catenin can shuttle to the 
nucleus where I) YAP and TAZ can promote SMAD2/3 transcriptional activity along with other 
co-transcriptional partners J) YAP can also prevent SMAD1 proteosomal degradation. Taken 
from: Piersma B “Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge.” Frontiers in 
Medicine. 2015;2:59. 
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vascular remodeling and maturation. To avoid vascular-dependent defects and to 
investigate the role of YAP in cardiac development, the authors then focused their 
attentions to E9.5 embryos. Interestingly, they found that YAP mutant mice had a 
significant reduced number of endocardial cells undergoing EndMT, partly because 
of a decreased endocardial proliferation, but also due to impaired mesenchymal 
transformation of endocardial cells. As a result, Tie2-Cre YAPf/f mice showed defects 
in the endocardial-cushion formation and heart valve development. To shed light on 
the molecular mechanism, the authors analyzed the expression of EndMT markers 
in the heart cushion and found that genetic depletion of YAP caused a marked 
down-regulation of Snai1, Snai2, Twist1, Msx1 and Msx2, whereas the expression 
of EndMT-triggering growth factors such as BMP2, TGFβ2 and Notch was not 
altered. Nonetheless, they also showed that YAP is required for TGFβ-mediated 
EndMT in in vitro cultured cells, by favoring SMAD2/3 but not SMAD1 nuclear 
localization, and Snai1 and Snai2 transcription. Thus, Zhang and colleagues 
proposed for the first time that YAP is required for the endocardial-cushion formation 
by sustaining cardiac EndMT during the embryonic development. 
Collectively, these studies showed for the first time that YAP is a key player in 
vascular biology by contributing to physiological vasculogenesis and to heart-
cushion EndMT, stimulating researchers to further investigate the role and the 
regulatory mechanisms of YAP in ECs. 
1.3.6.2 YAP is regulated differently in static and under-flow conditions 
A striking observation that prompted us and others to characterized YAP 
regulatory pathway in ECs, was that YAP sub-cellular localization and 
transcriptional activity was greatly dependent on cell-confluency state (Choi et al., 
2015; Giampietro et al., 2015). Indeed, increasing cell density paralleled increasing 
pYAP S127 and YAP nuclear exclusion, while sparse ECs showed a marked 
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accumulation of YAP in the nucleus and intensive transcriptional activity (Figure 15). 
Thus, we and others hypothesized that YAP sub-cellular localization and activity is 
regulated by cell-cell contact. Results confirmed that disruption of VE-cadherin 
mediated cell-cell adhesion led to YAP nuclear translocation and target genes 
expression (Ctgf, Cyr61, Inhba and Ankrd). We also noticed that YAP sub-cellular 
localization and activity negatively correlated with a newly-identified VE-cadherin 
partner, EGF-receptor kinase substrate 8 (EPS8). EPS8 bound to the b-catenin 
binding domain of VE-cadherin in sparse and early-confluent ECs and contributed 
to enhance VE-cadherin turnover. In long-confluent cells, instead, its expression 
and localization at the cell membrane were strongly reduced. Notably, the b-catenin 
binding domain of VE-cadherin mediates binding to a-catenin too, and previous 
studies had already reported that a-catenin binds to YAP-14-3-3 complex to restrain 
it in the cytoplasm (Schlegelmilch et al., 2011; Silvis et al., 2011). We therefore 
envisioned a competitive binding of EPS8 with YAP-14-3-3 complex for a-catenin, 
and observed indeed that in EPS8-null ECs YAP could be immunoprecipitated 
together with VE-cadherin and a-catenin, but not in EPS8+ ECs. This suggested 
that EPS8 expression in sparse cells restricts the interaction of YAP-14-3-3 with a-
catenin, and thus favors YAP nuclear translocation and transcriptional activity. 
Intriguingly, pYAP S127 was strongly increased in EPS8-null compared to EPS8+ 
ECs, but surprisingly not mirrored by an augmented MST1 and LATS1 
phosphorylation and activation, suggesting that the Hippo pathway did not take part 
in regulating YAP phosphorylation and localization in static confluent ECs. We then 
moved to identify the kinase responsible for pYAP S127 in ECs and found that Akt 
kinase is activated upon AJ clustering, triggering, in turn, YAP phosphorylation and 
nuclear exclusion. We also observed that, where junctions are better organized, 
YAP colocalizes together with VE-cadherin in vivo, like in brain and retina vessels, 
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while it did not in more-fenestrated vessels, like in the kidney and spleen. In 
conclusion, our results showed for the first time that YAP sub-cellular localization 
and activity are regulated by other mechanisms than the Hippo pathway, and 
depend on several mechanisms like EPS8-induced exclusion to a-catenin binding 
and confluency-activated Akt-mediated phosphorylation (Figure 15). In agreement 
with our results, Choi and colleagues also reported that YAP is phosphorylated by 
Akt and retained in the cytoplasm of confluent ECs. 
Figure 15. YAP regulatory mechanisms during junctional maturation and increasing cell 
density. When ECs are sparse, the PI3K/Akt pathway is prevented and so YAP translocates to 
the nucleus to sustain transcriptional activity. Instead, clustering of VE-cadherin in confluent ECs 
triggers PI3K/Akt pathway, which, in turn, stimulates YAP phosphorylation at Ser127. pYAP S127 
is then bound by 14-3-3, and this complex is retained at the cytoplasmic membrane thanks to a-
catenin mediated-binding to VE-cadherin. Exposure of ECs to permeability promoting factors 
causes junctional destabilization and, thus, YAP nuclear translocation and signaling. Taken from:	
Giampietro C. “VE-cadherin complex plasticity: EPS8 and YAP play relay at adherens junctions.” 
Tissue Barriers. 2016;4(4):e1232024. 
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Very recently, Nakajima and colleagues have reported that YAP nuclear 
localization in ECs is positively regulated by laminar shear stress in vitro and by 
blood flow in vivo (Figure 16) (Nakajima et al., 2017). Strikingly, they found that 
shear stress did not alter either pYAP S127 levels or LATS1/2 phosphorylation, 
suggesting that, under flow, ECs stimulates YAP nuclear translocation through a 
Hippo- and phosphorylation-independent mechanism. Moreover, laminar shear 
stress enhanced actin bundling in ECs, while its inhibition resulted in decreased 
YAP nuclear accumulation. Thus, actin bundling stimulated YAP nuclear localization 
in response to shear stress. Indeed, formation of F-actin bundles in response to 
shear stress promoted F-actin binding to AMOT and consequent YAP release from 
AMOT in the cytoplasm, leading ultimately to YAP nuclear translocation. 
Furthermore, all the three AMOT family members were found to negatively regulate 
YAP nuclear translocation in cultured ECs, also in static conditions. However, after 
6-24 hours of shear stress stimulus the nuclear accumulation of YAP decreased, 
suggesting that YAP localization and activity are regulated by shear stress 
Figure 16. YAP is regulated by F-actin bundling and AMOT under laminar shear stress in 
ECs. Under resting condition, AMOT binds and sequesters YAP in the cytoplasm, thus preventing 
its nuclear activity. Under laminar shear stress, instead, F-actin bundles bind to AMOT, causing 
YAP release and nuclear accumulation. Taken from: Nakajima H “Flow-Dependent Endothelial 
YAP Regulation Contributes to Vessel Maintenance.” Dev Cell. 2017;40(6):523-36 e6. 
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transiently and other mechanisms modulate them under different stimuli. In 
agreement with the in vitro results, in vivo analyses showed that the Amotl2a family 
member is necessary for preventing YAP nuclear accumulation in not-lumenized 
vessels, while its inhibitory effect is partly reduced by blood flow. Collectively, these 
results have shown for the first time that YAP nuclear localization in vascular ECs 
is transiently stimulated by laminar shear stress, likely due to F-actin fiber formation 
that binds to AMOT and releases YAP from its AMOT-mediated cytoplasmic 
segregation (Nakajima et al., 2017).  
Thus, in ECs, YAP localization and activity is finely controlled by different 
mechanisms depending on cell confluency, clustering of AJs, shear stress and 
lumen formation and, so far, they appeared to be modulated by other mechanisms 
along with the Hippo signaling pathway. 
1.3.6.3 YAP contributes to different biological processes to determine a proper 
vascular network formation 
As already mentioned in the previous sections, YAP is emerging as an important 
regulator of several vascular biology processes. Initially, YAP was identified as a 
key determinant of yolk-sac vasculogenesis, since total YAP KO mice failed to 
formed an organized vascular plexus in the yolk-sac (Morin-Kensicki et al., 2006). 
Moreover, YAP localized at the nuclei of invading ECs in the retina vessels, 
suggesting a role of YAP in ECs migration and sprouting (Choi et al., 2015). These 
observations were supported by in vitro analyses where silencing of YAP in resulted 
in defective HUVEC cells tubular network formation and impaired aortic ring 
sprouting. Notably, the authors reported no significant alteration in ECs viability and 
proliferation upon YAP siRNA transfection. Moreover, transient down-regulation of 
YAP by siRNA injection in mouse retina vessels led to a reduced vessel density and 
a decreased number of branching points. The authors identified Angiopoietin-2 
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(ANG-2) as a YAP transcriptional target gene, whose expression was required for 
YAP-mediated ECs sprouting and angiogenesis. Thus, the authors revealed for the 
first time that YAP contributes to ECs sprouting and angiogenesis, partly via up-
regulating ANG-2 (Choi et al., 2015). In agreement with these observations, 
generation of YAP/TAZ double EC-specific KO mice confirmed that these co-
transcription factors are essential players in both developmental and pathological 
angiogenesis (Kim et al., 2017). Indeed, double mutant mice exhibited a markedly 
decreased retinal vessel growth in terms of vascular density, radial length and 
number of branching points at P5 (post-natal day 5). Interestingly, the front vascular 
region of mutant mice presented a blunted-end, with tip ECs forming shorter and 
significantly less filopodia. The tip EC protrusions, moreover, showed a 
disorganized F-actin bundle and led to a defective lumen formation, suggesting that 
YAP/TAZ expression is crucial for sustaining sprouting angiogenesis and vascular 
growth during retinal development by controlling F-acting rearrangements and 
proper lumen formation. Defects in vascular sprouting and growth in YAP/TAZ 
double KO mice were in part due to a decreased number of proliferating ECs. 
Interestingly, these phenotypes were greatly rescued by crossing YAP/TAZ double 
KO mice with LATS1/2 KO mice. Thus, YAP/TAZ promote sprouting angiogenesis 
in the developing retina by tuning different biological mechanisms, and their 
angiogenic activity is under the control of the canonical Hippo pathway. At P12, 
double mutant mice exhibited severe retinal and brain hemorrhages, due to reduced 
tight (ZO1 and Claudin-5) and adherens (VE-Cadherin) junction protein expression, 
and consequent vascular leakage increase. Notably, no difference in terms of 
pericyte coverage in both retina and brain vessels was detected. Strikingly, the 
authors have shown for the first time that YAP/TAZ are required for BBB formation 
and integrity, since double KO mutants contained fewer vessels in the brain, with a 
tortuous and enlarged morphology, and displayed altered BBB markers expression 
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(increased PLVAP and TfR, while no change in GLUT1). Mutant mice eventually 
died, probably due to extensive brain hemorrhages and growth delay. Remarkably, 
the authors showed that YAP/TAZ are not required for everyday BBB and BRB 
integrity, but they are required for vascularization post-injury, showing for the first 
time that YAP/TAZ are required for pathological angiogenesis in adult mice. 
Furthermore, they showed that VEGF elicits YAP/TAZ nuclear translocation, and 
induces LATS1 and YAP dephosphorylation. VEGF treatments of HUVEC cells 
silenced for YAP/TAZ revealed that YAP/TAZ are important for EC migration and 
formation of both filopodia and lamellipodia. In addition, EC proliferation was 
negatively affected by YAP/TAZ KD due to G1 phase arrest, partly explained by 
reduced MYC expression and signaling. 
Interestingly, under blood flow, YAP accumulates in the nucleus and is required 
for the maintenance of the lumen structure of certain blood vessels, as recently 
shown by Nakajima (Nakajima et al., 2017). YAP null zebrafish reporters displayed 
normal vasculature development until 7 days post fertilization, although frequent 
vessel stenosis and vessel retraction were observed. Conversely, vessel regression 
was observed in YAP or TAZ overexpressing zebrafish mutants already at 48 hours 
post fertilization, during the segmentation of the dorsal part of the caudal vein plexus 
(dCVP) (Nagasawa-Masuda and Terai, 2017). Sustained nuclear YAP localization 
and activity, indeed, induced Ctgf expression and release, that in turn contributed to 
dCVP regression. Thus, YAP and TAZ activity are involved in the maintenance of 
the lumen structure, but the exact mechanisms need to be better clarified. 
Moreover, YAP and TAZ nuclear localization is stimulated by 24 hours of 
disturbed flow, resulting in ECs proliferation and activation of a pro-inflammatory 
program that contributes to atherosclerotic plaque formation (Wang et al., 2016a). 
Interestingly, the authors have also shown that YAP nuclear activity and the pro-
inflammatory response is attenuated by statins treatments, setting YAP and TAZ as 
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novel therapeutic targets to counteract atherosclerotic lesion development. 
Accordingly, Nakajima and colleagues have also observed that YAP driven gene 
transcription was more sustained in vessels where the flow was disturbed compared 
to the ones under laminar shear stress (Nakajima et al., 2017). Taken together, 
these results showed that flow contributes to define YAP sub-cellular localization 
and activity. 
In addition, by generating Tie2-Cre YAPf/f mice, Zhang has pointed YAP as a 
crucial regulator of physiological EndMT that occurs during the development of the 
heart cushion (Zhang et al., 2014). Whether YAP is also required for pathological 
EndMT is still an open question that would help identifying YAP as a novel 
therapeutic target to prevent mesenchymal and malignant transformation and, 
possibly, tumor dissemination. 
Collectively, these studies have shown that YAP is an important regulator of 
many physiological vascular processes and it is finely tuned by several up-stream 
regulatory mechanisms. Alterations of YAP localization and activity impinges on 
proper vascular development under physiological development and, likely, also 
under pathological conditions. It would be now important to investigate whether and 
how YAP activity is deregulated in vascular pathologies and in tumor angiogenesis, 
in order to better define its role in vascular biology and possibly provide novel 
molecular mechanisms that could be targeted for the treatment of vascular 
pathologies. 
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Chapter 2 - Materials and Methods 
2.1 Cell culture 
2.1.1 ECs isolation and culture 
Lung ECs were isolated and immortalized as previously described (Dong et al., 
1997) from a YAPf/f mouse (Xin et al., 2011). Briefly, mouse lungs were removed 
under sterile conditions, washed two times with PBS and minced finely with scalpels. 
Organ disaggregation was carried out by incubating minced lungs with collagenase 
A (1.5 mg/ml; Roche) and DNAse (25 μg/ml; Roche) in DMEM (37 °C for 3 hours 
(h)). After filtering through nylon screen, cells were collected, centrifuged at 1,200 
rpm for 10 minutes and then seeded in gelatin 0.1% coated 24 wells. 48 h 
afterwards, ECs were washed with PBS and infected with polyoma middle T antigen 
supernatant in order to specifically select and immortalize only ECs. Supernatant 
was then replaced with complete medium after 8 h. After 3 months in culture, we 
obtained a homogeneous population of ECs, whose purity was analyzed by 
performing extensive stainings for endothelial specific molecules. Yap floxed alleles 
were deleted by treating pure ECs in vitro with TAT-Cre recombinase using Hyclone 
ADCF-Mab medium (ThermoScientific), as previously described (Liebner et al., 
2008), thus generating YAP wild-type (WT) and KO immortalized lung EC lines. 
Lung ECs were grown on 1% gelatin coated plates in complete medium, containing 
MCDB-131 (GIBCO) supplemented with 20% South American (SA) fetal bovine 
serum (FBS) (HyClone), penicillin/streptomycin (100 units/L; Sigma), sodium 
pyruvate (1mM), L-glutamine (2mM; Sigma), heparin (100 μg/ml; Sigma) and EC 
growth supplement (5 μg/ml; Sigma).  
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2.1.2 Culture of HEK 293T 
293T packaging cells were provided by IFOM Cell Culture facility and cultured 
in DMEM medium (GIBCO) supplemented with 10 % SA FBS (Hyclone), and L-
glutamine (2 mM, Sigma). 
2.2 Cell treatments 
For 5 days TGFβ/BMP6 stimulation, ECs were seeded at 0.75*106 cells/21 cm2 
density. The day after plating, cells were starved overnight (O/N) with starving 
medium (MCDB-131, 1% bovine serum albumin (BSA)), followed by either 5 ng/ml 
TGFβ1 (PeproTech) or 100 ng/ML BMP6 (R&D) treatment. Fresh TGFβ/BMP6 in 
starving medium were added every day for 5 consecutive days.  
For TGFβ stimulation, WT ECs were seeded at 0.4*106 cells/9.5 cm2 density 
and KO ECs at 0.5*106 cells/9.5 cm2. Confluent monolayers of ECs were incubated 
with starving medium O/N, followed by treatment with 5 ng/ml TGFβ in starving 
medium for the indicated time points.  
For LiCl treatment, cells were grown till confluency and then incubated O/N with 
starving medium containing either 60 mM LiCl (Sigma Aldrich) or 60 mM NaCl 
(Sigma Aldrich). The day after, cells were stimulated for the indicated time points 
with 5 ng/ml TGFβ, dissolved in starving medium together with either 60 mM LiCl or 
NaCl.  
2.3 siRNA transfection 
For siRNA transfection, cells were plated at 0.6*106 cells/10 cm2 density in 
complete medium and transfected with either scrambled (scr) siRNA (ON-TARGET 
plus Non-targeting pool; GE Healthcare), or SMAD3 siRNA (ON-TARGET plus L-
040706-00; GE Healthcare), or TEAD1 (ON-TARGET plus L-048419; GE 
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Healthcare). Transfection was performed with Lipofectamine 2000 (Invitrogen) in 
accordance with the manufacturer’s instructions. 
2.4 Lentiviral infections 
Constitutively active YAP lentiviral plasmid (YAP 5SA) was a kind gift of Prof. 
Stefano Piccolo (Padua University, Italy) (Dupont et al., 2011), wherein a human 
Flag-YAP 5SA was inserted in a CSII-CMV-MCS-IRES2-Bsd lentiviral backbone 
plamid using EcoRI and NotI restriction sites. The lentiviral particles were produced 
in HEK 293T cells using a three-plasmid transfection system mediated by 
Lipofectamine 2000. 24 h before transfection, 2x106 HEK 293T cells were plated in 
57 cm2 petri dishes. The following day, cells were transfected with a 3 mL OptiMEM 
solution containing 4.5 µg psPAX2 (packaging plasmid encoding for Gag, Pol, Rev, 
and Tat), 1.5 µg of pMD2.G (envelope plasmid encoding for VSV-G), 6 µg of either 
empty or YAP 5SA lentiviral vector, and 36 µl of Lipofectamine 2000 per petri dish. 
This solution was kept 30 minutes at room temperature (RT), applied drop by drop 
on cells and left O/N for transfection. The day after, transfected HEK 293T medium 
was replaced with DMEM 10 % SA FBS and L-glutamine. In parallel, 2x106 of YAP 
WT and KO cells were seeded in 57 cm2 petri dishes. Lentivirus-containing 
supernatants were collected 48 and 72 h after cell transfection, passed through a 
0.45 μm filter and applied to YAP WT and KO cells using polybrene for 24 h. YAP 
WT and KO infected cells were then grown till confluency using complete culture 
medium, and then seeded for cell treatments as described. 
2.5 Western Blotting 
Western blot (WB) analysis was performed according to standard protocols. 
Confluent monolayers of ECs were lysed in boiling Laemmli sample buffer (SB) (2% 
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sodium dodedyl sulfate (SDS), 20% glycerol, and 125 mM Tris-HCl, pH 6.8). Protein 
concentration was determined using a BCA Protein Assay kit (Thermo Fisher 
Scientific). Equal amounts of proteins were loaded on gel, separated by SDS-PAGE 
and transferred to a Protran Nitrocellulose Membrane (Whatman). After blocking 
and incubation with primary and horseradish peroxidase-linked secondary 
antibodies, specific bindings were detected by a chemiluminescence system (GE 
Healthcare). WB bands have been quantified using optic densitometry software and 
normalized to the relative housekeeping. 
2.6 Nuclear-cytoplasmic (N/C) fractionation 
Confluent monolayers of ECs were lysed in pre-chilled cytosol buffer (20 mM 
Hepes pH 7.9 and 1 mM EDTA pH 8.0 and protease/phosphatase inhibitors). After 
centrifugation, the surnatant was collected (cytosolic fraction) while the pellet was 
washed three times with cytosol buffer, lysed in cold nuclear buffer (20 mM Hepes 
pH 7.9, 1 mM EDTA pH 8.0, 10% glycerol and 420 mM NaCl and 
protease/phosphatase inhibitors), followed by ultracentrifugation for 30 minutes at 
50000 g. The obtained surnatant was collected as nuclear fraction. 
2.7 Immunoprecipitation (IP) 
Following O/N starvation and treatment with TGFβ, confluent monolayers of 
ECs were solubilized in cold IP lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 
2 mM CaCl2, 0.1% Triton X-100, 0.1% NP-40 and protease/phosphatase inhibitors) 
and incubated on ice for 15 min. The protein lysate was then precleared with Protein 
A- or G- Sepharose beads (GE Healthcare) for 2 h at +4°C. Subsequently, protein 
concentration was determined with BCA Protein Assay Kit, and equal amounts of 
protein were incubated with immune antibodies and captured by protein A- or G- 
Sepharose beads O/N at +4°C. As a control, immune antibodies were incubated 
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with IP lysis buffer and protein A- or G- Sepharose beads O/N at +4°C. The following 
day, beads were washed several times with IP lysis buffer and boiled in an 
appropriate volume of SB. Immunoprecipitated material was analyzed through 
standard WB analysis. 
2.8 IP from N/C fractionation 
Cells were lysed with cold subcellular fractionation buffer (250 mM sucrose, 20 
mM HEPES pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 1mM EDTA, 1mM EGTA and 
protease/phosphatase inhibitors). Cytosolic membranes were disrupted by passing 
the lysate through a 22 Ga needle, followed by 5 minutes centrifugation at 720 G. 
The surnatant was collected as cytosolic fraction, further centrifuged at 10000 G for 
10 minutes and immunoprecipitated as previously described. The nuclear pellet was 
resuspended in cold IP lysis buffer and kept for an hour at 4°C under constant 
rotation. After a centrifugation at 13200 rpm for 20 minutes the surnatant containing 
the nuclear fraction was subjected to IP.  
2.9 Transcription factor binding site analysis  
The identification of putative TEAD or SMAD binding sequences on genomic 
DNA was performed using the software MatInspector (Genomatix), which predicts 
the transcription factor binding sites (TFBS) by using a large library of weight 
matrices. Using the RSAT software (http://rsat.sb-roscoff.fr/) we retrieved a 
sequence spanning from 5000 bp upstream and 1000 bp downstream the 
transcription start site (TSS) of Fn1, Serpine1, Snai1, Cdh2 and Acta2 genes.  
2.10 Chromatin Immunoprecipitation (ChIP) 
ChIP assays were performed as described elsewhere (Nakae et al., 2003). 
Briefly, cells were starved O/N and cross-linked with 1 % formaldehyde for 10 
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minutes at RT. 125 mM glycine for 5 minutes at RT was then added in order to 
inactivate formaldehyde. After two washes with ice-cold PBS ECs were lysed by 
scraping on ice-cold SDS buffer (NaCl 100 mM, Tris HCl pH 8.1 50 mM, EDTA 5mM, 
NaN3 0.2 %, SDS 0.5 %). The lysate was then collected and centrifuged at 1,300 
rpm for 5 minutes at 4°C. After removal of the supernatant, the pellet was 
resuspended with Immunoprecipitation buffer (1 volume of SDS Buffer + 0.5 volume 
of Triton Dilution Buffer [NaCl 100 mM, Tris HCl pH 8.6 100 mM, EDTA 5 mM, NaN3 
0.2 %, Triton X-100 5 %]). Sample sonication in microTUBE (COVARIS) was 
performed after 10 minutes of incubation using a COVARIS S220 according to the 
following conditions: Peak Incident Power 175.0 Watt, Duty Factor 10 %, 200 
Cycles/Burst. Sonicated chromatin was loaded on 1 % agarose gel to evaluate the 
size of the sonicated chromatin fragments. 0.5 mg (for YAP) or 0.3 mg (for SMAD3) 
of DNA fragments with an average size of 500 base pairs (bp) were incubated with 
either 8 µg of YAP (NB110-58358) or 1.5 µg SMAD3 (cs#9523) directed antibodies 
or rabbit IgG control O/N at 4 °C in the presence of protein G covered magnetic 
beads (Life Technologies). The following day, beads were recovered and washed 
three times with Mixed Micelle Washing Buffer (NaCl 150 mM, TrisHCl pH 8.1 20 
mM, EDTA 5 mM, Sucrose 5.2 % w/v, NaN3 0.02%, Triton X-100 1 %, 0.2 % SDS), 
500 Buffer (Deoxycholic acid 0.1 % w/v, NaCl 500 mM, HEPES pH 7.5 25 mM, 
EDTA 1 mM, NaN3 0.02 %, Triton X-100 1 %), LiCl Detergent Washing Buffer 
(Deoxycholic acid 0.5 % w/v, LiCl 250 mM, EDTA 1 mM, NP-40 0.5 % v/v, NaN3 
0.02 %, Tris HCl pH 8.0 10 mM). Proteins/DNA complexes were detached from 
beads by heating the samples at 65 °C for 10 minutes. De-crosslinking was 
performed at 65 °C O/N. DNA was precipitated and purified using phenol/cloroform 
and amplified by quantitive real-time polymerase chain reaction (qPCR) using 
oligonucleotides flanking the assayed promoter regions (listed below). Primers were 
designed using Primer3 software and always tested before, in order to avoid "auto-
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amplification" due to self-complementarity. qPCR reactions were carried out by 
diluting DNA in the presence of specific primers (0.4 μM each) to a final volume of 
25 μl in SYBR Green Reaction Mix (Perkin Elmer). S.D.S 2.2.1 software was used 
to convert qPCR curves in Ct values. For each region, the mean of the Cts of the 
inputs was calculated and subtracted to the Ct values of the immune samples (ΔCt). 
Then, the % of enrichment of input for the immune samples was obtained as 2^-ΔCt 
and multiplied by the % of input taken during the experiment. The same calculation 
was performed for the non-immune (IgG control) immunoprecipitated samples. To 
remove unspecific signal, the non-immune values were subtracted from the immune 
samples.  
 
Gene Position Forward Reverse 
Fn1 -0.3 KB 5’-GTAAGCCTTACCACCCCAGG 3’-GGGATGGGAAACGGCTGTAA 
Serpine1 -0.5 KB 5’-CAAAACCCAGCCGCACAAG 3’-GCATGTCTGACTCCCCACAT 
-4.3 KB 5’-CCCAGCTCTCCCAGTGAAAT 3’-GGTCAGCCTCCTTCCAGTTAC 
Table 1. List of primers used for ChIP 
2.11 Antibodies  
For WB, IF, IP and ChIP the following antibodies were used: phospho-SMAD3 
rabbit (9520, Cell Signaling; WB), SMAD3 rabbit (9523, Cell Signaling; WB), SMAD3 
mouse (sc-101154, Santa Cruz; WB), SMAD3 mouse (MA5-15663, Thermofisher; 
WB) phospho-SMAD1/5 rabbit (9516, Cell Signaling; WB), SMAD1 rabbit (9743, 
Cell Signaling; WB), phospo-SMAD2 (3108, Cell Signaling; WB), SMAD2 (ab33875, 
Abcam; WB and IF), SMAD4 (sc-1909, Santa Cruz; WB, IF and IP), YAP mouse 
(sc-101199, Santa Cruz; WB), YAP mouse (sc-271134, Santa Cruz; IF and IP), YAP  
rabbit (sc-15407, Santa Cruz; WB), TEF-1 mouse (610923, BD Bioscience; WB), 
Fn1 (ab23750, Abcam; WB), Snai1 (sc-10432, Santa Cruz), Tubulin mouse (T9026, 
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Sigma), Vinculin mouse (V9264, Sigma), Lamin B goat (sc-6216, Santa Cruz; WB); 
HRP-linked anti-mouse and anti-rabbit (Cell Signaling); HRP-linked anti-goat 
(Promega); AlexaFluor 555-conjugated donkey anti-goat (Invitrogen); AlexaFluor 
488-conjugated donkey anti-rat (Invitrogen). 
2.12 Quantitative real-time PCR (qPCR) analysis 
Total RNA was isolated using either the RNeasy micro kit (QIAGEN) for samples 
treated for 5 days with TGFβ/BMP or with Maxwell® RSC simplyRNA Tissue Kit 
(Promega) for all the other samples. Subsequently, 1 μg was reverse transcribed 
with random hexamers (High Capacity cDNA Archive kit; Applied Biosystems). 
cDNA was amplified with the TaqMan Gene Expression assay (Applied Biosystems) 
and a thermocycler (ABI Prism 7900HT; Thermo Fisher Scientific). For any sample, 
the expression level, normalized to the housekeeping genes encoding either Actb, 
Hrpt1, B2m was determined by the comparative threshold cycle method as 
described previously (Spagnuolo et al., 2004). 
2.13 Immunofluorescence (IF) 
Cells were fixed with 4% paraformaldehyde (PFA), permeabilized for 10 minutes 
with PBS 0,5% Triton-X, and incubated for 1h in a blocking solution of PBS with 2% 
BSA. Subsequently, samples were incubated with primary antibodies diluted in 
blocking buffer for 1h at RT, washed with PBS, followed by appropriate secondary 
antibodies incubation for 1h at RT, and mounted with VECTASHIELD with DAPI 
(Vector Biolabs). Confocal microscopy was performed at RT with a confocal 
microscope (TCS SP2AOBS; Leica) equipped with violet (405-nm laser diode), blue 
(488 nm; Argon), yellow (561 nm; solid state), and red (633 nm; HeNe) excitation 
laser lines before processing with ImageJ. Only adjustments of brightness and 
contrast were used in the preparation of the figures. For comparison purposes, 
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different sample images of the same antigen were acquired under constant 
acquisition settings. Image acquisition was performed using a 63×/1.4 NA oil 
immersion objective (HCX PL APO 63× Lbd BL; Leica) with spectral detection bands 
and scanning modalities optimized for removal of channel cross talk. Confocal 
software (Leica) and ImageJ version 1.33 were used for data analysis. 
Quantification of nuclear accumulation was made measuring the intensity of SMAD 
staining with ImageJ, using DAPI nuclear staining as a region of interest to identify 
cell nuclei. 
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Chapter 3 - Results 
3.1 Generation of immortalized lung YAP WT and KO ECs 
In order to study the role of YAP in the vascular endothelium, and, in particular, 
characterize how it contributes to EndMT, we generated an in vitro cell culture model 
system by isolating ECs from lungs of a YAPf/f mouse, as described in materials and 
methods section 2.1.1. Once the cells have been immortalized with polyoma middle-
T, we performed genetic recombination by means of TAT-Cre enzyme, which cut at 
the level of loxP sites flanking the third exon of Yap gene and created a STOP codon 
in the corresponding YAP transcript (Xin et al., 2011). As a result, Yap mRNA is no 
longer transduced in recombined cells. In this way, we obtained two immortalized 
EC lines coming from the same genetic background, one harbouring a WT Yap gene 
and one that no longer expressed YAP. WB analyses verified YAP recombination 
and genetic deletion (KO) (Figure 17). Thus, YAP WT and KO immortalized ECs 
were then cultured and used for subsequent in vitro experiments. 
Figure 17.  Generation of lung immortalized YAP WT and KO ECs. The drawing schematically 
represents how YAP WT and KO ECs were generated. Three months after isolation and 
immortalization of cells, WB analyses confirmed YAP recombination. Tubulin was used as a 
loading control.   
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3.2 YAP positively modulates TGFβ-mediated EndMT 
Previous studies have reported YAP as an important promoter of EMT 
(Overholtzer et al., 2006; Yuan et al., 2016), while, at the beginning of my PhD 
studies, no scientific evidence proving a positive correlation between YAP 
expression and EndMT were yet provided. Interestingly, we and other have shown 
that prolonged exposure to TGFβ/BMP family of ligands is strongly correlated to 
physiological and pathological EndMT (Azhar et al., 2009; Maddaluno et al., 2013; 
Medici et al., 2010). We thus moved to investigate whether YAP contributes to 
EndMT in response to TGFβ/BMP family of ligands, by chronically treating YAP WT 
and KO ECs with either 100 ng/mL BMP6 or 5 ng/mL TGFβ for 5 consecutive days 
in order to stimulate an EndMT response. As shown in Figure 18, we observed that 
both BMP6 and TGFβ triggered the expression of EndMT marker genes in WT cells, 
as expected, in particular of Klf4, Stem-cells antigen 1 (Sca1) and Fsp1 in response 
to BMP6 (Figure 18 A) and of Acta2, Fn1, Cdh2 and Snai1 after TGFβ stimulation 
(Figure 18 B). Interestingly, genetic loss of YAP negatively affected the EndMT 
response induced by TGFβ, since KO cells showed a significantly impaired mRNA 
up-regulation of Acta2, Fn1, Cdh2 and Snai1 compared to WT treated cells (Figure 
18 B).  
In order to verify that the genetic ablation of YAP specifically affects the EndMT 
markers expression induced by TGFβ, we analyzed the EndMT proteins expression 
through WB in WT and KO treated cells. 
TGFβ chronic stimulation strongly induced Fn1, N-cadherin (encoded by Cdh2) 
and Snai1 protein expression in WT but not in KO cells, further suggesting that in 
ECs YAP is required for proper EndMT markers expression in response to TGFβ 
and set YAP as a positive regulator of TGFβ-mediated EndMT (Figure 19). 
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Moreover, these results are in line with what observed by Zhang and colleagues in 
other EC line systems (Zhang et al., 2014). 
 
Figure 18. Loss of YAP negatively affects EndMT genes expression. qPCR analysis of the 
EndMT markers: A) Klf4, Fsp1 and Sca1 and of canonical targets of ALK1/SMAD1 and 
ALK5/SMAD3, Id1 and Serpine1; B) Acta2, Fn1, Cdh2 and of the EndMT- driving transcriptional 
factor Snai1, Id1 and Serpine1. Cells were treated with A) 100 ng/mL BMP6 or B) 5 ng/mL TGFβ 
for 5 days. Unstimulated cells (CTR) were kept in starving medium for 5 days without addition of 
TGFβ. Data are mean ± standard deviation (SD) of A) two independent experiments (n=2) and 
B) n=4. Beta-2 microglobulin (b2m) was used as housekeeping gene. *p<0.05, **p<0.01, t-test.  
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3.3 YAP contributes to TGFβ-induced SMAD3- but not SMAD1- 
signaling  
Considering that YAP KO affected the EndMT markers up-regulation upon 5 
days of TGFβ treatment and that TGFβ primarily signals through R-SMADs, we 
sought of characterizing whether loss of YAP might impact on SMAD3 and/or 
SMAD1 signaling activation in response to TGFβ in ECs. SMAD3 is considered the 
canonical effector of TGFβ, while SMAD1 the one of BMP growth factors (Goumans 
and Ten Dijke, 2017). Nevertheless, SMAD1 activation and transcriptional activity 
can also occur in response to TGFβ in ECs (Goumans et al., 2002). We thus 
checked for the mRNA expression levels of Id1 and Serpine1, canonical targets of 
ALK1/SMAD1 and ALK5/SMAD3 signaling respectively, to assess whether YAP is 
required for R-SMAD signaling (Dennler et al., 1998; Goumans et al., 2002). 
Results showed that 5 days of TGFβ treatment induced Id1 up-regulation both 
in WT and in KO treated cells at a similar level (Figure 18B). On the contrary, 
Serpine1 expression, which is known to be driven by SMAD3 (Dennler et al., 1998), 
Figure 19. YAP positively regulates TGFβ-induced EndMT marker expression. WB of WT 
and KO cells treated with TGFβ for 5 consecutive days. The blot is representative of n=3 
independent experiments. Tubulin and Vinculin were used as loading controls. 
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was significantly lower in KO compared to WT treated cells. Of note, prolonged 
BMP6 treatment resulted in a marker Id1 upregulation both in WT and KO treated 
cells too, while Serpine1 expression was not induced in response to this growth 
factor (Figure 18A). 
Given that the phosphorylation and activation of the signaling cascade in 
response to TGFβ occurs around 45 minutes from the beginning of the treatment 
(Rudini et al., 2008), we evaluated whether SMAD1 and SMAD3-driven signaling 
activities were already activated and modulated 2 h after stimulation.  
Interestingly, in line with the chronic TGFβ stimulation, 2 h of treatment induced 
Id1 up-regulation at a similar level in both cell lines, while Serpine1 expression was 
significantly affected upon loss of YAP (Figure 20). 
We therefore concluded that TGFβ down-stream signaling is affected in YAP 
KO ECs and that YAP is specifically required for SMAD3 but not SMAD1 signaling 
in ECs.  
Figure 20. YAP specifically contributes to SMAD3-driven gene expression. qPCR analysis 
of Serpine1 and Id1 mRNA expression levels in YAP WT and KO cells treated with 5 ng/mL TGFβ 
for 2 h. Samples are normalized to WT untreated cells. Data are mean ± SD of n=3 independent 
experiments. *p<0.05 **p<0.01 ***p<0.001, t-test. 
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3.4 YAP is not required for SMAD3 and SMAD1 C-term 
phosphorylation 
TGFβ-family of ligands signals by binding to an heteromeric complex formed by 
two TbRI and two TbRII, leading to R-SMADs phosphorylation and downstream 
signaling cascade activation. Since we observed that YAP is required for TGFβ-
induced EndMT and for SMAD3-driven signaling activity, we next aimed at 
investigating at which step of the TGFβ signaling cascade YAP contributes to.  
First, we looked at whether there was a differential activation of the TGFβ 
signaling pathway between the two cell lines, which could be the result of a 
decreased expression of components of the TbRI family of receptors or due to an 
impaired phosphorylation activity of the receptors. We tested the mRNA expression 
levels of ALK5 receptor (or Tgfbr1), responsible for SMAD2 and -3 phosphorylation 
and activation, and ALK1 (or Acvlr1), responsible for SMAD1 -5 and -8 in ECs 
(Goumans and Ten Dijke, 2017). Quantitative analysis of the expression levels of 
Tgfbr1 and of Acvlr1 did not reveal any significant difference between WT and KO 
cells (Figure 21), suggesting that genetic loss of YAP had no effect on the two main 
TbRI expression.  
Figure 21. Genetic ablation of YAP in ECs does not affect TbRI expression levels. qPCR 
analysis of mRNA expression of Tgfbr1 (ALK5) and Acvlr1 (ALK1) in untreated conditions. B2m 
was used as house keeping gene. n=3 ± SD. 
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Upon TGFβ stimulation TbRI phosphorylates R-SMADs in a specific SSxS 
consensus-motif lying at their C-term. In particular, activated ALK1 phosphorylates 
SMAD1 at S463 and S465 (pSMAD1), while ALK5 phosphorylates SMAD3 at S423 
and S425 (pSMAD3) (Goumans and Ten Dijke, 2017). By means of WB analyses, 
we then tested whether exposing WT and KO cells to TGFβ for 45 minutes could 
induce SMAD3 and SMAD1 C-term phosphorylation at a similar level in both cell 
lines. 
Results clearly showed that 45 minutes TGFβ treatment induced a strong and 
significant C-term phosphorylation of SMAD3 and SMAD1 in both WT and KO cells, 
indicating that YAP expression is not necessary for TGFβ signaling activation 
(Figure 22). 
Interestingly, loss of YAP in ECs caused a significant reduction of SMAD3 and 
SMAD1 total protein levels. Nevertheless, our previous data showed that SMAD1 
signaling activity is not affected by YAP KO (Figure 20), indicating that SMAD1-
reduced levels in KO cells are not enough to prevent downstream signaling 
activation. YAP, instead, was required for SMAD3 protein accumulation and relative 
signaling activity (Figure 20 and Figure 22), suggesting that YAP specifically 
contributes to SMAD3 but not SMAD1 signaling activity in response to TGFβ. Of 
note, others have instead reported that silencing of YAP in HUVEC cells did not 
significantly affect SMAD3 and SMAD1 expression (Zhang et al., 2014). 
In order to test whether the absence of YAP might result in a faster SMAD3 C-
term dephosphorylation and, thus, in a quicker SMAD3 signaling activity switch off, 
we performed a TGFβ time course in both cell lines and checked for the C-term 
phosphorylation levels of SMAD3 over time. Results showed that SMAD3 C-term 
phosphorylation occurred at comparable levels between the two cell lines and that, 
2 h after stimulation, the signal was not significantly decreased in KO cells compared 
 92 
to WT cells, suggesting that loss of YAP did not influence SMAD3 C-term 
phosphorylation kinetic up to 2 h from TGFβ stimulation (Figure 23). 
Collectively these results showed that loss of YAP did not decrease the 
expression of the two main TbRI in ECs, and that TGFβ signaling is activated at the 
Figure 22. Expression of YAP in ECs does not influence SMAD3 and SMAD1 C-term 
phosphorylation. Representative WB of C-term phosphorylated SMAD3 and SMAD1 (pSMAD3 
and pSMAD1) protein in WT and KO cells treated with TGFβ for 45 minutes, and relative total 
SMAD3 and SMAD1 expression levels. WB bands have been quantified using optic densitometry 
software and normalized to the relative Vinculin band (housekeeping). The ratio between 
normalized pSMAD3/1 and SMAD3/1 levels were then calculated for each sample, and expressed 
as fold change referred to WT untreated cells (arbitrary units, AU). Data are mean of n=3 
independent experiments ± SD. *p<0.05, **p<0.01, t-test. 
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same level both in WT and KO cells in terms of R-SMADs phosphorylation, thus 
indicating that YAP is not required for the first steps of signaling activation. Of note, 
YAP expression is necessary for SMAD3 and SMAD1 protein expression. 
 
3.5 YAP is required for SMAD3 nuclear accumulation 
Following receptor-mediated phosphorylation, R-SMADs form a complex with 
SMAD4 and together shuttle to the nucleus (Goumans and Ten Dijke, 2017). Since 
our data showed that YAP is necessary for SMAD3-driven signaling activity (Figure 
20), but not for TGFβ-induced cascade activation (Figure 22), we next moved to 
Figure 23. Loss of YAP does not influence SMAD3 C-term phosphorylation kinetic. 
Representative WB of YAP WT and KO cells treated with TGFβ for the indicated times. WB bands 
have been quantified using optic densitometry software and normalized to the relative Vinculin 
band (housekeeping). The ratio between normalized pSMAD3 and SMAD3 levels were then 
calculated for each sample, and expressed as fold change referred to WT untreated cells in AU. 
Data are mean of n=3 independent experiments ± SD. 
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investigate whether YAP is involved in the downstream R-SMADs nuclear 
accumulation.  
First, we assessed whether SMAD3 can form a complex together with SMAD4 
even in the absence of YAP. To address this question, we performed IP of SMAD3 
from total cell extracts of WT and KO ECs, and observed that SMAD3 co-
immunoprecipitated together with SMAD4 at a similar level in both cell lines, 
suggesting that loss of YAP does not affect SMAD3-SMAD4 complex formation 
(Figure 24). Moreover, these analyses revealed that SMAD3 formed a protein 
complex together with YAP both in control and stimulated conditions.  
We then treated WT and KO cells for 2 h with TGFβ and analyzed R-SMAD 
sub-cellular localization, in order to determine whether YAP is important for R-
SMADs nuclear accumulation in response to TGFβ. 
N/C fractionation assays showed that ECs stimulation with TGFβ induced a 
marked SMAD3, -1, -2 and -4 nuclear accumulation in WT and KO cells. However, 
while SMAD1, -2 and -4 nuclear translocation occurred at comparable levels in both 
cell lines, loss of YAP significantly affected SMAD3 nuclear accumulation (Figure 
25). Thus, we concluded that YAP specifically contributes to SMAD3 nuclear 
Figure 24. SMAD3 co-immunoprecipitates with SMAD4 in response to TGFβ. Representative 
WB of SMAD3 IP (right side) from total cell lysate (input, left side). Cell were treated with TGFβ 
for 45 minutes before performing IP as described in materials and methods section. SMAD3 sc- 
101154 was used for IP, while SMAD3 cs-9523 for detecting WB bands, Asterisk (*) indicate an 
unspecific band detected in KO cells. Tubulin was used as input loading control. N=3 independent 
experiments. 
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accumulation upon TGFβ treatment and our results are in agreement with what 
previously described (Zhang et al., 2014). Moreover, despite SMAD1 protein levels 
are down-regulated in KO cells (Figure 22), we observed similar nuclear SMAD1 
accumulation levels in the two cell lines, which could partly explain why we did not 
detect a reduced SMAD1 signaling activity in KO cells compared to WT cells (Figure 
20). On the other hand, our data showed that YAP is required for both SMAD3 
protein accumulation (Figure 22) and nuclear translocation (Figure 25), and, 
overall, for SMAD3 signaling activity (Figure 20), further suggesting that YAP and 
SMAD3 cooperate to drive TGFβ-induced signaling in ECs. 
Figure 25. YAP is required for SMAD3 nuclear accumulation. Representative WB of N/C 
fractionation after 2 hours of TGFβ treatment. Asterisks in the blot indicate pSMAD3 C-term 
specific band. Right: Data are mean of at least n=3 independent experiments ± SD *p<0.05 
**p<0.01. Fold changes are referred to either nuclear or cytoplasmic WT untreated cells. Lamin 
B is used as loading control for the nuclear fraction. Tubulin is used as loading control for the 
cytoplasmic fraction and to verify the purity of the nuclear fraction. 
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To further confirm these data, we performed IF stainings of SMAD3, -1, -2 and 
-4 in WT and KO treated cells (Figure 26). In line with N/C fractionation analyses, 
results showed that SMAD1, -2 and -4 nuclear relocalization upon TGFβ treatment 
occurred at a comparable level between the two cell lines, while SMAD3 nuclear 
accumulation was reduced in YAP KO cells.  
In conclusion, loss of YAP did not impair SMAD3 and SMAD4 complex 
formation, but it strongly reduced the amount of SMAD3 that shuttles to the nucleus 
upon TGFβ treatment. Moreover, we observed a protein interaction between YAP 
and SMAD3 both in basal and stimulated conditions, but how YAP contributed to 
SMAD3 nuclear accumulation was still unknown. 
Figure 26. SMAD3 nuclear accumulation is impaired in absence of YAP. Representative IF 
stainings of total SMAD3, -1, -2 and -4 in WT and KO cells treated with TGFβ for 2 h. Arrowheads 
point to nuclei. Scale bar = 20 µm. n=5 for SMAD3 and SMAD1 and n=2 for SMAD2 and SMAD4. 
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3.6 YAP does not shuttle to the nucleus in response to TGFβ 
In confluent epithelial cells, YAP binds and sequesters SMAD3 in the cytoplasm, 
thereby preventing SMAD3 nuclear translocation and transcriptional activity upon 
TGFβ stimulation (Grannas et al., 2015; Varelas et al., 2010). In confluent ECs, 
instead, SMAD3 translocated to the nucleus in response to TGFβ despite YAP 
expression, while SMAD3 nuclear accumulation was significantly reduced when 
YAP expression was lost (Figure 25 and Figure 26).  
 In order to define how YAP contributed to SMAD3 nuclear accumulation, we 
first checked whether YAP sub-cellular localization varied upon TGFβ treatment. To 
do so, we performed TGFβ time-course treatment of YAP WT cells and analyzed 
pYAP Ser127 levels over-time, since 14-3-3 protein recognizes and causes pYAP 
Ser127 cytoplasmic retention (Basu et al., 2003). Interestingly, we found that TGFβ 
did not affect phosphorylation of YAP at Ser127 at any time point tested (Figure 
Figure 27. pYAP Ser127 levels are not modulated by TGFβ. Representative WB of YAP WT 
cells treated with TGFβ for the indicated times. WB bands have been quantified using optic 
densitometry software and normalized to the relative Vinculin band (housekeeping). The ratio 
between normalized pYAP Ser127 and YAP levels were then calculated for each sample, and 
expressed as fold change referred to WT untreated cells in AU. The chart represents 
quantification of n=4 independent experiments ± SD. 
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27), suggesting that YAP does not shuttle to the nucleus in response to TGFβ 
stimulation. 
In order to exclude a possible YAP nuclear translocation, we then performed 
both N/C and IF analyses and checked YAP sub-cellular localization in presence of 
a TGFβ stimulus (Figure 28). In line with our previous observations and with what 
described in other cells systems (Giampietro et al., 2015; Varelas et al., 2010), YAP 
predominantly localizes in the cytoplasm of confluent ECs, although a small amount 
of YAP is anyway present in the nucleus. By treating WT cells with TGFβ for 2 h, 
we did not detect any YAP nuclear accumulation, and therefore we concluded that 
TGFβ did not modulate YAP sub-cellular localization. 
Figure 28. YAP subcellular localization is not influenced by TGFβ. A) Left: representative 
WB of N/C fractionation after 2 h of TGFβ treatment. Right: mean quantification of n=3 
independent experiments ± SD. Fold changes are referred to either nuclear or cytoplasmic YAP 
WT untreated cells. Lamin B is used as a loading control for the nuclear fraction. Tubulin is used 
as a loading control for the cytoplasmic fraction and to verify the purity of the nuclear fraction. B) 
Left: IF staining of YAP in WT confluent cells after 2 h of TGFβ treatment. Arrowheads point to 
nuclei. Scale bar = 10 µm. Right: quantification of the ratio between the nuclear and the 
cytoplasmic intensity of the staining. Samples are normalized to YAP WT untreated cells. Data 
are mean of n=3 independent experiments ± SD. 
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Interestingly, by performing IP of SMAD4 from total cell lysate in presence or 
absence of a TGFβ stimulus, we could not observe an interaction between SMAD4 
and YAP (Figure 29), suggesting that SMAD3 binds to YAP or to SMAD4 under 
different conditions and they do not form a trimeric complex that together shuttles to 
the nucleus.  
Collectively, these data showed for the first time that YAP sub-cellular 
localization is not modulated by TGFβ stimulus and that YAP does not take part into 
SMAD4-mediated SMAD3 nuclear translocation. Thus, how YAP contributed to 
SMAD3 nuclear accumulation and why YAP formed a complex with SMAD3 was yet 
to be elucidated. 
3.7 TGFβ induces a dissociation of SMAD3 from cytoplasmic YAP, 
while inducing a nuclear YAP-SMAD3 complex formation 
Since our previous observations showed that YAP and SMAD3 can form a 
protein complex and that the absence of YAP negatively impacts on SMAD3 nuclear 
accumulation, we then wondered whether YAP can play a role in SMAD3 nuclear 
accumulation by binding it in the nucleus in response to TGFβ. In order to address 
Figure 29. SMAD4 does not form a complex together with YAP. WB showing of SMAD4 IP 
(right side) from total cell lysate (input, left side). Cell were treated with TGFβ for 2 h before 
performing IP as described in materials and methods section. As a negative control (Neg Ctr) we 
used a species-matching antibody. N=3  
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this question, we performed IP of YAP both from nuclear and cytosolic cell fractions 
in response to 45 minutes TGFβ stimulation. 
Very interestingly, we observed that YAP and SMAD3 interacted with each other 
in the nucleus and their binding was further increased in response to TGFβ 
treatments (Figure 30). At the same time, cytoplasmic YAP formed a complex 
together with SMAD3 in basal conditions, while exposure to TGFβ induced their 
dissociation. 
In conclusion, our data showed that YAP acted by sustaining TGFβ-mediated 
EndMT, SMAD3-driven signaling, SMAD3 protein and nuclear accumulation, and, 
also, that TGFβ reinforced SMAD3 binding to nuclear YAP in ECs. In light of these 
results, we hypothesized that YAP could bind to SMAD3 in the nucleus, strengthens 
SMAD3 binding to DNA and regulate together EndMT genes expression, while at 
the same time preventing SMAD3 nuclear exit by acting as a transcriptional cofactor. 
Figure 30. TGFβ induces a dissociation of SMAD3 from cytoplasmic YAP, while inducing 
a nuclear YAP-SMAD3 complex formation. Representative WB of WT cells immunoprecipitated 
for YAP (sc-271134) from either nuclear or cytosolic cell fraction. Cells were treated with TGFβ 
for 45 minutes. Input represent either nuclear (left) or cytoplasmic (right) protein pools. YAP sc-
15407 was used to detect the corresponding WB band. N=3 independent experiments.  
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3.8 EndMT genes contain putative binding sites for TEAD and 
SMAD3 
Previous studies have described YAP as a SMAD3 transcriptional cofactor in a 
variety of cell systems, including ECs (Beyer et al., 2013; Fujii et al., 2012; Hiemer 
et al., 2014; Zhang et al., 2014). In order to determine whether YAP and SMAD3 
can function as transcriptional cofactor in driving EndMT genes expression, we 
analyzed the promoter region of several EndMT genes, spanning -5.0 KB to +1.0 
KB around the TSS. We looked for either SMAD3 or TEADs putative binding sites, 
as TEAD family of transcription factor is known to cooperate together with YAP in 
driving gene transcription (Vassilev et al., 2001; Zhao et al., 2008), and also 
because previous reports have already shown that YAP/SMAD/TEAD complex work 
together to regulate gene expression in human embryonic stem cells and cancer 
cells (Beyer et al., 2013; Fujii et al., 2012; Hiemer et al., 2014). 
Analyses revealed that the EndMT genes Fn1, Acta2 and Cdh2, along with the 
EndMT-driving transcription factor Snai1 contain SMAD3 putative binding sites, 
while TEAD binding sites are found only on Acta2 and Cdh2 promoter regions 
(Figure 31). As internal control, we analyzed also Serpine1 promoter and found that 
contains one TEAD and four different SMAD3 binding sites. We then focused our 
attention on Fn1 and Serpine1, since preliminary studies (not shown) showed that 
their expression is up-regulated at early time points (within 24h). 
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3.9 Silencing of TEAD1 does not impair EndMT genes expression 
Since previous studies have reported that YAP/SMAD/TEAD complex work 
together to regulate gene expression (Beyer et al., 2013; Fujii et al., 2012; Hiemer 
et al., 2014), we evaluated whether YAP, SMAD3 and TEAD1 can form a protein 
complex in our cell system and together induce gene expression upon TGFβ 
treatment. By performing SMAD3 pull-down assays in WT and KO treated cells, we 
observed that TGFβ strengthened SMAD3-TEAD1 interaction in both WT and KO 
cells, although this effect was partially reduced in absence of YAP (Figure 32). This 
Figure 31. EndMT genes promoter analysis. The above figure schematically illustrates the 
promoter regions spanning - 5.0 KB to + 1.0 KB around the transcription start site (TSS) of 
Serpine1, Fn1, Acta2, Cdh2 and Snai1. Boxes represent either SMAD3 (blue) or TEAD (yellow) 
putative binding site. Analysis has been performed retrieving the sequence from RSAT and then 
searching for putative binding sites using MatInspector software.  
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suggested that probably a portion of total SMAD3 requires YAP to interact with 
TEAD1, while other SMAD3 molecules might engage with other interactors to form 
a complex together with TEAD1, like TAZ, or SMAD3 might directly bind to TEAD1 
without the aid of YAP.  
Although Fn1 does not contain TEAD putative binding sites, while Serpine1 
bears only one of them (Figure 31), we wanted to investigate whether 
YAP/TEAD1/SMAD3 can cooperate to drive the transcription of these genes, as we 
couldn’t exclude that YAP/TEAD could function at distal sites (enhancers) to 
modulate SMAD transcriptional activity (Stein et al., 2015; Zanconato et al., 2015).  
If TEAD1 is involved in Fn1 and Serpine1 expression, its removal would then 
result in a decreased expression of the analyzed genes in YAP WT stimulated cells. 
However, by silencing TEAD1 through siRNA approach, we could not detect a 
significant down-regulation in Fn1 and Serpine1 expression neither at 6 nor at 24 h 
after TGFβ stimulation (Figure 33), suggesting that TEAD1 is not involved in the 
regulation of these genes. 
Hence, these results indicated that SMAD3 can form a protein complex together 
with TEAD1 and that YAP might partly contribute to their interaction. TEAD1, 
however, is not required for Fn1 and Serpine1 expression, suggesting that YAP and 
Figure 32. SMAD3 co-immunoprecipitates together with TEAD1. WB showing IP of SMAD3 
(cs#9523) from total cell lysate of WT and KO cells treated with TGFβ for 45 minutes. Blot for: 
YAP (sc-271134), TEAD1 (BD 610923) and SMAD3 (MA5-15663). N=3 independent 
experiments. Vinculin was used a loading control of inputs (total cell lysate). 
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SMAD3 are likely responsible for the expression of these genes by forming a 
complex that does not comprise TEAD1. Whether other components of TEAD family 
are involved in EndMT genes expression remains yet to be elucidated. 
3.10 YAP and SMAD3 bind to the same Fn1 binding site 
Having established that Serpine1 and Fn1 contain several SMAD3 putative 
binding sites, we next assessed whether YAP and SMAD3 act as transcriptional 
regulators of TGFβ-induced EndMT genes by binding to their identified putative 
binding sites (Figure 31). Interestingly, it was previously reported that YAP and 
SMAD3 directly mediate Snai1 transcription by binding to its promoter region in 
Figure 33. TEAD1 is not required for Fn1 and Serpine1 expression. qPCR analysis of Fn1, 
Serpine1 and Tead1 mRNA expression levels in YAP WT and KO cells treated with 5 ng/mL TGFβ 
for either 6 h or 24 h. Samples are normalized to WT untreated cells. Data are mean ± SD of n=3 
independent experiments. *p<0.05 **p<0.01, ns= not significant, t-test. 
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response to TGFβ stimulus (Zhang et al., 2014), prompting us to focus our attention 
to other genes, that is Fn1 and Serpine1. In order to assess whether YAP and 
SMAD3 binds to Fn1 and Serpine1 promoter regions, we performed ChIP assays of 
WT and KO cells stimulated with TGFβ for 6 h, because preliminary data have 
shown that is the earliest time point at which Fn1 expression is significantly up-
regulated (data not shown). 
Interestingly, we found that both YAP and SMAD3 bound to Fn1 promoter region 
at the level of a SMAD3 putative binding site, suggesting that they possibly work as 
Fn1 transcriptional regulators (Figure 34). However, we did not retrieve any YAP or 
SMAD3 bound to Serpine1 promoter region #A1 (SMAD3 putative binding site, -0.5 
KB from TSS, Figure 31) nor to region #C (TEAD putative binding site, -4.3 KB from 
Figure 34. YAP and SMAD3 bind to Fn1 promoter. ChIP analysis of YAP (blue) and SMAD3 
(red) binding to Fn1 and Serpine1 promoters. WT and KO cells were treated for 6 h with TGFβ. 
DNA levels are normalized to the relative inputs. Columns are mean ±SD of triplicates from a 
representative experiment out of three with comparable results. 
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TSS, Figure 31) (Figure 34 and data not shown). Unfortunately, due to technical 
problems, we could not amplify the other putative binding sites shown in Figure 31 
and thus we could not investigate whether YAP and/or SMAD3 bind to Serpine1 
promoter region at these sites.  
In order to verify that SMAD3 is required for the expression of both Fn1 and 
Serpine1, we silenced SMAD3 in both WT and KO cells and analyzed the 
expression of EndMT genes in response to TGFβ treatment. As shown in Figure 
35, we found that SMAD3 is necessary for inducing Fn1 and Serpine1 expression 
upon TGFβ stimulation, further indicating that this transcriptional factor is important 
for driving EndMT genes transcription. Interestingly, in KO cells, Fn1 and Serpine1 
expression tend to be even more reduced upon SMAD3 silencing, suggesting that, 
in absence of both YAP and SMAD3, the transcription of these genes is strongly 
reduced compared to WT treated cells.  
Figure 35. SMAD3 is required for Fn1 and Serpine1 expression. qPCR analysis of Fn1, 
Serpine1 and Smad3 mRNA expression levels in YAP WT and KO cells treated with 5 ng/mL 
TGFβ for 24 h. Samples are normalized to WT untreated cells. Data are mean ± SD of n=4 
independent experiments. *p<0.05 ***p<0.001, t-test. 
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Of note, we observed also that SMAD3 mRNA expression is significantly lower 
in KO compared to WT cells, already at a basal level, partly explaining the reduced 
amount of total SMAD3 observed upon loss of YAP (Figure 22). 
Collectively, these results showed that both YAP and SMAD3 bind to Fn1 
promoter region and probably act as transcriptional regulators, suggesting that YAP 
can function as SMAD3 co-transcriptional factor to drive EndMT genes expression 
in response to TGFβ stimulation. 
3.11 YAP gain-of-function partially restores EndMT genes 
expression 
Our previous data have so far demonstrated that loss of YAP in ECs resulted in 
an impaired EndMT response induced by TGFβ, and that YAP specifically 
contributed to SMAD3 expression and signaling activity. We thus assessed whether 
reintroducing a constitutively and transcriptionally active form of YAP, that cannot 
be phosphorylated in any of the 5 crucial serine residues required for YAP 
cytoplasmic retention and therefore localizes predominantly in the nucleus (YAP 
5SA) (Dupont et al., 2011; Zhao et al., 2007), could restore the ability of KO cells to 
undergo EndMT upon TGFβ treatments. To do so, we infected WT and KO cells 
with lentiviral vectors expressing YAP 5SA, stimulated them with TGFβ for 24 h and 
analyzed the EndMT genes expression profile.  
By observing the morphology of infected cells at phase-contrast microscope, we 
noticed that the overexpression of constitutively active YAP led to the formation of 
clusters of cells growing on top of the EC monolayer, as if the cells had lost contact-
inhibition of growth (Figure 36). This phenotype resembled what previously 
described in other cell systems and, per se, showed that controlling the correct 
subcellular localization of YAP is useful to maintain a quiescent EC monolayer.  
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We then stimulated infected cells with TGFβ for 24 h and assessed the EndMT 
response in terms of Fn1 and Serpine1 mRNA and protein expression. Interestingly, 
qPCR analyses revealed that YAP 5SA strongly induced Fn1 and Serpine1 
expression in both WT and KO cells already at basal levels, suggesting that active 
nuclear YAP is important for the transcription of these genes. Moreover, TGFβ 
treatment further increased Fn1 and Serpine1 expression in WT and KO YAP gain-
of-function cells, leading to comparable EndMT genes transcription levels between 
KO 5SA and WT empty treated cells (Figur).  Of note, YAP 5SA expression in KO 
cells did not upregulate the expression of EndMT genes at the same levels as in 
WT 5SA treated cells. Accordingly, Fn1 protein expression was strongly up-
regulated in KO YAP 5SA cells, yet not as much as in WT 5SA treated cells (Figure), 
suggesting that nuclear YAP activity is not enough to fully rescue SMAD3-driven 
signaling.  
Along with EndMT genes expression, we also analyzed whether YAP 5SA 
expression is sufficient to restore SMAD3 mRNA and protein expression.  
Figure 36. Expression of YAP 5SA abolishes contact-inhibition of growth in WT and KO 
cells. Representative pictures of WT and KO cells infected with either empty or YAP 5SA 
expressing lentiviral vectors as described in materials and methods section. Pictures have been 
acquired through transmitted light microscope (EVOS, ThermoFisher). Scale bar = 400 µm 
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Figure 38. YAP 5SA partially restores Fn1 and SMAD3 protein expression. Representative 
WB of YAP WT and KO cells that were infected with either EMPTY or YAP 5SA lentiviral vectors 
and treated with 5 ng/mL TGFβ for 24 h. WB bands have been quantified using optic densitometry 
software and normalized to the relative Tubulin band (housekeeping). The fold change is referred 
to either WT or KO Empty untreated cells. Data are mean ± SD of n=3 independent experiments. 
*p<0.05 **p<0.01, t-test. 
Figure 37. YAP 5SA partially restores Fn1 and Serpine1 mRNA expression. qPCR analysis 
of Fn1, Serpine1 and Smad3 mRNA expression levels in YAP WT and KO cells that were infected 
with either Empty or YAP 5SA lentiviral vectors and treated with 5 ng/mL TGFβ for 24 h. Samples 
are normalized to WT Empty untreated cells. Data are mean ± SD of n=3 independent 
experiments. *p<0.05 **p<0.01, t-test. 
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Interestingly, re-introducing a constitutively active form of YAP in KO cells did 
not rescue SMAD3 mRNA expression (Figur), while it strongly increased SMAD3 
protein expression (Figure). These results indicated that YAP is not directly involved 
in Smad3 gene transcription, rather YAP seems likely to be involved in SMAD3 
protein stabilization. 
Collectively, these results showed that reintroducing a constitutive form of YAP 
in KO cells partially restored EndMT genes expression both at mRNA and protein 
levels, adding further evidence that YAP is an important transcriptional regulator of 
these genes. Moreover, YAP 5SA expression in KO cells restored SMAD3 protein 
but not mRNA expression, opening up the possibility that YAP expression in ECs is 
important for SMAD3 protein stabilization and turnover. 
3.12 YAP prevents SMAD3 phosphorylation at S204 
Previous studies have reported that, upon BMP stimulation and subsequent C-
term phosphorylation, SMAD1 is phosphorylated by CDK8/9 in its linker region at 
S206 and S214, which allows the binding of co-transcriptional factors such as YAP, 
and target genes transcription. Binding of co-transcription factors to SMAD1, 
moreover, prevents SMAD1 subsequent phosphorylation by GSK3β, thus impeding 
SMAD1 targeting to proteosomal degradation. In this way, while ensuring target 
genes transcription, binding of co-transcription factors to SMAD1 prevents its 
degradation (Alarcon et al., 2009; Aragon et al., 2011). A similar turnover pathway 
has been described concerning SMAD3, wherein CDK8/9 phosphorylates SMAD3 
at T179 and S208, favoring co-transcriptional partners binding while priming SMAD3 
to GSK3β-mediated phosphorylation at S204, and ultimately targeting SMAD3 to 
proteosomal degradation (Alarcon et al., 2009; Aragon et al., 2011). Nevertheless, 
it has never been suggested before that YAP might play this double role in case of 
SMAD3, that is sustaining SMAD3 transcriptional activity while preventing its 
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turnover. Since we observed that re-introducing a transcriptionally constitutively 
active form of YAP in ECs resulted in a marked SMAD3 protein accumulation in KO 
cells, we hypothesized that YAP might function as SMAD3 co-transcription factor to 
drive EndMT genes transcription while preventing phosphorylation at S204 and 
subsequent degradation. 
In order to verify this hypothesis, we first analyzed whether lack of YAP 
expression in ECs might result in an increased phosphorylation of SMAD3 at S204. 
Remarkably, TGFβ time course treatment revealed that SMAD3 is phosphorylated 
at a higher level in KO versus WT cells already at basal conditions, suggesting that 
YAP expression prevents SMAD3 pS204 even in absence of a TGFβ stimulus 
(Figure 39). Very interestingly, 45 minutes TGFβ treatment led to a marked increase 
Figure 37. YAP prevents SMAD3 phosphorylation at S204. Representative WB of YAP WT 
and KO cells treated with TGFβ for the indicated times. WB bands have been quantified using 
optic densitometry software and normalized to the relative Vinculin band (housekeeping). The 
ratio between normalized pSMAD3 S204 and SMAD3 levels were then calculated for each 
sample, and expressed as fold change referred to WT untreated cells in AU. Data are mean of 
n=3 independent experiments ± SD. *p<0.05 **p<0.01, t-test. 
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in SMAD3 pS204 levels in KO cells, which lasted till about 90 minutes from the 
beginning of the treatment. Conversely, SMAD3 pS204 levels in WT cells were only 
slightly increased 45 minutes after TGFβ stimulation, and, over time, were kept at 
lower levels compared to KO cells. 
Moreover, YAP 5SA expression in KO cells resulted in a marked decrease of 
pSMAD3 S204 compared to Empty KO cells (Figure 40), indicating that a 
transcriptionally active form of YAP contributed to prevent SMAD3 phosphorylation 
at S204, likely by engaging SMAD3 as a co-transcriptional factor and impeding 
phosphorylation at S204 involved in protein turnover. 
 
In conclusion, these results showed for the first time that, upon genetic loss of 
YAP in ECs, SMAD3 undergoes extensive phosphorylation at S204 (Figure 39) and 
it is less expressed (Figure 22), indicating that YAP likely contributes to stabilize 
SMAD3 protein and prevent its degradation. Moreover, TGFβ treatments result in a 
stronger phosphorylation at SMAD3 S204 in cells lacking YAP expression while 
Figure 38.  YAP 5SA reduces SMAD3 pS204 levels in KO cells. Representative WB of YAP 
WT and KO cells infected with either EMPTY or YAP 5SA lentiviral vectors and treated with 5 
ng/mL TGFβ for 24 h. WB bands have been quantified using optic densitometry software and 
normalized to the relative Tubulin band (housekeeping). The fold change is referred to either WT 
or KO Empty untreated cells. Data are mean of n=3 independent experiments ± SD. *p<0.05, t-
test. 
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expression of a transcriptionally active form of YAP decreases pSMAD3 S204 levels 
in KO cells, suggesting that YAP possibly prevents SMAD3 pS204 and subsequent 
degradation by engaging SMAD3 as a co-transcriptional factor. 
3.13 SMAD3-GSK3β association is increased in absence of YAP 
Previously, Wang and colleagues demonstrated that, in epithelial cells, the 
kinase responsible for SMAD3 pS204 is GSK3β (Wang et al., 2009a). Given that 
our former data clearly showed increased SMAD3 pS204 levels in ECs lacking YAP 
expression, we sought of investigating whether GSK3β is the kinase responsible for 
SMAD3 pS204 in ECs too.  
We therefore performed pull-down assays to explore whether SMAD3 and 
GSK3β associated in YAP WT and KO ECs both at basal conditions and in response 
to TGFβ treatments. Results showed for the first time that SMAD3 and GSK3β form 
a complex in ECs (Figure 41). Moreover, we observed for the first time that genetic 
ablation of YAP in ECs led to an increased association between SMAD3 and GSK3β 
at basal conditions, that was further increased in response to TGFβ treatments. 
Hence, these results showed that GSK3β forms a complex together with 
SMAD3 in ECs and, very interestingly, the degree of their association is increased 
Figure 39. SMAD3-GSK3β binding increases in YAP KO cells. Representative WB of SMAD3  
pull-down assay from total cell lysate. Cell were treated with TGFβ for 45 minutes before 
performing IP as described in materials and methods section. SMAD3 cs-9523 was used for IP, 
while SMAD3 MA5-15663 for detecting WB bands. Vinculin was used as input loading control. 
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upon genetic removal of YAP, suggesting that the expression of this co-
transcriptional factor might hamper SMAD3-GSK3β interaction and possibly 
SMAD3 protein turnover. 
3.14 GSK3β kinase activity is responsible for SMAD3 pS204 and 
protein turnover 
Our previous data showed that, in YAP KO cells compared to WT cells, SMAD3 
pS204 levels are increased (Figure 39) as well as SMAD3-GSK3β association 
(Figure 41). Since GSK3β is known to induce SMAD3 S204 phosphorylation in 
epithelial cells(Wang et al., 2009a), we investigated whether GSK3β is the kinase 
responsible for SMAD3 pS204 in ECs too and whether the phosphorylation at this 
site targets SMAD3 for proteosomal degradation.  
To do so, we took advantage of an inhibitor of GSK3β activity, namely LiCl (Klein 
and Melton, 1996), and analyzed SMAD3 total protein and S204 phosphorylation 
levels in both WT and KO treated cells. 
Interestingly, we observed a marked decrease in S204 phosphorylation upon 
LiCl treatment occurring both at basal and TGFβ-treated conditions in KO cells, 
suggesting that GSK3β kinase activity is required for SMAD3 pS204 in ECs (Figure 
42). Moreover, exposure of KO cells to LiCl led to an increased SMAD3 protein 
expression, that reached levels similar to the ones observed in WT cells.  
In light of these results, we also analyzed whether SMAD3 nuclear accumulation 
is restored in KO cells upon inhibition of protein degradation through LiCl and in 
response to TGFβ. Interestingly, we observed a significant increase in SMAD3 
nuclear accumulation in KO cells treated with LiCl and TGFβ compared to control 
KO cells treated with TGFβ (Figure 43 and Figure 44), suggesting that inhibition of 
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GSK3β-mediated SMAD3 protein turnover is sufficient to restore SMAD3 nuclear 
accumulation in KO cells. 
To conclude, these results showed for the first time that GSK3β is the kinase 
responsible for SMAD3 pS204 in ECs, targeting SMAD3 for protein degradation, 
and that GSK3β inhibition combined with TGFβ treatments results in increased 
SMAD3 nuclear accumulation in KO cells.  
  
Figure 40. GSK3β phosphorylates SMAD3 and targets it to degradation. Representative 
WB and relative quantification of WT and KO cells treated with either 60 mM LiCl or NaCl 
(control) O/N in starving medium, followed by 2 h TGFβ stimulation (for further details see 
materials and methods section). Data are mean of n=4 independent experiments ± SD. *p<0.05, 
t-test. 
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Figure 41. SMAD3 nuclear accumulation is restored in KO cells upon LiCl-mediated GSK3β 
inhibition. Representative IF stainings of total SMAD3 in WT and KO cells treated with either 60 
mM LiCl or NaCl (control) O/N in starving medium, followed by 2 h TGFβ stimulation. Scale bar = 
40 µm. The bottom chart represents the mean intensity of nuclear SMAD3 ± SD from n=3 
independent experiments, expressed as a fold change referred to WT NaCl treated cells. *p< 
0.05, t-test 
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3.15 SMAD3 protein stabilization through GSK3β inhibition is not 
sufficient to restore TGFβ-induced EndMT in YAP KO ECs 
Since GSK3β inhibition resulted in an increased SMAD3 protein stability and 
nuclear accumulation in KO cells, we wondered whether the defective EndMT 
response observed in KO cells was due to decreased levels in SMAD3 protein 
expression and nuclear accumulation or whether SMAD3 effectively requires YAP 
as a transcriptional co-factor that, at the same time, prevents protein turnover.  
In order to address this question, we analyzed EndMT genes expression in WT 
and KO cells stimulated with TGFβ and LiCl. Interestingly, inhibition of GSK3β by 
LiCl significantly up-regulated Fn1 and Serpine1 mRNA expression in WT but not in 
KO cells in response to TGFβ (Figure 45). Moreover, LiCl treatments did not have 
any effect on SMAD3 mRNA expression levels, further indicating that GSK3β 
inhibition plays a role in SMAD3 protein stabilization rather than protein 
transcription. 
Hence, we showed that the SMAD3 protein accumulation occurring upon LiCl-
mediated GSK3β inhibition was not sufficient for restoring EndMT genes 
transcription in cells lacking YAP expression, while it significantly increased Fn1 and 
Figure 42. SMAD3 nuclear accumulation is restored in KO cells upon LiCl-mediated GSK3β 
inhibition. Representative WB of total SMAD3 in WT and KO cells treated with either 60 mM LiCl 
or NaCl (control) O/N in starving medium, followed by 2 h TGFβ stimulation. Asterisk (*) indicate 
unspecific bands. Lamin B was used as nuclear loading control, while tubulin as cytosolic 
housekeeping gene. N=2 independent experiments. 
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Serpine1 mRNA levels in WT cells. In conclusion, our results strongly suggested 
that the expression of YAP is required not only for SMAD3 expression, but also as 
a SMAD3 co-transcriptional regulator of EndMT genes. 
 
 
 
 
  
Figure 43. SMAD3 protein accumulation upon GSK3β inhibition is not enough to restore 
EndMT genes transcription in KO cells. qPCR of Fn1, Serpine1 and Smad3 mRNA expression 
levels in YAP WT and KO cells treated with either 60 mM LiCl or NaCl (control) O/N in starving 
medium, followed by 24 h TGFβ stimulation. Samples are normalized to WT NaCl untreated cells. 
Data are mean ± SD of n=4 independent experiments. *p<0.05 **p<0.01, t-test. 
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Chapter 4 - Discussion 
EndMT refers to a biological process that allows the transdifferentiation of 
quiescent ECs into mesenchymal cells, thus originating cells capable of novel 
functions required to meet the needs of the surrounding environment (van Meeteren 
and ten Dijke, 2012). During this process, ECs lose their peculiar features and 
markers, like VE-cadherin, Claudin-5, CD31 and others, and begin to display 
mesenchymal-like characteristics, that is increased migration and invasiveness, and 
the expression of a plethora of markers such as Snai1, Snai2, aSMA, Fn1, FSP1, 
KLF4, N-Cadherin, and Serpine1. Physiologically, EndMT regulates endocardial 
cushion formation during embryo development, and it is stimulated by growth factors 
belonging to the TGFβ/BMP family of ligands. Conversely, EndMT does not 
generally occur in the adulthood, unless ECs are challenged with continuous 
inflammatory stimuli, leading to organ fibrosis, or during pathological conditions 
such as tumor progression and FOP. Besides, our group has been the first one to 
identify EndMT as a key biological mechanism that drives CCM pathology onset and 
progression, and revealed that, once again, TGFβ/BMP family of ligands are deeply 
involved in fueling this newly-characterized EndMT process (Maddaluno et al., 
2013). Therefore, it is becoming more and more crucial to characterize the 
molecular regulators cooperating with TGFβ signaling in sustaining this fundamental 
biological process, in order to possibly provide novel therapeutic targets to treat 
these life-threatening conditions. 
We focused our attention on YAP, a co-transcriptional regulator involved in 
many fundamental cell biology processes, like cell proliferation, cell migration, 
apoptosis, but also EMT (Overholtzer et al., 2006). This process shares some 
similarity with EndMT and occurs in epithelial cells in pathological conditions, such 
as tumor progression and metastasis, and during development (Kalluri and 
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Weinberg, 2009). Since EndMT is considered a “specialized” form of EMT, we 
hypothesized that YAP could also be an important regulator for EndMT. Additionally, 
over the last decade, YAP has been repeatedly shown to interplay with TGFβ/BMP 
signaling both in a positive and a negative manner in epithelial cells, suggesting a 
possible YAP-TGFβ crosstalk in ECs too.  
Under theses premises, we hypothesized that YAP contributes to EndMT by 
modulating TGFβ/BMP signaling, and tested our hypothesis by generating lung 
immortalized ECs either WT or KO for YAP.  
YAP WT and KO ECs were then chronically stimulated for 5 consecutive days 
with either BMP6 or TGFβ in order to elicit an EndMT response. Interestingly, BMP6 
stimulated EndMT markers expression in WT ECs, and even more in KO cells, thus 
suggesting that YAP might play a protective role in BMP6-induced EndMT. Although 
we did not further investigate this aspect, we can hypothesize a role of YAP in CCM 
pathology, where BMP6 expression is strongly up-regulated (Maddaluno et al., 
2013). On the other hand, loss of YAP in ECs resulted in a defective TGFβ-induced 
EndMT response. Chronic TGFβ treatment, indeed, induced a strong upregulation 
of the EndMT markers Acta2, Fn1, Cdh2, Snai1 and Serpine1 in WT cells, while 
their expression levels were significantly reduced in YAP KO ECs. Hence, our 
results support the idea that YAP is required for TGFβ-mediated EndMT. 
Accordingly, Zhang and colleagues have later on shown that endothelial-specific 
YAP KO mice resulted in defective EndMT during the atrioventricular cushion 
formation, and observed that cultured ECs silenced for YAP did not respond to 
TGFβ-mediated EndMT (Zhang et al., 2014). YAP is therefore emerging as a key 
player for the mesenchymal switch of both endothelial and epithelial cells, but very 
little is known about the underlying mechanism. We thus aimed at better defining 
the molecular mechanism through which YAP contributes to TGFβ-mediated 
EndMT, bearing in mind that this would also help identifying novel ways to target 
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pathological conditions where EndMT occurs, like CAFs generation or during organ 
fibrosis. 
In ECs, TGFβ binds to two different TbRI, ALK5 and ALK1, and trigger parallel 
SMAD-mediated signaling cascades (Goumans and Ten Dijke, 2017). Binding of 
TGFβ to ALK5, indeed, stimulates SMAD2 and SMAD3 C-term phosphorylation, 
which, in turn, trigger the expression of target genes, like Serpine1 (Dennler et al., 
1998; Goumans et al., 2002). TGFβ-ALK1 binding, instead, induces SMAD1/5 C-
term phosphorylation and leads to the expression of genes such as Id1 (Goumans 
et al., 2003b). Interestingly, after 5 days of chronic TGFβ stimulation, we found that 
genetic loss of YAP in ECs negatively affected Serpine1 up-regulation compared to 
WT cells, while Id1 expression was increased at the same level in both cell lines. 
These findings were further supported by analyses performed in acute stimulation 
(2 h), strongly suggesting a positive role of YAP in mediating SMAD3, but not 
SMAD1, signaling activity.  
Subsequently, we excluded that the differential SMAD3 signaling activation 
observed between the two cell lines could be due to differences in terms of ALK5 
and ALK1 expression levels and in terms of SMAD3 C-term phosphorylation. 
Unexpectedly, by observing SMAD3 and SMAD1 total protein levels in the two cell 
lines, we found a significant SMAD3 and -1 reduction in KO versus WT cells, which 
could partly explain SMAD3 impaired signaling activity in YAP KO cells. SMAD1 
reduced levels, however, did not impact on SMAD1-driven signaling in YAP KO 
cells. Of note, our results are in sharp contrast with a previous report, where the 
authors observed a negative correlation between YAP and SMAD3 expression in 
tumor-initiating breast cancer cells (Sun et al., 2016), and also with what Zhang and 
colleagues have reported in HUVEC cells (Zhang et al., 2014). These discrepancies 
could be due to the employment of different cell types (Sun et al., 2016), further 
stressing the importance of dissecting molecular mechanisms in specific biological 
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context, or could be due to different protein expression levels observed under acute 
(YAP KD) or chronic and total (YAP KO) silencing methods (Zhang et al., 2014). 
Nonetheless, our results clearly supported a role of YAP in sustaining SMAD3 
protein levels and SMAD3-driven EndMT response.  
SMAD3 mRNA levels were also significantly reduced in YAP KO cells, opening 
up the possibility that YAP could regulate SMAD3 transcription and, in this way, 
TGFβ-mediated EndMT. However, by reintroducing a transcriptionally active form 
of YAP (YAP 5SA) in KO cells, we did not observe an increase in SMAD3 mRNA 
transcription, rather YAP 5SA expression led to a significant up-regulation of 
SMAD3 protein levels. This very interesting finding suggested that nuclear YAP 
could play a double role in SMAD3 signaling activity, functioning at the same time 
as SMAD3 co-transcriptional factor while preventing its turnover in response to 
TGFβ.  
Previous reports in epithelial cells have suggested that cytoplasmic YAP (pYAP) 
is capable of binding to SMAD2/3 in response to TGFβ, thus preventing SMAD2/3-
mediated TGFβ signaling (Grannas et al., 2015; Varelas et al., 2010). Although our 
results showed that YAP specifically sustains SMAD3-driven target genes 
expression in ECs, we could not rule out the possibility that cytoplasmic YAP could 
prevent SMAD3 nuclear accumulation in ECs too. We therefore performed co-
immunoprecipitation analyses from nuclear and cytosolic cell compartments and 
observed that, conversely to what described in epithelial cells, cytoplasmic YAP 
binds to SMAD3 in basal conditions, while exposure to TGFβ induces a dissociation 
of the observed complex. Moreover, we found that YAP genetic deletion did not 
impact on SMAD4-mediated SMAD3 nuclear translocation, still YAP was specifically 
required for SMAD3 nuclear accumulation, as shown by N/C fractionation analyses 
and IF stainings. Our results are in agreement with previously published findings 
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(Zhang et al., 2014) and, collectively, show once again the importance of YAP in 
supporting SMAD3-driven signaling activity in ECs.  
Interestingly, TGFβ stimulation did not influence pYAP Ser127 levels – a marker 
for cytoplasmic YAP – as well as YAP nuclear accumulation, suggesting that TGFβ 
does not have a direct effect on YAP activation in ECs. Nevertheless, we found that 
TGFβ increased the levels of SMAD3 bound to YAP in the nucleus, indicating that 
SMAD3 and nuclear YAP form a complex in response to TGFβ treatments and likely 
work together as transcriptional regulators of EndMT genes.   
We therefore investigated whether Acta2, Fn1, Cdh2, Snai1 and Serpine1 
EndMT genes contain putative binding sites for SMAD3 and/or for TEAD, a family 
of transcriptional factors often bound by YAP that also contributes to EMT (Zhao et 
al., 2008). Moreover, it has been reported before that YAP/SMAD3/TEAD work 
together to regulate gene expression in different biological contexts where cells are 
undergoing differentiating or transforming processes, such as during development 
in human embryonic stem cells (Beyer et al., 2013) or in cancer model systems (Fujii 
et al., 2012; Hiemer et al., 2014), suggesting that YAP/SMAD3/TEAD complex 
controls the expression of genes involved in highly plastic processes. We therefore 
investigated whether the same occurred during EndMT. EndMT genes promoter 
analysis, indeed, revealed many putative binding sites for both TEAD and SMAD 
within a region spanning -5 KB to +1 KB around their TSS, while Fn1 and Snai1 
presented only SMAD putative binding sites. Previously, Zhang and colleagues 
showed that YAP and SMAD3 are responsible for Snai1 gene transcription (Zhang 
et al., 2014), and so we focused our attention on Fn1 and Serpine1, whose 
expression increased already 24 h after TGFβ stimulation. Interestingly, we found 
that both SMAD3 and YAP bound to the same Fn1 region, strongly suggesting that 
they work together as co-transcriptional factors driving the expression of this gene. 
We are currently cloning this Fn1 region in a luciferase reporter plasmid and 
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transfect it along with YAP and SMAD3 expressing plasmids, so to further confirm 
that they work together as active Fn1 transcriptional regulators in response to TGFβ. 
Unfortunately, we did not retrieve any YAP or SMAD3 bound to some identified 
putative binding sites on Serpine1 promoter region. However, due to technical 
problems, we could not analyze all Serpine1 putative binding sites, and will be 
analyzed in the next future. By means of siRNA approach, we also confirmed that 
SMAD3 is required for Fn1 and Serpine1 expression. Taken together, these results 
strongly indicate that YAP and SMAD3 work together as co-transcriptional factors 
that drive the expression of EndMT genes like Fn1, Serpine1 and Snai1 in response 
to TGFβ stimulation. Although these genes do not contain TEAD putative binding 
sites, apart from Serpine1, we could not exclude that YAP/TEAD could modulate 
SMAD3 transcriptional activity by binding to distal sites (enhancers), as previously 
reported by others (Stein et al., 2015; Zanconato et al., 2015). After observing an 
increased YAP-SMAD3-TEAD1 complex formation in both WT and KO cells upon 
TGFβ stimulation, we hypothesized that this complex might regulate the expression 
of EndMT genes. It has to be noted, however, that YAP KO did not fully prevent 
SMAD3-TEAD1 binding, suggesting that other co-transcriptional factors like TAZ 
could mediate their binding. Interestingly, we found that TEAD1 silencing in ECs did 
not significantly affect Fn1 and Serpine1 up-regulation induced by TGFβ, thus 
suggesting that TEAD1 is not required for the expression of these EndMT genes. 
Whether other TEAD family members are involved in EndMT genes transcription 
will be investigated in the next future.  
Collectively, these results showed for the first time that YAP and SMAD3 are 
required for Fn1 and Serpine1 expression in ECs, likely working as EndMT genes 
transcriptional regulators in response to TGFβ stimulation. 
Since our data showed that reintroducing a transcriptionally active form of YAP 
(YAP 5SA) in KO cells led to a significant up-regulation of SMAD3 protein levels, we 
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also tested the hypothesis that nuclear YAP could play a double role in SMAD3 
signaling activity, that is sustaining SMAD3-mediated transcriptional regulation 
while preventing protein turnover. In support of this hypothesis, other reports have 
previously shown that, upon BMP stimulation, SMAD1 is phosphorylated in its linker 
region by CDK8/9, allowing the binding of co-transcriptional regulators like YAP that, 
at the same time, prevent the subsequent GSK3β-mediated phosphorylation and 
SMAD1 targeting to protein degradation (Alarcon et al., 2009; Aragon et al., 2011). 
Whether YAP could play a similar function for SMAD3 has never been reported 
before. We therefore decided to test if the levels of SMAD3 pS204 – the 
phosphorylation described to target SMAD3 for protein degradation (Aragon et al., 
2011) – were more strongly increased after TGFβ treatments in cells lacking YAP 
expression compared to a WT situation. Remarkably, we found for the first time that 
SMAD3 pS204 levels are strongly increased in ECs lacking YAP expression while 
only slightly up-regulated in WT cells. YAP 5SA expression in KO cells, moreover, 
markedly reduced SMAD3 pS204 levels, further indicating that nuclear YAP 
prevents SMAD3 S204 phosphorylation in ECs treated with TGFβ.  
Of note, we observed that SMAD3 pS204 levels were significantly increased in 
YAP KO cells compared to WT cells even without TGFβ stimulation, suggesting a 
novel function of YAP in protecting SMAD3 protein degradation already at basal 
conditions. Literature reports have previously shown that SMAD3 S204 can be 
phosphorylated either by Erk2 MAPK in unstimulated conditions (Alarcon et al., 
2009) or by GSK3β in response to TGFβ (Wang et al., 2009a). We are therefore 
planning to investigate whether YAP inhibits SMAD3 pS204 mediated by Erk2 in 
basal conditions.  
Considering that our primary goal was to better define the molecular mechanism 
through which YAP contributes to TGFβ-induced EndMT, we moved to identify the 
kinase responsible for the increased SMAD3 S204 phosphorylation levels observed 
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in KO cells in response to TGFβ. Interestingly, co-immunoprecipitation analyses 
revealed a higher amount of GSK3β bound to SMAD3 in ECs lacking YAP 
expression, that was further increased after TGFβ stimulation. Moreover, inhibition 
of GSK3β activity by LiCl cell treatments was capable of reducing the amount of 
SMAD3 pS204 in TGFβ-stimulated YAP KO cells, showing that GSK3β is the kinase 
responsible for SMAD3 pS204 occurring in TGFβ-treated ECs. Very interestingly, 
ECs treatments with LiCl led to total SMAD3 protein levels accumulation in response 
to TGFβ, which also resulted in an increased SMAD3 nuclear accumulation in KO 
stimulated cells. However, preventing SMAD3 protein turnover through LiCl-
mediated GSK3β inhibition was not sufficient to restore EndMT genes transcription, 
strongly suggesting that SMAD3 requires YAP as a co-transcriptional factor in order 
to drive an effective EndMT response upon TGFβ stimulation. Accordingly, YAP 
5SA strongly induced Fn1 and Serpine1 expression in KO treated cells, indicating 
that nuclear YAP is required for the expression of these EndMT genes in response 
to TGFβ. 
We therefore propose here a novel mechanism through which YAP contributes 
to TGFβ-mediated EndMT (Figure 46). ECs respond to TGFβ stimulation by 
triggering C-term phosphorylation of SMAD3, which then shuttle to the nucleus to 
drive target genes transcription. To do so, SMAD3 binds to different co-
transcriptional regulators, that not only increase SMAD3-DNA binding affinity, but 
also help modulating the type of response activated by SMAD3. Remarkably, we 
found that the co-transcriptional partner YAP works together with SMAD3 to induce 
EndMT genes transcription, and, at the same time, prevents GSK3β-mediated 
SMAD3 linker phosphorylation and subsequent proteosomal degradation.  
In light of our in vitro results, we propose YAP as a possible candidate target to 
limit TGFβ-mediated EndMT occurring in pathological conditions. Although we have 
not yet investigated this aspect, several lines of evidence support our hypothesis. 
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YAP can be pharmacologically targeted by different molecules, like Verteporfin (VP) 
or statins. Statins have been shown to promote YAP cytoplasmic retention, and thus 
interfere with YAP transcriptional activity (Sorrentino et al., 2014). VP, instead, was 
initially discovered as an inhibitor of YAP-TEAD interaction during a screening of a 
panel of clinically Food and Drug Administration- (FDA-) approved pharmacological 
compounds. VP is indeed currently used to treat neovascular macular degeneration 
Figure 44. Proposed working model on how YAP regulates TGFβ-mediated EndMT. Binding 
of TGFβ to the TGFβ receptor complex stimulates SMAD3 C-term phosphorylation (blue dot). 
Subsequently, SMAD3 shuttles to the nucleus where it is phosphorylated likely by CDK8/9 
kinases in two residues lying within SMAD3 linker region, T179 and S208 (green dot). 
Phosphorylation at these sites favors the recruitment of the co-transcriptional factor YAP, which 
contributes to SMAD3-driven EndMT target genes expression. Moreover, binding of nuclear YAP 
to SMAD3 inhibits SMAD3 S204 phosphorylation (red dot), mediated by GSK3β kinase, and so 
prevents targeting of SMAD3 to proteosomal degradation. Modified from: Aragon, E., Goerner, 
N., Zaromytidou, A.I., Xi, Q., Escobedo, A., Massague, J., and Macias, M.J. (2011). A Smad 
action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev 25, 
1275-1288. 
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(Kawczyk-Krupka et al., 2015). Importantly, Liu-Chittenden and colleagues also 
tested VP anti-neoplastic activity in YAP transgenic mouse models, as YAP gain-of-
function mutations were previously reported to cause oncogenic transformation in 
liver (Camargo et al., 2007; Dong et al., 2007). Remarkably, the authors greatly 
rescued the liver overgrowth observed in vehicle-treated mice, proving that VP could 
be a potential drug to prevent YAP-oncogenic activity (Liu-Chittenden et al., 2012). 
A 2016 report, moreover, has also proposed VP as therapeutic molecule to reduce 
in vivo kidney fibrosis, a pathological process known to be driven by continuous 
TGFβ exposure (Szeto et al., 2016). Interestingly, in this study, the authors have 
observed that YAP and TAZ protein expression were strongly reduced in cultured 
fibroblasts upon VP treatments. Strikingly, VP also decreased the expression of the 
TGFβ-downstream effectors SMAD2 and SMAD3 and this effect was further 
exacerbated in presence of TGFβ. As a result, TGFβ-induced SMAD3 
transcriptional activity and, thus, profibrotic genes expression (Col3A1, Col4A1 and 
Acta2) were markedly reduced after VP treatments. Finally, the authors observed 
that VP was capable of attenuating renal fibrosis in mouse models of unilateral 
ureteral obstruction (UUO), by reducing YAP/TAZ levels and thus their profibrotic 
activity. These results not only set VP as a putative therapeutic strategy to treat 
kidney fibrosis, but also suggest that YAP functions as a SMAD transcriptional 
cofactor, and its expression is required to prevent SMAD2 and -3 protein 
degradation, as also stated by the authors themselves (Szeto et al., 2016). This 
strongly indicates that our identified mechanism on how YAP regulates TGFβ-
mediated EndMT does not only occur in ECs, but also in other cell systems, like in 
fibroblasts. Therefore, it would be now important to explore whether our identified 
mechanism is applicable also to other cell systems. 
Previous studies have shown that EndMT is a source of activated 
(myo)fibroblasts that contribute to kidney fibrosis (Zeisberg et al., 2008). 
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Importantly, SMAD3-null mice display a reduced kidney fibrosis in UUO mouse 
models (Inazaki et al., 2004). Moreover, Li and colleagues have later shown that 
blocking SMAD3 with pharmacological agents led to reduced EndMT and, 
consequently, decreased diabetes-induced kidney fibrosis (Li et al., 2010). Taken 
together, these results clearly suggest that blocking TGFβ-mediated EndMT can be 
a valid therapeutic strategy to treat kidney fibrosis, and that YAP is emerging as a 
possible target to attenuate this pathological condition. 
TGFβ-mediated EndMT can occur also in other fibrotic conditions, like in cardiac 
fibrosis (Zeisberg et al., 2007b). Although it has been proposed that YAP plays a 
role in promoting cardiac regeneration upon injury (Xin et al., 2013), it remains to be 
elucidated whether it is involved in pathological EndMT contributing to heart fibrosis. 
Along with fibrotic conditions, EndMT was shown to contribute to the formation 
of CAFs in tumor mouse models of malignant melanoma and pancreatic tumors 
(Zeisberg et al., 2007a). In this study, the authors stated that the observed EndMT 
was specifically driven by TGFβ, and, although they did not clearly demonstrate that 
TGFβ was involved in the in vivo mechanism, results showed a locally increased 
TGFβ secretion in FSP1+ fibroblasts areas. These very interesting findings need 
stronger in vivo validation, but clearly suggest EndMT as a key process contributing 
to cancer progression. Accordingly, the EndMT response occurring in endoglin 
mutant pancreatic tumor mouse models contributes to an increased metastatic 
dissemination (Anderberg et al., 2013). Intriguingly, this observed EndMT was partly 
driven by ALK5-mediated signaling. Thus, TGFβ is emerging as a leading growth 
factor that fosters tumor progression by promoting EndMT/EMT and chemotherapy 
resistance, thus rendering TGFβ an important therapeutic target to prevent cancer 
development (Colak and Ten Dijke, 2017). In this respect, several TGFβ targeting 
agents are currently under clinical trials (Colak and Ten Dijke, 2017). Since we and 
other have observed that EndMT is triggered by chronic TGFβ stimulation, tackling 
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possible common TGFβ-driven EMT and EndMT mechanisms would potentially 
help reducing tumor progression and, also, metastatic spread (Gasparics et al., 
2016). In this regard, Krizbai and coworkers have recently proposed that TGFβ 
secreted by melanoma cancer cells (B16F10) is capable of inducing EndMT in brain 
endothelial cells, decreasing the expression of components of AJs and TJs while 
triggering EndMT markers expression. Importantly, they showed that blocking 
B16F10-secreted TGFβ strongly reduced the amount of melanoma cells adhering 
to ECs along with the number of cancer cells transmigrating through the EC 
monolayer (Krizbai et al., 2015). In light of these in vitro results, the authors 
proposed that endothelial transdifferentiation into mesenchymal cells is a process 
that favors metastatic extravasation by providing de novo expression of N-cadherin 
– and thus favoring circulating tumor cells attachment – as well as downregulating 
components of AJs and TJs to allow cancer cells extravasation. Clearly, these in 
vitro results need to be validated in vivo, but suggest that EndMT should be 
thoroughly investigated in tumor context too. On this basis, we are planning to study 
whether YAP is important for driving TGFβ-mediated EndMT in vivo by analyzing 
the EndMT response stimulated during cancer development, in order to possibly 
suggest YAP as a novel potential therapeutic target to counteract tumor 
progression. In parallel, we will also investigate whether YAP and YAP-driven 
TGFβ-mediated EndMT can possibly regulate tumor-associated angiogenesis 
(Welch-Reardon et al., 2015), since angiogenesis is essential for tumor growth and 
metastasis and its limitation is a promising approach to restrain cancer progression,  
In conclusion, our results have set YAP as an important positive regulator of 
TGFβ-mediated EndMT by specifically sustaining SMAD3-driven signaling activity, 
providing a novel potential in vivo target to treat TGFβ-driven pathological conditions 
like tumor dissemination or organ fibrosis.  
 131 
APPENDIX 
 
 
 
 
 
JCB: Article
JCB 1
The Rockefeller University Press  $30.00
J. Cell Biol.
www.jcb.org/cgi/doi/10.1083/jcb.201501089
Introduction
Endothelial cells (ECs) form the inner lining of blood vessels, 
and one of their most important properties is to separate blood 
from underlying tissues. Their role as a selective permeability 
barrier is mainly achieved through the coordinated opening and 
closure of cell-to-cell junctions. In addition to maintaining ad-
hesion between neighboring cells, junctions play crucial roles 
in transducing chemical and mechanical signals that regulate 
contact-induced inhibition of cell growth, apoptosis, gene ex-
pression, and vessel formation and stability (Vandenbroucke et 
al., 2008; Giampietro et al., 2012; Giannotta et al., 2013).
EC homotypic adhesion is mainly controlled by two types 
of adhesive structures: tight and adherens junctions (AJs; Mc-
Crea et al., 2009; Vestweber et al., 2009; Giannotta et al., 2013). 
The key component of AJs is transmembrane vascular endo-
thelial (VE)–cadherin, an endothelial-specific member of the 
cadherin family. VE-cadherin is physically connected to a large 
number of intracellular partners that mediate its anchorage to 
the actin cytoskeleton and the transfer of signals essential to 
modulate endothelial functions (Vestweber et al., 2009; Dejana 
and Giampietro, 2012). Not surprisingly, changes in the struc-
ture and composition of AJs have profound effects on vascu-
lar permeability as well as on the overall vascular homeostasis 
(Vestweber et al., 2010).
Junctions are dynamic structures whose regulation and 
structural changes strongly impact adhesion strength and tis-
sue plasticity. ECs from different types of vessels and also from 
different organs show differences in junction composition and 
organization (Orsenigo et al., 2012; Kluger et al., 2013).
Recent studies revealed that the cotranscriptional regu-
lator YAP (Yes-associated protein), originally characterized as 
the molecular target of the size-controlling Hippo pathway (Va-
relas, 2014), is a key relay for the transmission of mechanical 
inputs into gene transcriptional programs (Dupont et al., 2011). 
Indeed, multiple signaling pathways integrating biophysical 
Vascular endothelial (VE)–cadherin transfers intracellular signals contributing to vascular hemostasis. Signaling through 
VE-cadherin requires association and activity of different intracellular partners. Yes-associated protein (YAP)/TAZ tran-
scriptional cofactors are important regulators of cell growth and organ size. We show that EPS8, a signaling adapter 
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VE-cadherin complex controls YAP transcriptional activity.
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and biochemical cues converge to regulate the activity of YAP 
(Morgan et al., 2013). YAP, in turn, is essential to modulate 
cell proliferation and differentiation, apoptosis, organ size, and 
morphogenesis of various tissues (Zhao et al., 2011). In epithe-
lial tissues, for example, YAP has been shown to be regulated by 
the formation of cell–cell contacts, to be required for contact in-
hibition of cell proliferation (Zhao et al., 2007), and to respond 
to mechanical perturbation of the epithelial sheet (Aragona et 
al., 2013). In all these situations, actin cytoskeletal–based me-
chanical forces have been shown to be the overarching regula-
tor of the activity of YAP and its related molecule TAZ, setting 
responsiveness to a variety of key signaling axes, including the 
Hippo, WNT, and G protein–coupled receptor pathways. Nota-
bly, Yap−/− mice display an early embryonic lethal phenotype 
resulting from defects in yolk sac vasculogenesis, chorioallan-
toic fusion, and embryonic axis elongation (Morin-Kensicki et 
al., 2006), suggesting a role of this protein also in the control of 
endothelial morphogenetic processes. The molecular determi-
nants through which ECs control YAP regulation remain, how-
ever, largely unexplored.
The EGF receptor kinase substrate 8 (EPS8) is a signal-
ing adapter protein involved in the transduction of signal from 
RAS to RAC (Scita et al., 1999). EPS8 also directly binds to 
actin filaments controlling the rate of polymerization/depolym-
erization by capping the fast-growing ends of filaments (Croce 
et al., 2004; Disanza et al., 2004, 2006; Hertzog et al., 2010). 
Consistently, EPS8, in vivo, is required for optimal actin-based 
motility impacting migratory properties of different cells (Frit-
toli et al., 2011). Furthermore, EPS8 regulates the proper ar-
chitectural organization of actin-based structures, including 
intestinal microvilli and stereocilia (Disanza et al., 2006; Hert-
zog et al., 2010; Tocchetti et al., 2010; Manor et al., 2011). One 
Figure 1. EPS8 is a novel component of AJ complexes in ECs. (A) Detection of full-length VE-cadherin–EPS8 interaction by LUM IER (top); the data are 
representative of five independent experiments. Association of EPS8 to full-length VE-cadherin (bottom). Coimmunoprecipitation and Western blot of en-
dogenous VE-cadherin and EPS8 from extract of VE-Cadherin–positive ECs. The dashed line indicates an LIR of 3, a conservative LIR cutoff. (B) Analysis 
of VE-cadherin cytoplasmic tail and EPS8 full-length interaction in vitro by His-tag pull-down assay (left). Analysis of the interaction between VE-cadherin 
cytoplasmic tail and EPS8 deleted mutants (asterisks) in vitro by GST pull-down assay (right). (C) Association of EPS8 to VE-cadherin full-length (VE-cad), 
Δ-p120, and Δ-βcat mutants upon transient expression in COS-1 cells. Cells were transfected with the indicated constructs, immunoprecipitated with specific 
EPS8 antibody or isotype control IgG, and blotted as indicated. (D) IF microscopy of VE-cadherin–positive ECs in early confluent (24 h) conditions. Cells 
were double stained with anti–VE-cadherin (red) and anti-EPS8 (green) antibodies. Junctional EPS8 colocalizing with VE-cadherin (arrows) was detected. 
The dashed outline indicates the magnified area to the right. (E) WB analysis (left) of EPS8 expression levels in various stages of confluence conditions (see 
Materials and methods section). Vinculin is the loading control. IF microscopy (right) of WT lung–derived ECs in various stages of confluence conditions. 
The IF of Eps8− ECs confirmed the specificity of the staining. Cells were stained with anti-EPS8 antibody (green) and DAPI (blue). Bars: (D and E) 20 µm; 
(magnification) 10 µm. IVB, in vitro binding; TOT, total cell lysate.
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additional cellular process in which EPS8 is implicated is the 
regulation of intracellular trafficking of various membrane re-
ceptors (Lanzetti et al., 2000; Di Fiore and Scita, 2002; Auciello 
et al., 2013). EPS8 exerts this function either through its direct 
interaction with the GTPase-activating protein, RN-tre, which 
controls the activity of RAB5, a master regulator of early en-
dosomes (Lanzetti et al., 2000; Di Fiore and Scita, 2002), or by 
interacting with the clathrin-mediated endocytosis machinery 
(Taylor et al., 2012; Auciello et al., 2013).
Here, we identified EPS8 as a novel partner of VE- 
cadherin at AJs. We also found that EPS8 regulates the dynamic 
organization of endothelial junctions and the transduction of in-
tracellular signals by tuning YAP transcriptional activity.
Results
EPS8 is a novel component of 
AJ complexes
To identify novel components of the VE-cadherin signaling 
complex, we set up a LUM IER (luminescence-based mamma-
lian interactome mapping) automated high throughput screen-
ing. This approach is designed for the systematic mapping of 
dynamic protein–protein interaction networks in mammalian 
cells (Barrios-Rodiles et al., 2005). Full-length VE-cadherin 
and Δ-βcat mutant, devoid of the C-terminal interaction domain 
with β-catenin (Fig. 1 C, bottom; Navarro et al., 1995), were 
fused to Renilla luciferase (RL) and coexpressed with a library 
Figure 2. Effect of EPS8 expression on AJ organization and dynamics. (A) WB (left) and qRT-PCR (right) analysis of EPS8 reconstitution in eps8−/− lung– 
derived ECs. Cells were infected with either WT EPS8-GFP (EPS8+) or control GFP (EPS8−) lentiviral vectors. The gene expression level has been represented 
as fold changes ± SEM of three independent experiments. (B) qRT-PCR analysis of VE-cadherin (P = 0.06) and β-catenin (P = 0.07) in EPS8+ and EPS8− 
ECs. For each tested gene, the expression level has been represented as fold changes ± SEM of four independent experiments. (C) WB analysis (left) of 
VE-cadherin and β-catenin expression in extracts of EPS8+ and EPS8− ECs in confluent condition. Vinculin is shown as the loading control. The graph (right) 
represents the WB quantification. Columns are means ± SEM of three independent experiments. The dashed line indicates that relative levels for the Eps8+ 
cells were set to 1. (D) IF microscopy of confluent EPS8+ and EPS8− cells stained with anti–VE-cadherin and –β-catenin antibody. An increase of junctional 
proteins’ distribution is observed in the absence of EPS8. Bar, 20 µm. (E) IP of VE-cadherin from EPS8+ and EPS8− cell extracts followed by WB analysis 
of phosphorylation on serine 665 residue and ubiquitin level (top). Quantifications of three independent experiments are shown as means ± SD at the 
bottom. *, P < 0.05; **, P < 0.01.
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of individual Flag-tagged partners in mammalian HEK293T 
cells. We next assessed the association of VE-cadherin wild-
type (WT) and mutant proteins with Flag-tagged proteins by 
performing a luciferase assay on anti-Flag immunoprecipitates. 
Among a variety of identified interactors, we focused our in-
vestigation on EPS8, which bound full-length VE-cadherin-RL, 
but not Δ-βcat-RL mutant (Fig.  1 A, top). We validated the 
physiological relevance of this association by coimmunopre-
cipitation of endogenous proteins from whole WT EC extracts 
(Fig. 1 A, bottom). In vitro pull-down experiments using re-
combinant purified proteins indicated that EPS8 binds directly, 
through its C-terminal domain, to the C-terminal region of 
the cytoplasmic tail of VE-cadherin (Fig.  1  B). Coimmuno-
precipitation experiments between EPS8 and a set of deletion 
mutants of VE-cadherin corroborated the results obtained 
with LUM IER. EPS8 efficiently bound to WT and a VE-cad-
herin mutant devoid of the interaction domain with p120 (Δ-
p120; Lampugnani et al., 1997) but failed to associate with a 
Δ-βcat VE-cadherin, which binds neither endogenous β-catenin 
nor α-catenin (Fig. 1 C, top), indicating that the region span-
ning amino acids 703–784 of VE-cadherin is indispensable 
for this interaction. Confocal analyses of early confluent WT 
(24 h) ECs showed that EPS8 was enriched along cell-to-cell 
junctions and largely colocalized with VE-cadherin (Fig. 1 D, 
arrows and magnification). Notably, EPS8 expression and junc-
tional localization were down-regulated in long confluent WT 
EC culture (72 h; Fig. 1 E). To confirm the specificity of the 
staining, we also performed immunofluorescence (IF) analy-
sis on early confluent Eps8-null ECs (EPS8−) that consistently 
did not reveal any signal.
EPS8 increases the dynamic turnover of 
VE-cadherin
To gain functional cues into the role of EPS8 in ECs, we derived 
ECs from lungs of eps8-null mice, which were subsequently 
reconstituted with either WT EPS8-EGFP (EPS8+ cells) or con-
trol EGFP (EPS8− cells) lentiviral vectors (Fig. 2 A; Menna et 
al., 2009). EC populations are characterized by high phenotypic 
heterogeneity (Ribatti et al., 2002); thus, we decided to use this 
approach to work with the same cell line, differing only for the 
expression of EPS8. The level of the EPS8 in EPS8+ ECs is 
∼30% more than WT ECs (Fig. S1 A), but this does not sig-
nificantly impact the molecular mechanisms studied, as shown 
in the following paragraph. In the absence of EPS8, the major 
components of the AJ complexes were up-regulated (Fig. 2 C) 
at junctions (Fig. 2 D), but the corresponding mRNAs remained 
unchanged (Fig. 2 B), suggesting a posttranscriptional effect. 
VE-cadherin is internalized through clathrin-mediated path-
ways in a process that requires VE-cadherin phosphorylation 
and ubiquitination (Gavard and Gutkind, 2006; Orsenigo et al., 
2012). Expression of EPS8 increased VE-cadherin phosphory-
lation on serine 665 and ubiquitination (Fig. 2 E), suggesting 
enhanced VE-cadherin turnover.
EPS8 and YAP localization at junctions is 
mutually exclusive
Cadherin complexes can either repress or stimulate gene tran-
scription. Considering the role of EPS8 in cytoskeletal or-
ganization, we asked whether the association of EPS8 with 
VE-cadherin might influence signaling pathways modulated by 
actin remodeling. We focused on the transcriptional cofactor 
YAP because its nuclear-cytoplasmic shuttling and activity may 
be regulated by cadherin-mediated cell–cell contacts (Kim et 
al., 2011) and cytoskeletal-dependent mechanical forces (Du-
pont et al., 2011). YAP was, as shown in other cell types (Ara-
gona et al., 2013), almost entirely localized in the nucleus of 
sparse WT ECs (Fig. 3, A and B). Conversely, in early confluent 
and long confluent WT endothelial monolayers, it was gradu-
ally excluded from the nuclei (Fig. 3, A and B) and redistributed 
along cell-to-cell junctions, where it colocalized with VE-cad-
herin (Fig. 3, A and B). To detect the junctional localization of 
YAP, cells have been fixed with 1% PFA in 2.5-mM triethanol-
amine (see Materials and methods section IF microscopy). In 
vivo, YAP localization at cell–cell junctions was detectable in 
the vessels of the brain and the retina of neonatal mice. Con-
versely, in vessels of other organs such as spleen, kidney, and 
liver, where the junctions are loose, YAP expression at junctions 
was decreased (Fig. 3 C).
Overall, these in vitro and in vivo data suggest that EPS8 
and YAP localize at junctions in a mutually exclusive and 
temporally distinct manner. In particular, EPS8 is a marker 
of early and dynamic junctions, whereas YAP is mostly re-
cruited at stable junctions.
We then asked whether EPS8 might regulate YAP signal-
ing. To this end, we compared EPS8+ to EPS8− ECs in early 
confluent conditions when EPS8 is prominently localized at 
intercellular junctions in WT ECs (Fig. 1 E). Under these con-
ditions, we found that in EPS8− ECs, YAP phosphorylation on 
serine 127, an inhibitory posttranslational modification (Zhao et 
al., 2007), was increased (Fig. 4 A), and YAP nuclear fraction 
was diminished (Fig. 4, B and C) as well as the expression of 
its target genes (Fig. 4 D), whose mRNAs are reduced by ∼10-
fold. Of note, as reported in Fig. S1 B, the expression of YAP 
target genes was significantly high in sparse conditions, and it 
was not affected by the presence or absence of EPS8. YAP tar-
get gene expression was strongly reduced by early cell conflu-
ence as previously published (Schlegelmilch et al., 2011), but 
the reductions were significantly less in the absence of EPS8, 
supporting the idea that EPS8 sustained YAP transcriptional ac-
tivity only when it was localized at AJs (Fig. 1 E).
Inhibition of YAP transcriptional activity 
is mediated by the activation of the 
PI(3)K–Akt pathway upon VE-cadherin 
clustering at AJs
A phosphorylation-dependent “shuttling” between the cyto-
plasm and the nucleus regulates the transcriptional activity of 
Figure 3. YAP is localized at junctions in long confluent monolayers in vitro and in the more stabilized vessels in vivo. (A, top) Confocal microscopy anal-
ysis of YAP (red) colocalization with VE-cadherin (green) and nuclei (DAPI, blue) in WT lung–derived ECs at different stages of confluence conditions (see 
Cell lines in the Materials and methods section). Bar, 20 µm. (A, bottom) Pixels presenting the colocalization of VE-cadherin and YAP are highlighted in 
white. Bars, 10 µm. Nuclei are highlighted with arrowheads, and junctions are highlighted with arrows. (B) Quantification of the number of colocalizing 
pixels between YAP and DAPI (top) or VE-cadherin (bottom) is shown. Data are means ± SEM of three independent experiments. *, P < 0.05; **, P < 0.01. 
(C) Confocal microscopy analysis of Pecam-1 (red) and YAP (green) localization in different organs of P9 mice (top). Bars, 50 µm. Pixels presenting the 
colocalization of Pecam-1 and YAP are highlighted in white. Quantification of the number of colocalizing pixels between YAP and Pecam-1 (bottom). Data 
are means ± SEM of five mice analyzed. *, P < 0.05 for retina, kidney, liver, and spleen versus brain.
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YAP (Varelas, 2014). We found that VE-cadherin expression 
and clustering was important to limit YAP transcriptional ac-
tivity. As reported in Fig. S2 A, and consistent with previously 
published literature (Choi et al., 2015), the up-regulation of YAP 
target genes was severely inhibited in VE-cadherin–positive as 
compared with VE-cadherin–null ECs in confluent conditions. 
VE-cadherin clustering is known to activate Akt through PI(3)
K (Carmeliet et al., 1999; Taddei et al., 2008). Akt, in turn, 
was shown to be able to phosphorylate YAP in serine 127 in 
vitro and in ECs (Basu et al., 2003; Choi et al., 2015). We 
therefore investigated whether EPS8 localization at AJs might 
affect Akt activation and Akt-dependent YAP phosphoryla-
tion. Both Akt and YAP phosphorylation were increased in 
EPS8− cells as compared with EPS8+ cells (Fig. 5 A). Pharma-
cological inhibition of PI(3)K with LY294002 reduced both 
Akt and YAP phosphorylation in EPS8+ and EPS8− cells to a 
comparable level. LY294002 treatment also restored the ex-
pression of YAP-dependent genes in EPS8− ECs to levels sim-
ilar to those observed in EPS8+ cells (Fig. 5 B). Conversely, 
the ectopic expression of myr-Akt, a constitutively active form 
of Akt (Brown et al., 2005), increased the phosphorylation of 
YAP in EPS8+ but not in EPS8− ECs. This lack of effect is 
likely a result of an already high basal AKT phosphoryla-
tion in the latter cell type (Fig. 5 C). myr-Akt infection was 
also able to reduce YAP target gene expression in EPS8+ but 
not EPS8− ECs (Fig. 5 D).
In epithelial cells, YAP transcriptional activity is reduced 
by the organization of E-cadherin–based AJs through the acti-
vation of the Hippo signaling pathway (Kim et al., 2011) and by 
the activity of small GTPases that act primarily through regula-
tion of the actin cytoskeleton (Dupont et al., 2011). Of note, in 
ECs small GTPase activity is controlled by VE-cadherin clus-
tering (Pannekoek et al., 2011; Giannotta et al., 2013; Goddard 
and Iruela-Arispe, 2013). However, neither the Hippo pathway 
(Fig. S3 A) nor the activity of RHO (Fig. S3 B) and RAC1 (Fig. 
S3 C) was altered by removal of EPS8.
Collectively, these data suggest that in ECs inhibition of 
PI(3)K–Akt is the prominent pathway through which EPS8 
increases YAP activity.
Inhibition of YAP transcriptional activity 
is mediated by YAP sequestration by 
α-catenin at AJs
The association of YAP with α-catenin limits its transcriptional 
activity (Silvis et al., 2011). α-Catenin sequesters YAP in the 
cytoplasm, thus preventing its dephosphorylation and nuclear 
translocation (Schlegelmilch et al., 2011; Silvis et al., 2011). 
We investigated whether EPS8 might play a role in the regula-
tion of this pathway. An endogenous YAP–α-catenin complex 
could be detected by coimmunoprecipitation only in EPS8−, 
but not in EPS8+ ECs (Fig. 5 E). This complex associated with 
VE-cadherin as revealed by coimmunoprecipitation experi-
ments (Fig.  5 F), and α-catenin was required for YAP–VE- 
cadherin interaction. Notably, removal of the VE-cadherin 
binding surface for β-catenin, which is required for α-catenin 
binding but not for p120, reduced, as expected, YAP phosphor-
ylation (Fig. S4 A), prevented YAP binding to VE-cadherin 
(Fig. S4 B), and enhanced YAP transcriptional activity (Fig. S4 
C). Finally, silencing of α-catenin impaired YAP localization 
at AJs (Fig. 5 F), reduced YAP phosphorylation (Fig. 5 G), and 
increased its transcriptional activity (Fig. 5 H) in a way more 
marked in the absence than in the presence of EPS8. These 
results suggest that EPS8 restrains the interaction of YAP with 
α-catenin. As a consequence, upon removal of EPS8, YAP is 
more efficiently sequestered into junctional complexes that 
prevent its nuclear translocation and transcriptional activity. 
Of note, and in line with what has been previously published 
(Schlegelmilch et al., 2011; Silvis et al., 2011), we were un-
able to detect a complex between TAZ, the related protein of 
YAP, and α-catenin, suggesting that TAZ activity may be regu-
lated by different mechanisms, but specific studies are required 
to test this hypothesis.
Figure 4. EPS8 expression modulates YAP phosphorylation, localization, and transcriptional activity in confluent ECs. (A) YAP phosphorylation (Phospho- 
YAP serine 127) in confluent EPS8+ and EPS8− cells. Total cell lysates were analyzed by WB for phosphorylated and total YAP expression by using specific 
antibodies. (B, left) WB analysis of nuclear/cytoplasmic distribution of YAP in confluent EPS8+ and EPS8− cells. On EPS8 removal (right), YAP shifted from 
a preferentially nuclear to a preferentially cytoplasmic localization. NP-95 and tubulin were used as nuclear and cytoplasmic markers, respectively. The 
graph on the right represents the quantification of four independent experiments. (C) IF microscopy of YAP (red) nuclear localization (arrowheads) in EPS8+ 
and EPS8− ECs. Bar, 20 µm. (D) qRT-PCR analysis of connective tissue growth factor (Ctgf), Cysteine-rich angiogenic inducer 61 (Cyr61), and Inhibin β A 
(Inhba) in EPS8+ and EPS8− ECs to measure YAP transcriptional activity. The absence of EPS8 strongly inhibited YAP transcriptional activity. For each tested 
gene, the expression level has been represented as fold changes ± SEM of three independent experiments. **, P < 0.01.
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EPS8 and the 14–3-3–YAP complex 
compete for binding to α-catenin
A common mechanism of cytoplasmic retention of nuclear 
proteins is mediated by the binding of 14–3-3 proteins, which 
interact with phosphorylated serine and threonine residues 
(Muslin and Xing, 2000). Consistently, YAP phosphorylated on 
serine 127 interacts with 14–3-3 proteins (Zhao et al., 2007), 
which were also shown to mediate its association with α-catenin 
(Schlegelmilch et al., 2011) in keratinocytes. To assess whether 
a similar complex could be detected in WT ECs, we immuno-
precipitated YAP from EC extracts (36 h of culture). We were 
able to detect a VE-cadherin–α-catenin–14–3-3–YAP complex 
from which EPS8 was excluded (Fig. 6 A). In contrast, α-catenin 
and VE-cadherin, but neither YAP nor 14–3-3 proteins, were re-
covered in EPS8 immunoprecipitates. These results support the 
idea of two different, mutually exclusive pools of VE-cadherin. 
EPS8 may compete with the 14–3-3–YAP complex for the in-
teraction with α-catenin, ultimately controlling YAP activation 
by inhibiting its retention at AJs. We verified this hypothe-
sis using recombinant purified proteins in in vitro pull-down 
Figure 5. YAP phosphorylation and transcriptional activity are regulated through differential PI(3)K–Akt pathway activation and binding to α-catenin. 
(A) WB analysis of YAP and Akt phosphorylation upon inhibition of the PI(3)K–Akt pathway. Cells were grown to 90% confluence, starved for 24 h, and 
incubated overnight in complete medium with the PI(3)K inhibitor LY294002 (10 µM). Vinculin is shown as a loading control. (B) qRT-PCR analysis of 
Cyr61, Ctgf, and Inhba to measure YAP transcriptional activity upon inhibition of PI(3)K in EPS8+ and EPS8− ECs. (C) WB analysis of YAP phosphorylation 
upon overexpression of constitutively active Akt (myr-Akt) in EPS8+ and EPS8− ECs. Vinculin is shown as a loading control. (D) qRT-PCR analysis of Cyr61, 
Ctgf, and Inhba to measure YAP transcriptional activity upon myr-Akt expression in EPS8+ and EPS8− ECs. (E) Coimmunoprecipitation and WB analysis 
of the YAP–α-catenin complex in EPS8+ and EPS8− ECs. (F) IP of VE-cadherin and WB analysis of the YAP–α-catenin complex localization at cell–cell con-
tacts in EPS8+ and EPS8− cells upon specific siRNA of α-catenin. (G) WB analysis of YAP phosphorylation upon specific siRNA of α-catenin in EPS8+ and 
EPS8− ECs. Vinculin is shown as a loading control. (H) qRT-PCR analysis of Ctgf, Cyr61, and Inhba to measure YAP transcriptional activity upon siRNA 
of α-catenin. For each tested gene, the expression level has been represented as fold changes ± SEM of three independent experiments. *, P < 0.05; 
**, P < 0.01. TOT, total cell lysate.
 on Novem
ber 2, 2017
jcb.rupress.org
Downloaded from
 
 138 
  
??? ???????8
experiments. We found that EPS8 directly bound α-catenin 
through its N-terminal domain (Fig. 6 B). This latter observa-
tion suggested that EPS8 and the 14–3-3–YAP complex may 
compete for binding to α-catenin. By monitoring the direct as-
sociation of purified α-catenin to immobilized 14–3-3 proteins 
(Schlegelmilch et al., 2011), we found that this interaction was 
abrogated in the presence of an equimolar amount of EPS8 
(Fig. 6 C), supporting the idea of a competition between EPS8 
and 14–3-3–YAP for α-catenin binding.
A critical role of YAP is to release epithelial cells from 
contact inhibition of cell growth (Zhao et al., 2011). This lat-
ter phenomenon is induced by the formation of cadherin junc-
tional complexes that, in addition to physically sequestering 
YAP at junctions (Zhao et al., 2011), also promote YAP phos-
phorylation, further impairing YAP nuclear translocation and 
transcriptional activity (Dupont et al., 2011). The growth inhib-
itory function was ascribed to VE-cadherin in ECs (Caveda et 
al., 1996; Giampietro et al., 2012), suggesting that EPS8 may 
contribute to this effect through the regulation of VE-cadherin 
stability at junctions (Fig. 2) and the consequent modulation of 
YAP localization and activity (Fig. 4).
To provide evidence in this direction, we monitored con-
tact inhibition of cell growth in WT ECs, and we found that 
with the establishment of cell confluence, both Akt and YAP 
increased their phosphorylation level (Fig. 7 A), and in parallel 
YAP transcriptional activity was reduced (Fig. 7 B). Consis-
tently, the removal of EPS8, which both dampens YAP activity 
and increases VE-cadherin localization at junctions, signifi-
cantly reduced the number of confluent cells needed to achieve 
growth arrest (Fig. 7 C).
A correct control of proliferation and the proper estab-
lishment of junctional complexes are the crucial steps for 
the fine regulation of permeability exerted by ECs. Thus, 
we analyzed whether the absence of Eps8 and the conse-
quent alteration in the transcriptional activity of YAP could 
impact the regulation of permeability. We found that Eps8− 
ECs displayed increased permeability compared with Eps8+ 
ECs (Fig. 7 D). EPS8 is therefore emerging as a key induc-
tor of YAP activity that acts both by preventing Akt-depen-
dent phosphorylation of YAP, as well as by restraining the 
binding of the 14–3-3–YAP complex to α-catenin, allowing 
YAP nuclear translocation.
These EPS8 activities are novel and unrelated to its 
well-established role in remodeling actin cytoskeleton. Indeed, 
ECs expressing an EPS8 mutant devoid of actin capping and 
bundling functions (Hertzog et al., 2010) showed a YAP ac-
tivity almost equal to EPS8+-expressing cells as measured by 
serine 127 phosphorylation levels (Fig. 8 A) and by the induc-
tion of target gene expression (Fig. 8 B). So far, we have deci-
phered a new molecular mechanism (Fig. 8 C) through which 
EPS8, a novel partner of VE-cadherin, is able to modulate YAP 
transcriptional activity.
The absence of EPS8 alters YAP 
activity in vivo
To confirm the in vivo relevance of the mechanisms described 
in the previous paragraphs, we analyzed YAP nuclear local-
ization in vessels of WT and eps8-null mice. Consistent with 
what we previously observed, YAP nuclear localization was 
increased in the vasculature of eps8-null mice (Fig. 9, A and 
B). Furthermore, freshly isolated ECs obtained from eps8-null 
mice showed ∼30% reduction of YAP target gene expression 
compared with WT mice (Fig. 9 C). Finally, in agreement with 
cultured cells, the absence of eps8 increased VE-cadherin local-
ization at AJs in vivo too (Fig. 10 A).
To test whether the observed defects in permeability 
shown in cultured ECs were also present in vivo, we tested 
small- and large-size tracers (cadaverine–Alexa Fluor 555 
and 0.1-µm-diameter green fluorescent microsphere, respec-
tively) in WT and eps8-null mice (Figs. 10 B and S5). The 
analysis revealed a specific increase (∼30%) in the accumu-
lation of cadaverine in the parenchyma of brain and lungs 
in eps8-null mice (Fig.  10  B), whereas no difference in 
the extravasation of the high-size green fluorescent micro-
spheres was found (Fig. S5).
Collectively, these findings support the idea that the sig-
naling mechanisms uncovered by in vitro analyses are present 
also in vivo, and Eps8 plays a role in controlling permeability, 
but only to small molecular size tracers.
Figure 6. EPS8 and 14–3-3–YAP complex compete for binding to α- 
catenin. (A) IP of YAP or EPS8 from VE-cadherin–positive cell extracts fol-
lowed by WB analysis of α-catenin, 14–3-3, and VE-cadherin association. 
EPS8 and YAP–14–3-3 are mutually exclusively bound to VE-cadherin and 
α-catenin. (B) Analysis of the interaction between α-catenin and EPS8- 
deleted mutants (asterisks) in vitro by GST pull-down assay. (C) In vitro 
competition assay between EPS8 and 14–3-3 for binding with α-catenin. 
14–3-3 bound α-catenin in the absence of EPS8, and EPS8 reduced this 
direct interaction in a dose-dependent manner. The dashed lines indicate 
the blot has been cropped. IVB, in vitro binding; TOT, total cell lysate.
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Discussion
Endothelial cell-to-cell junctions not only maintain intercellu-
lar adhesion but also transfer multiple intracellular signals that 
modulate contact inhibition of cell growth, cell polarity, lumen 
formation, and permeability (Dejana et al., 2009; McCrea et al., 
2009). The complexity of VE-cadherin signaling is a result of 
the large number of identified intracellular partners that have 
been shown to be directly or indirectly associated with AJs in 
the endothelium (Dejana and Vestweber, 2013).
These signaling proteins can assemble into distinct types 
of complexes, which would vary in composition in the different 
vessels, stages of development, and even within the same cell. 
Furthermore, VE-cadherin association with one or another part-
ner is reversible and can be spatially and temporally regulated.
We report here the identification of EPS8 as a new partner 
of the VE-cadherin complex in ECs that mediates the transduc-
tion of signals impinging on the regulation of the transcriptional 
coactivator YAP. EPS8 promotes VE-cadherin phosphorylation 
and ubiquitination. These posttranslational modifications in-
variably associate with increased internalization and enhance 
cell surface turnover of VE-cadherin (Gavard and Gutkind, 
2006; Orsenigo et al., 2012). Notably, EPS8 is not a stable 
component of VE-cadherin junctions, but it is transiently and 
rapidly recruited at cell-to-cell contacts during dynamic re-
modeling of junctions in early stages of confluency It is likely, 
therefore, that EPS8 contributes to increase junction dynamics. 
Conversely, EPS8 loss reduces the turnover of VE-cadherin 
and favors its clustering, a condition previously shown to pro-
mote the activation of the PI(3)K–Akt pathway (Carmeliet et 
al., 1999; Taddei et al., 2008). Consistent with our results, Choi 
and Kwon (2015) recently found that YAP subcellular local-
ization and activity in ECs are regulated by the VE-cadherin– 
mediated PI3K–Akt pathway. In keeping with these notions, we 
showed that the removal of EPS8 correlates with an increased 
localization of VE-cadherin at AJs and increased activation of 
the PI(3)K–Akt pathway.
YAP has long been shown to be a direct downstream 
target of Akt (Basu et al., 2003). This posttranslational modi-
fication creates binding sites for 14–3-3 proteins, a family of 
Figure 7. The absence of EPS8 induces earlier contact inhibition of cell growth and impairs EC permeability. (A) WB analysis of Phospho-YAP, YAP, Phos-
pho-Akt, and Akt in WT lung–derived ECs at different stages of confluence conditions. Vinculin is the loading control. (B) qRT-PCR analysis of YAP target 
genes in WT lung–derived ECs at different stages of confluence conditions. Data are means ± SEM of four independent experiments. (C) Cell density 
analysis performed on EPS8+ and EPS8− ECs. Equal numbers of cells were seeded at day 1 and subsequently counted at set time points. In the absence 
of EPS8, VE-cadherin localization is higher, and, consequently, cell–cell contact inhibition of proliferation is increased. Data are means ± SEM of eight 
independent experiments. (D) Paracellular tracer flux assay. Permeability to FITC-dextran (70 kD) was assayed. Data are means ± SEM of three independent 
experiments. At all time values from 60 min onward, Eps8+ ECs were statistically lower than Eps8− ECs. *, P < 0.05; **, P < 0.01.
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phosphoserine-binding proteins, that may retain YAP in the 
cytoplasm, preventing its nucleocytoplasmic trafficking and 
transcriptional activity (Zhao et al., 2007). By associating with 
14–3-3, YAP was shown to bind α-catenin in epithelial cells 
(Schlegelmilch et al., 2011). We report here that this interac-
tion also occurs in ECs, where the loss of EPS8 promotes the 
localization of hyperphosphorylated YAP at AJs in a trimeric 
complex with 14–3-3 and α-catenin.
We also found that EPS8 is able to bind directly to α- 
catenin, competing with the 14–3-3–YAP complex. Coimmu-
noprecipitation experiments show the existence of two differ-
ent, mutually exclusive protein complexes of VE-cadherin at 
AJs: in one complex, VE-cadherin binds α-catenin and EPS8, 
whereas in the other, VE-cadherin binds α-catenin, 14–3-3, 
and YAP. As a consequence, elevation of EPS8 levels inhibits, 
by competition for binding to α-catenin, the formation of the 
YAP–14–3-3–α-catenin protein assembly, ultimately inducing 
YAP nucleocytoplasmic shuttling and transcriptional activity. 
The exclusion of YAP from cell junctions by EPS8 is of par-
ticular relevance under conditions of dynamic remodeling of 
junctions, when endothelial monolayers may not have yet com-
mitted to a full growth arrest.
It was shown that actin cytoskeleton and tensional forces 
can modulate YAP activity (Dupont et al., 2011; Aragona et 
al., 2013). EPS8 is an actin-capping and -bundling protein that 
influences actin dynamics in migratory cells. This function re-
sides in the C-terminal effector region of EPS8. We show here 
that EPS8 can interact with α-catenin through its N-terminal 
domain at junctions in a topological arrangement that would 
enable EPS8 to execute its actin regulatory activity via its free 
effector C-terminal domain. However, the finding that an EPS8 
mutant unable to interact with actin (Hertzog et al., 2010) is 
fully competent in restoring YAP translocation to the nucleus 
in EPS8-null ECs argues against this possibility. Our findings 
reveal, instead, an unexpected way of signaling of Eps8 that is 
apparently independent from its ability to control actin dynam-
ics, but relies on a specific set of protein–protein interactions.
It will be important in future studies to determine the 
mechanism through which EPS8 is only transiently recruited 
to junctions. It is possible that increased tension across junc-
tions is the key initiating cue that translates into the formation 
of a set of specialized complexes required to promote the nec-
essary dynamics and plasticity of otherwise relatively stable 
structures and tissues.
Under in vitro and in vivo conditions, AJs are highly dy-
namic structures. Conditions that perturb this equilibrium might 
also perturb vascular permeability.
In eps8-null mice, VE-cadherin localization is increased 
at cell-to-cell contacts, likely through inhibition of turnover. As 
in cultured cells, eps8-null mice show an increase in vascular 
permeability, and the small-size tracer cadaverin accumulates 
in the parenchyma of different organs. However, large-size 
fluorescent beads did not cross the vessels more efficiently in 
the absence of eps8, suggesting a size-selective impairment of 
permeability. This result is consistent with the fact that eps8-
null mice are viable and fertile and apparently devoid of macro-
scopic vascular abnormalities.
A possible explanation for the absence of a more dramatic 
phenotype is that inactivation of Eps8 may be compensated 
for by other members of the family of related genes (Scita et 
al., 1999). Double and triple knockout of EPS8-related genes 
may clarify this aspect. Alternatively, it is possible that under 
Figure 8. EPS8 modulation of YAP phosphorylation and transcriptional activity is independent from its actin capping and bundling functions. (A) WB 
analysis of YAP phosphorylation in EPS8+, EPS8−, and EPS8ΔB+C ECs. Vinculin is shown as a loading control. (B) qRT-PCR analysis of Ctgf, Cyr61, 
and Inhba in confluent EPS8+, EPS8−, and EPS8ΔB+C cells. Significant differences in YAP transcriptional activity has been detected only in EPS8− ECs. 
For each tested gene, the expression level has been represented as fold changes ± SEM of three independent experiments. *, P < 0.05; **, P < 0.01. 
(C) Suggested model for the regulation of YAP phosphorylation, localization, and transcriptional activity. EPS8 transiently binds VE-cadherin during junctional 
remodeling a) while YAP is localized in the nuclei of ECs; b) when junctions are stabilized, VE-cadherin clustering induces PI(3)K–Akt–YAP phosphorylation 
and, c) consequently, YAP is sequestered at the plasma membrane. a) The transient direct bond of Eps8 to α-catenin prevents that of 14–3-3–phospho-YAP.
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specific pathological conditions, eps8-null mice present alter-
ations that are undetectable in healthy conditions.
In conclusion, we show here that the transient localiza-
tion of EPS8 at endothelial junctions modulates VE-cadherin 
organization and induces YAP nuclear translocation and tran-
scriptional activity. Further studies are required to characterize 
in more detail the relevance of this novel molecular pathway in 
additional in vivo models.
Materials and methods
Cell lines
Murine ECs genetically ablated for Cdh5 (VE-cadherin null) and 
modified to express the human WT VE-cadherin (VE-cadherin 
positive) or VE-cadherin Δ-p120 (lacking aa 621–702 of human 
VE-cadherin cDNA, which correspond to the p120-catenin– 
binding region) and Δ-βcat (lacking aa 703–784 of human VE- 
cadherin cDNA, which correspond to the β-catenin–binding region) 
were obtained and cultured as described previously (Giampietro et 
al., 2012). ECs isolated from lungs (Dong et al., 1997; Balconi et al., 
2000) of eps8-null adult mice were lentivirally infected with EGFP 
alone or EGFP-EPS8 (Menna et al., 2009). For the experiments, 
1,800 cells/cm2 and 42,000 cells/cm2 were seeded to obtain sparse 
and confluent cultures; and 40,000 cells/cm2 were seeded and cul-
tured for 24 h, 36 h, and 72 h to reach different stages of confluency 
(early confluent, confluent, and long confluent, respectively). For all 
ECs of murine origin, the culture medium was DMEM with 20% 
FCS, 2-mM glutamine, 100 U/liter penicillin/streptomycin, 1-mM so-
dium pyruvate, 100 µg/ml heparin (from porcine intestinal mucosa; 
Sigma-Aldrich), and 5 µg/ml EC growth supplement (made from calf 
brain; complete culture medium).
The starving medium was MCDB 131 (Invitrogen) with 1% BSA 
(EuroClone), 2-mM glutamine, 100 U/liter penicillin/streptomycin, 
and 1-mM sodium pyruvate.
The epithelial AD-HEK293 cell line (human embryonic kidney; 
American Type Culture Collection) used for adenoviral production 
was grown in DMEM (Cambrex Bioscience) supplemented with 10% 
FBS (HyClone), 2-mM glutamine, 100 U/liter penicillin/streptomycin, 
and 1-mM sodium pyruvate.
Figure 9. EPS8 expression modulates YAP localization and transcriptional activity in vivo. (A) Confocal microscopy analysis of YAP (white) and VE- 
cadherin (red) localization in paraffin sections of brains of WT and eps8-null P9 mice. Bars: (A) 50 µm; (magnification) 20 µm. The dashed outlines indicate 
the areas magnified below. (B) Quantification of the main intensity of YAP nuclear localization. Data are means ± SEM of six WT and six eps8-null mice 
analyzed. (C) qRT-PCR analysis of Ctgf and Cyr61 expression levels in freshly isolated ECs from WT and eps8-null mice. Data are means ± SEM of five 
WT and five Eps8-null mice analyzed. The levels of Ctgf and Cyr61 expression have been normalized on the amount of VE-cadherin gene expression. 
*, P < 0.05; **, P < 0.01.
 on Novem
ber 2, 2017
jcb.rupress.org
Downloaded from
 
 142 
  
??? ?????????
The COS-1 cell line (monkey kidney fibroblast-like cells; Ameri-
can Type Culture Collection) used for transient transfection was grown 
in DMEM supplemented with 10% FBS and 2-mM glutamine. All cells 
were cultured at 37°C in a humidified atmosphere of 5% CO2/air.
Antibodies
For IF, Western blotting, and immunoprecipitation (IP), the follow-
ing antibodies were used: VE-cadherin (C-19) goat (sc-6458; Santa 
Cruz Biotechnology, Inc.); VE-cadherin rat BV13 (ab91064; Abcam; 
Corada et al., 2002); EPS8 mouse (610144; BD); α-tubulin mouse 
(T9026; Sigma-Aldrich); vinculin mouse (V9264; Sigma-Aldrich); 
Ub P4D1 mouse (sc-8017; Santa Cruz Biotechnology, Inc.); pY665-
VE-cadherin rabbit (gift from J. Gavard, Institut Cochin, Paris, France; 
Gavard and Gutkind, 2006); YAP (63.7) mouse (sc-10199; Santa Cruz 
Biotechnology, Inc.; Western blot [WB]); phospho-YAP (serine 127) 
rabbit (4911; Cell Signaling Technology); Rac mouse (610650; BD); 
YAP (H-9) mouse (sc-271134; Santa Cruz Biotechnology, Inc.; IF); 
pan 14–3-3 (K-19) rabbit (sc-629; Santa Cruz Biotechnology, Inc.); 
α-catenin rabbit (C2081; Sigma-Aldrich; WB); α-catenin rabbit 
(2028–1; Epitomics; IP); β-catenin mouse (610154; BD); Mst1 rabbit 
(3682; Cell Signaling Technology); Mst2 rabbit (3681; Cell Signaling 
Technology); phospho-Mst1 (threonine 183)/Mst2 (threonine 180) 
rabbit (3681; Cell Signaling Technology); LATS1 (G-16) goat (sc-
12494; Santa Cruz Biotechnology, Inc.); phospho-LATS1 (serine 909) 
rabbit (9157; Cell Signaling Technology); Akt rabbit (9271; Cell Sig-
naling Technology); phospho-Akt (threonine 308) rabbit (9275; Cell 
Signaling Technology); Pecam-1 (CD31; ab28364; Abcam); HRP-
linked anti-mouse, anti-rat, and anti-rabbit (Cell Signaling Technol-
ogy); HRP-linked anti-goat (Promega); Alexa Fluor 555–conjugated 
donkey anti-mouse and anti-goat (Invitrogen); Alexa Fluor 488– 
conjugated donkey anti-mouse (Invitrogen); and GST (Z-5) rabbit 
(sc-459; Santa Cruz Biotechnology, Inc.).
Quantitative RT-PCR (qRT-PCR) analysis
Total RNA was isolated using the RNeasy mini kit (QIA GEN), and 
1 µg was reverse transcribed with random hexamers (High Capacity 
cDNA Archive kit; Applied Biosystems). cDNA was amplified with the 
TaqMan Gene Expression assay (Applied Biosystems) and a thermocy-
cler (ABI Prism 7900HT; Thermo Fisher Scientific). For any sample, 
the expression level, normalized to the housekeeping genes encoding 
18S, was determined by the comparative threshold cycle method as de-
scribed previously (Spagnuolo et al., 2004).
Figure 10. The absence of EPS8 alters the AJ organization and impairs the correct control of permeability in vivo. (A) Confocal microscopy analysis of 
VE-cadherin (green) localization in cryosections of brains of WT and eps8-null adult (2 mo old) mice (left). Quantification of the main intensity of VE-cadherin 
expression; data are means ± SEM of four WT and four eps8-null mice analyzed. Bars: (A) 50 µm; (magnification) 20 µm. The dashed outlines indicate 
the areas magnified on the right. (B) In vivo permeability assay. Mice were injected with 25 mg/kg cadaverine–Alexa Fluor 555, and 2 h later they 
were sacrificed and their organs were collected. Whole brains and lungs were photographed, and cadaverine was quantified. Bar, 500 µm. The pres-
ence of cadaverine in the organs was expressed in arbitrary units as mean fluorescence. n = 4 for WT and eps8 null. The dashed outline highlights the 
brain area.*, P < 0.05.
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Mice
All procedures involving animals and their care were performed in 
conformity with the guidelines established by the Italian Foundation 
for Cancer Research Institute of Molecular Oncology Foundation– 
European Institute of Oncology Campus Principles of Laboratory Ani-
mal Care (directive 86/609/EEC).
The generation of eps8−/− mice has been described previously 
by Scita et al. (1999). In brief, we isolated mouse genomic eps8 clones 
from a 129SV library (Agilent Technologies). We used a 7-kb XhoI–
XhoI fragment for 5′ homology and a 2.5-kb EcoRV–NotI fragment 
for 3′ homology. A phosphoglycerate kinase–neo cassette replaced 
an exon-containing eps8 genomic 1.7-kb XhoI–EcoRV fragment. The 
eps8 SH3 domain is encoded by two exons, and the targeting construct 
excluded the first and part of the second of these exons. A genomic 
probe, flanking the targeting construct at the 5′ end, was used to de-
tect the WT (2.6 kb) and targeted (9.5 kb) alleles. Of note, this genetic 
lesion resulted in the complete loss of the eps8 gene product as deter-
mined by mRNA analysis and immunoblotting with antipeptide serum 
raised against the N-terminal region of EPS8. Electroporation into 
mouse embryonic day 14 embryonic stem cell clones, and subsequent 
manipulations leading to mice heterozygous and homozygous for the 
mutant Eps8 allele, were performed as described previously (Levéen 
et al., 1994). A targeted embryonic stem cell clone was injected into 
C57BL/6 blastocysts, and germline chimeras and mice heterozygous 
and homozygous for the eps8 mutant allele were derived. DNA analy-
ses, derivation of chimeras, and subsequent identification of germline 
transmission, and mice heterozygous and homozygous for the mutant 
eps8 allele, were described previously (Levéen et al., 1994). eps8-null 
mice were backcrossed for >20 generations to C57BL/6 mice. Age- and 
sex-matched C57BL/6 mice were used as controls.
Intravenous injection of lysine-fixable cadaverine conjugated to 
Alexa Fluor 555 and microsphere
Cadaverine conjugated to Alexa Fluor 555 (3.125 mg/ml in saline) was 
injected intravenously into the tail vein of adult (2 mo old) 25-mg/kg mice 
eps8 null and controls. The circulation time was 2 h. For in situ detection of 
cadaverine, the anesthetized mice were perfused for 1–2 min with HBSS, 
followed by 5 min of perfusion with 4% PFA in PBS, pH 7.2. The organs 
were then removed and postfixed in 4% PFA at 4°C for 5–6 h. Images of 
dissected organs were captured using a stereomicroscope (SZX16; Olym-
pus) equipped with a fluorescence long-pass filter for RFP (excitation, 
530–550 nm; emission, 575 nm). Image acquisition was performed using 
a 1× objective with a total magnification of 0.35×, supported by an RGB 
camera (Digital Sight DS-5Mc; Nikon). The ImageJ open-source software 
(National Institutes of Health) was used for data analysis. The mean fluo-
rescence was calculated as the ratios of the total fluorescence signals to the 
number of pixels in the areas, expressed as arbitrary units.
For in situ detection of microspheres, the anesthetized mice 
were intravenously injected with green fluorescent microspheres (0.1-
µm diameter; 50 ml; Duke Scientific) and then perfused for 1–2 min 
with HBSS, followed by 5 min of perfusion with 4% PFA in PBS, pH 
7.2. The tracheas were then removed and postfixed in 4% PFA at 4°C 
for 1 h and then processed for IF analyses.
Histology and tissue IF
Mouse organs were embedded in optimal cutting temperature com-
pound (Tissue-Tek; Sakura) and snap frozen or embedded in paraffin. 
5-µm-thick sections were cut. Frozen sections were fixed in cold meth-
anol or 4% PFA and subjected to IF. Paraffin sections were subjected to 
IF. Blocking (2 h), primary (overnight), and secondary (3 h) antibodies 
were diluted in PBS with 2% BSA. Sections were then counterstained 
with DAPI and mounted in Vectashield.
Retinal immunohistochemistry
Eyes from WT C57BL/6 postnatal day 9 mice were fixed in 2% PFA 
overnight before retinas were dissected. Retinas were incubated in 5% 
donkey serum, 1% BSA, and 0.5% Triton X-100 in PBS overnight and 
the day after, stained with primary antibodies overnight. Then retinas 
were incubated with fluorophore-conjugated antibodies and mounted 
with ProLong gold (Invitrogen).
IF microscopy
Cells were cultured and then fixed with 4% PFA or, if specified in the 
text, with 1% PFA in 2.5-mM triethanolamine, pH 7.5, containing 0.1% 
Triton X-100 and 0.1% NP-40 to optimize junctional staining. Fixed 
cells were permeabilized and incubated for 30 min in a blocking solu-
tion of PBS with 2% BSA.
Cells were then incubated overnight with primary antibodies 
diluted in blocking buffer. Appropriate secondary antibodies were 
applied on cells for 45 min at RT. Confocal microscopy was per-
formed at RT with a confocal microscope (TCS SP2AOBS; Leica) 
equipped with violet (405-nm laser diode), blue (488 nm; Argon), 
yellow (561 nm; solid state), and red (633 nm; HeNe) excitation 
laser lines before processing with Photoshop (Adobe). Only adjust-
ments of brightness and contrast were used in the preparation of 
the figures. For comparison purposes, different sample images of 
the same antigen were acquired under constant acquisition settings. 
Image acquisition was performed using a 63×/1.4 NA oil immer-
sion objective (HCX PL APO 63× Lbd BL; Leica) with spectral 
detection bands and scanning modalities optimized for removal of 
channel cross talk. Confocal software (Leica) and ImageJ version 
1.33 were used for data analysis.
LUM IER assay
The automated high throughput technology LUM IER to analyze 
dynamic protein–protein interaction networks in mammalian cells 
was performed as previously described (Barrios-Rodiles et al., 
2005). Full-length human VE-cadherin and Δ-βcat mutant were 
C-terminally tagged with RL (VE-cadherin-RL and Δ-βcat-RL). In 
brief, HEK293T cells from a library of 640 3× Flag-tagged cDNAs 
that encode proteins comprised of diverse signaling-associated do-
mains (Miller et al., 2009), plated in dishes, were robotically trans-
fected using PolyFect (QIA GEN). After 48 h, cells were lysed and 
then immunoprecipitated using anti-Flag M2 monoclonal antibody 
(Sigma-Aldrich). Luciferase activity in immunoprecipitates and in 
aliquots of total cell lysates was determined using the Renilla Lucif-
erase Assay system (Promega).
Lung EC isolation
Lungs were excised from mice and digested with collagenase type I 
(Roche) for 2 h at 37°C. The ECs were then separated using Dynabeads 
(Invitrogen) coated with Pecam-1 antibody (BD) according to the man-
ual’s instructions and immediately processed for RNA isolation. cDNA 
synthesis and qRT-PCR were performed as described in the Quantita-
tive RT-PCR (qRT-PCR) analysis section.
Statistical analysis
A Student’s two-tailed unpaired t test was used to determine statistical 
significance. The significance level was set at P < 0.05.
IP
Cells were incubated with 100 µg/ml dithiobis(succinimidyl)propio-
nate (Thermo Fisher Scientific) for 20 min at 37°C and then solubi-
lized in lysis buffer (100-mM Tris-HCl, pH 7.4, 150-mM NaCl, 1% 
Triton X-100, 1% deoxycholic acid, 0.1% SDS, 2-mM CaCl2, and 
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protease/phosphatase inhibitors) on ice for 30 min. Precleared cell 
extracts were subjected to antibody precipitation overnight at 4°C, 
and immune complexes were captured by protein G–Sepharose beads 
(GE Healthcare). Immunoprecipitated material was separated on Tris- 
glycine SDS-PAGE, blotted onto nitrocellulose membrane, and ana-
lyzed by standard methodologies.
Western blotting
Confluent cells were lysed by boiling in a modified Laemmli sam-
ple buffer (2% SDS, 20% glycerol, and 125-mM Tris-HCl, pH 6.8). 
Equal amounts of proteins were loaded on gels, separated by SDS-
PAGE, and transferred to a nitrocellulose membrane (Protran; What-
man). After incubation with primary and HRP-linked secondary 
antibodies, specific bindings were detected by a chemiluminescence 
system (GE Healthcare).
Gelatin-glutaraldehyde cross-linking
To enhance EC adhesion, slides were coated with glutaraldehyde–
cross-linked gelatin as follows. The culture supports were incubated 
for 1 h at RT with 1% gelatin, followed by a cross-linking with 2% glu-
taraldehyde solution for 15 min at RT. The glutaraldehyde was replaced 
by 70% ethanol. After 1 h, five washes with PBS followed by overnight 
incubation with PBS containing 2-mM glycine were performed. Before 
cell seeding, slides were washed five times with PBS.
Paracellular tracer flux analysis
Cells were seeded on 6.5-mm-diameter Transwell permeable supports 
(pore size 0.4 µm; Corning), cultured in complete culture medium, and 
assayed for permeability to FITC-dextran (70 kD; Sigma-Aldrich). 
Next, FITC-dextran was added to the medium of the Transwell apical 
compartment at a concentration of 1 mg/ml. At different times of in-
cubation, a 50-µl aliquot of the medium was collected from the basal 
compartment, and the paracellular tracer flux was measured as the 
amount of FITC-dextran in the medium using a fluorometer (Wallac 
Victor3 1420 multilabel counter; PerkinElmer).
Active Rho and Rac pull-down assay
To detect active Rho, we used the Active Rho Pull-Down and Detec-
tion kit (Thermo Fisher Scientific) in accordance with the manufac-
turer’s instructions. To detect active Rac, we used the G-LISA Rac 
activation assay (Cytoskeleton, Inc.) in accordance with the manu-
facturer’s instructions.
Treatments
ECs were starved overnight before any treatment. 10-µM LY294002 
(Cell Signaling Technology) was added overnight at 37°C.
Constructs
A form of Akt that is constitutively active (myr-Akt) was a gift from 
C. Daly (Regeneron Pharmaceuticals Inc., Tarrytown, NY). Cytomeg-
alovirus promoter–based, elongation factor-1 promoter–based eukary-
otic expression vectors, and GST bacterial expression vectors were 
generated by recombinant PCR. His6-tagged α-catenin full-length was 
a gift from B. Weis and W.J. Nelson (Stanford University, Stanford, 
CA). MBP–14–3-3 was procured from GeneCopoeia. All constructs 
were verified by sequencing.
Protein purification
Recombinant full-length His-EPS8, His-Irsp53, and GST-EPS8 
fragments were expressed and purified as previously described 
(Disanza et al., 2006, 2013; Hertzog et al., 2010). In brief, recom-
binant fragments were expressed as His- or GST-fusion proteins 
in the BL21 Escherichia coli strain (Agilent Technologies) and 
affinity purified using GS4B glutathione–Sepharose beads (GE 
Healthcare) or nickel–nitrilotriacetic acid agarose. Eluted proteins 
were dialyzed in 50-mM Tris-HCl, 150-mM NaCl, 1-mM DTT, 
and 20% glycerol. GST–VE-cadherin intracellular domain was ex-
pressed in BL21 Rosetta strain (Agilent Technologies) and affinity 
purified using GS4B glutathione–Sepharose beads. His–α-catenin 
was expressed in the BL21 E. coli strain (Agilent Technologies) 
and affinity purified using nickel–nitrilotriacetic acid (Ni-NTA) 
agarose according to standard procedures. Recombinant puri-
fied protein was eluted with 200-mM imidazole and dialyzed in 
50-mM Tris, pH 7.8, 150-mM NaCl, 1-mM DTT, and 5% glycerol. 
MBP–14–3-3 was purified by standard procedures using amylose– 
Sepharose affinity purification.
In vitro binding assay
MBP–14–3-3–α-catenin ± EPS8. Recombinant purified proteins were 
incubated overnight at 4°C in Xb buffer (50-mM Tris-HCl, pH 7.4, 
150-mM NaCl, 0.02% Triton X-100, 20-mM imidazole, 1-mM DTT, 
and protease inhibitor cocktail). Samples were then incubated for 1 h 
at 4°C with amylose–Sepharose beads and washed three times with Xb 
buffer. Amylose–Sepharose beads were resuspended in a 1:1 volume of 
2× SDS-PAGE sample buffer, boiled for 5 min at 95°C, spun down for 
1 min, and loaded on acrylamide gels.
EPS8 full-length/VE-cadherin cytoplasmic tail. Recombinant pu-
rified His-EPS8 and VE-cadherin–C-terminal fragment were incubated 
for 1 h at 4°C with Ni-NTA beads in Xa buffer (50-mM Tris, pH 8, 
300-mM NaCl, 0.1% Triton X-100, 20-mM imidazole, 1-mM DTT, 
and protease inhibitor cocktail). Samples were washed three times in 
Xb buffer. Beads were resuspended in a 1:1 volume of 2× SDS-PAGE 
sample buffer, boiled for 5 min at 95°C, spun down for 1 min, and 
loaded on acrylamide gels.
EPS8 fragments/α-catenin full length. Recombinant purified 
GST-EPS8 fragments and His–α-catenin were incubated for 1 h at 4°C 
with Ni-NTA beads in Xb buffer. Samples were washed three times in 
Xb buffer. Beads were resuspended in a 1:1 volume of 2× SDS-PAGE 
sample buffer, boiled for 5 min at 95°C, spun down for 1 min, and 
loaded on acrylamide gels.
EPS8 fragments/VE-cadherin cytoplasmic tail. Equal amounts 
of cell lysates overexpressing VE-cadherin cDNA were incubated with 
GST-EPS8 fragments (GST as control) for 2 h at 4°C in the presence of 
GS4B glutathione–Sepharose beads. Samples were washed three times 
in lysis buffer. Beads were resuspended in a 1:1 volume of 2× SDS-
PAGE sample buffer, boiled for 5 min at 95°C, spun down for 1 min, 
and loaded on acrylamide gels.
RNAi
To interfere with α-catenin, we used siRNA (ON-TAR GETplus 
L-048960-01; SMA RTpool duplex Ctnna1) from GE Healthcare and 
the corresponding nontargeting pool (ONT ARGETplus). Transfection 
was performed with Lipofectamine 2000 (Invitrogen) in accordance 
with the manufacturer’s instructions.
Online supplemental material
Fig. S1 describes EPS8 reconstitution in EPS8− ECs. Fig. S2 shows 
that YAP transcriptional activity is regulated by VE-cadherin. Fig. S3 
shows that EPS8 expression does not influence the Hippo pathway 
and Rho and Rac activity in ECs. Fig. S4 shows that YAP binding 
to VE-cadherin negatively regulates its transcriptional activity. 
Fig. S5 shows the high-size permeability control in vivo. Online 
supplemental material is available at http ://www .jcb .org /cgi /content /
full /jcb .201501089 /DC1.
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